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General introduction and outline  
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Allergic airway inflammation
Asthma and allergic rhinitis are common, chronic diseases of the respira-
tory tract. Both conditions often coexist and show systemic manifestations 
including atopy and blood eosinophilia (1). Worldwide, the prevalence of 
asthma is estimated at 1-18% and allergic rhinitis at 10-25% of the population, 
respectively (1,2). In the past 20 years, the incidence of the allergic airways 
disease has increased, especially among children. In the US, the annual direct 
and indirect expenses for asthma are estimated at $13 billion (1998 values) 
and for allergic rhinitis at $2 to 5 billion (2003 values) (1,3). Although severe 
or life-threatening in only a minority, allergic airways disease affects the 
quality of daily life of many patients with impact on school attendance and 
productivity at work. The World Health Organization has estimated that 15 
million disability adjusted life years (dalys) are lost annually due to asthma, 
representing 1% of the global disease burden. Despite modern medications, 
still too many patients are not adequately controlled. In addition, asthma and 
ar are chronic conditions that cannot be cured and most patients require 
lifelong controller medication and lifestyle adjustments. Hence, there is still 
an unmet need for novel targeted treatments and more accurate monitoring 
methods of the disease process (4,5).
Pathophysiology – early and late allergic reaction
In spite of recent progress in elucidating several inflammatory mechanisms 
of allergic airway disease still many etiological and pathophysiological ques-
tions remain unanswered. The pathogenesis of asthma is multifactorial and 
its expression depends on the interactions of several susceptibility genes and 
environmental factors. Atopy is the strongest identifiable predisposing factor 
for developing allergic airways disease (6). Overall, the allergic inflammation 
within bronchial and nasal tissues is very similar with some local differences 
(figure 1) (7,8). Exposure to a new allergen results in uptake and processing 
by dendritic cells. In genetically predisposed individuals, the presentation of 
processed allergen by dendritic cells to naïve T helper (Th) cells induces the 
development of Th2 cells (9). Subsequently, Th2 cells release interleukins 
(il)-4 and il-13 which results in differentiation of b cells into allergen specific 
immunoglobulin (Ig)-E-producing plasma cells (10). The airway epithelium 
also participates in the allergic response by producing thymic stromal lym-
phopoietin (tslp) which is thought to stimulate dendritic cells, b cells and 
mast cells (11,12). The newly synthesized IgE subsequently binds to surface 
receptors of mast cells and basophils inducing ‘priming’ (sensitization). 
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Upon re-exposure, the allergen binds to the cell surface-bound IgE resulting 
in cross-linking of the receptors causing degranulation of mast cells releasing 
preformed pro-inflammatory mediators (histamine, chymase and tryptase) 
and de novo synthesis of other pro-inflammatory mediators (leukotrienes, 
prostaglandins, platelet activating factor and bradykinin) (13). These media-
tors have been shown to possess bronchoactive and pro-inflammatory prop-
erties in various species, causing airway smooth muscle contraction, vaso-
dilatation, increased vascular permeability, mucus hypersecretion, and the 
recruitment of pro-inflammatory cells (14,15). Inhalation of a relevant allergen 
by sensitized subjects produces an early airway response (ear) in both aller-
gic asthma and allergic rhinitis (8). The ear-related events are organ-specific 
and include bronchoconstriction, dyspnea, wheezing and cough within the 
lower airways and itching, sneezing, rhinorrhea, and congestion within the 
upper airways accompanied by ocular symptoms (16). 
Evidence points to the involvement of early pro-inflammatory mediators in 
the development of the late allergic response (lar) which follows in approxi-
mately 50% of patients, usually occurring between 3 to 12 hours post-allergen 
(7,17). Within the lower airways, the lar is characterized by persistent 
broncho-obstruction, allergen-induced airway hyperresponsiveness (ahr) 
and structural airway changes (remodeling) (8,17). In this inflammatory 
process, several effector cells and their products participate and interact. 
Epithelial and inflammatory cells are stimulated to produce chemoattrac-
tants (e.g. eotaxin, rantes) (13,18). Pro-inflammatory mediators including 
tumor necrosis factor (tnf)α, granulocyte-macrophage colony stimulating 
factor (gm-csf), il-4 and il-13 stimulate the expression of vascular adhesion 
molecules on endothelial cells. These events result in an increased recruit-
ment of leukocytes (mostly eosinophils, but also basophils and neutrophils) 
and lymphocytes into the bronchial and nasal mucosa. In addition, il-4 and 
il-13 have the ability to induce production of transforming growth factor 
alpha (tgf-α) by epithelial cells. tgf-α through autocrine signaling results 
in mucous metaplasia and fibroblast proliferation (19). Simultaneously, the 
secretion of il-5 by Th2-cells produces further activation and infiltration of 
eosinophils (20). Allergens can also trigger the release of pro-inflammatory 
neuropeptides (e.g. the tachykinins: neurokinin A and substance P) from 
sensory nerves within the airways causing the so-called neurogenic inflam-
mation (figure 1). Substance P in particular has been shown to possess pro-
inflammatory properties inducing vasodilation, microvascular leakage, and 
mucus hypersecretion within both airway compartments (21,22). Similarly, 
within the upper airways, the lar is characterized by a long-lasting nasal con-
gestion, accompanied by nasal eosinophilia and increased hyperreactivity (7). 
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figure 1 Cells and mediators involved in the early and late allergic response in allergic asthma and 
allergic rhinitis. ecp = eosinophilic cationic protein, gm-csf = granulocyte-macrophage 
colony stimulating factor, ige = immunoglobulin-e, il = interleukin, mbp = major basic 
protein, paf = platelet activating factor, tgf-α = transforming growth factor alpha,  
th = t helper, tnf-α = tumor necrosis factor alpha, tslp = thymic stromal lymphopoietin.
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One airway disease
In addition to similarities in airway responses and components of inflamma-
tion, several studies provided evidence for a systemic, bidirectional cross-talk 
between the two airway compartments. Segmental allergen challenge in 
non-asthmatic patients with allergic rhinitis caused increased inflammatory 
cell numbers in both bronchial and nasal mucosa in association with symp-
toms of allergic rhinitis and blood eosinophilia (23,24). Inversely, a nasal aller-
gen challenge in non-asthmatics with allergic rhinitis resulted in increased 
expression of adhesion molecules and uptake of eosinophils in the bronchial 
mucosa, while topical treatment with nasal corticosteroids reduced markers 
of lower airway inflammation (25,26). Supported by this data, asthma and 
allergic rhinitis are considered manifestations of the same allergic airway 
syndrome, the so-called combined allergic rhinitis and asthma syndrome 
(caras) (27). Based on (non)-invasive sampling techniques, the list of play-
ers involved in allergic airway disease is continuously expanding and offers 
still novel targets for drug development and clinical monitoring. Examples 
comprise novel approaches including ccr3 antagonists and toll like receptor 
agonists as potential targeted treatment for allergic airway disease (28,29).
Heterogeneity of asthma and allergic rhinitis 
In view of the heterogeneity of both asthma and rhinitis, assessment of tradi-
tional disease markers, including symptoms and lung function, does not suf-
fice for clinical monitoring and drug development. Especially in asthma, these 
measures appeared to be poorly related to the underlying airway inflamma-
tion (30). In addition, several factor analyses revealed that symptoms and lung 
function, markers of airway inflammation and airway hyperresponsiveness 
provide complementary information on the disease severity and activity of 
asthma in both adults and children (31,32). Hence, the combination of (as 
much as possible of) these outcome parameters is a prerequisite for future 
disease management and early drug development (33,34).
Biomarkers as efficacy measures in drug development/clinical 
monitoring
A biological marker (biomarker) is a physical sign or laboratory measurement 
that can serve as an indicator of normal biological processes, pathophysiolo- 
gical processes or pharmacological response to a therapeutic intervention 
(35). There is an ongoing exploration of new biomarkers that are closely 
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linked to asthma and allergic rhinitis. In principle, all biological compounds  
of the inflammatory cascade could serve as biomarkers. 
Biomarkers can be employed for various purposes, including diagnosis,  
staging, indicator of disease activity/progression or predictor of a treat-
ment response. Validated biomarkers are of major value in early clinical trials 
to establish “proof of mechanism” of novel drugs (36). Ideally, a biomarker 
should have the following characteristics (35):
Clinical relevance: i.e. there is a clear relationship between the bio- •	
marker and the pathophysiological events leading to a clinical endpoint.
Sensitivity and specificity for intervention effects. •	
Reliability and repeatability: the biomarker should be measured in a •	
preciseand reproducible way.
Simplicity of sampling methodology (preferably via non- or semi-invasi-•	
ve sampling techniques) and measurement to promote widespread use.
We propose that a combination of these properties make a biomarker 
“applicable” for research and development purposes. Implementation of 
biomarkers in early drug development has several advantages. They can be 
used as substitutes for clinical endpoints to demonstrate a significant treat-
ment effect in studies requiring long-term treatment or large study popula-
tions. Biomarkers also allow the possibility to explore the pathophysiological 
mechanism of novel interventions. However, since one biomarker may – if at 
all - capture only a small fraction of the intervention effect, it is important to 
sample multiple biomarkers whenever possible. Regulatory authorities, such 
as the emea and the fda, advocate incorporation of validated biomarkers 
into early clinical studies to speed up timelines of drug development (Critical 
Path Initiative; fda 2004). 
When implementing biomarkers in clinical trials or monitoring of asthma and 
allergic rhinitis, it is important to consider the heterogeneous nature of the 
inflammatory response which may affect the selection of adequate biomark-
ers (37). In addition, for proof of mechanism studies, one should bear in mind 
that airway inflammation is only present in patients and, not in non-atopic, 
healthy subjects. Hence, to assess efficacy of novel anti-asthma/allergy 
therapy, it is mandatory to move into patients as soon as possible in early drug 
development.
Applicability of inflammatory biomarkers in allergic asthma  
and allergic rhinitis
As described previously, multiple pro-inflammatory mediators are involved 
in the early and late allergic responses and a summary of the most important 
players is listed in Figure 1. 
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Consequently, sampling the airways for the measurement of inflammatory 
components adds novel information on the pathophysiology of disease, 
helps to validate novel biomarkers and generates a rationale for novel targets 
in drug development. For example, in the beginning of the 20th century, 
histamine was isolated from ergot extracts and its role in the pathophysiol-
ogy of anaphylaxis and allergy was elucidated in the subsequent years (38). 
Four decades later, this knowledge translated into the development of anti-
histamines. To date, anti-histamines are still the cornerstone of targeted 
pharmacotherapy for allergic rhinitis and other allergic disorders (39,40). 
More recent examples of targeted drugs are anti-leukotrienes and anti-IgE. 
In 1940 Kellaway and Trethewie discovered the ‘‘slow reacting substance of 
anaphylaxis’’, which appeared to constitute of leukotrienes (41). In the follow-
ing decades, the important role of leukotrienes in inflammatory processes, 
including asthmatic airway inflammation was established. In 1982, Bengt 
Samuelsson received the Nobel Prize for his extensive research in this field. 
This discovery lead to the development of anti-leukotrienes (leukotriene syn-
thesis inhibitors and leukotriene receptor antagonists) for the treatment of 
asthma. In the second half of the 1990s, these drugs were launched as a novel 
targeted class of anti-asthma therapy since 25 years (10). 
IgE is a hallmark of allergic disease and high serum levels are associated 
with an increased risk for the development of asthma in later life (42). 
Omalizumab (a humanized monoclonal antibody directed against circulating 
IgE) decreases levels of serum IgE. Based on its specific anti-inflammatory 
properties, Omalizumab effectively improved disease control allowing 
reduction of the daily ics dose in two-thirds of patients with allergic asthma 
and/or allergic rhinitis (43,44). Recent gina and aria guidelines implicated 
this drug as add-on therapy for the treatment of therapy-resistant, severe 
allergic asthma and ar (2,40,45). The therapeutic dose of Omalizumab is 
based on the body weight and should be guided by total serum IgE levels (46). 
However, not all mediators involved in the inflammatory cascade qualify for 
biomarkers or drug targets. It was anticipated that il-5, being the primary 
interleukin involved in eosinophil activation and recruitment would provide 
a new target for anti-inflammatory therapy (47). However, while a single intra-
venous dose of anti-il-5 (mepolizumab) produced a near-complete depletion 
of serum eosinophils, it failed to protect against allergen-induced lar and 
the associated ahr in patients with mild persistent asthma (48). Likewise, 
another anti-il-5 antibody, sch55700 failed to show any clinical efficacy in 
terms of symptoms, airway obstruction and ahr following a single intra-
venous dose (49). Based on a bronchial biopsy study evaluating the effects 
of 20 weeks of treatment with anti-il-5 therapy, it has been speculated that 
subtotal reduction in bronchial eosinophils may possibly account for the lack 
of clinical effect (50). In conclusion, these data underscore the importance 
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of ensuring that changes in the selected inflammatory biomarker translate 
into a clinically significant effect and targeting this biomarker with novel 
treatment should result in clinically meaningful improvements. In addition, 
samplings of the biomarker should preferably be conducted in the most rel-
evant environment, i.e. in the target organs, being the lung and nose, instead 
of the serum. Ideally, one mediator could serve as a biomarker of both asthma 
and ar. Cleaved Secretory Leukocyte Protein (cslpi) could potentially be 
such a mediator. It is present in both the lower and upper airways and is a bio-
marker of chymase activity in vitro (51). Chymase is a protease, released from 
mast cells, important effector-cells in the pathophysiology of allergic airway 
inflammation, ahr and airway remodeling (52,53). The in vivo role of cslpi is 
explored in this thesis.
Currently applied biomarkers in asthma 
In line with these observations, in recent years, several biomarkers derived 
from the airways were tested as predictors for disease control. An example, 
is the trial by Sont and colleagues comparing a treatment strategy aimed 
at reducing airway hyperresponsiveness (ahr strategy) with the asthma 
management according to current guidelines (reference strategy) to achieve 
long-term disease control in patients with mild to moderate persistent 
asthma (54). After 24 months, patients in the ahr group had better asthma 
control (expressed as improvement in lung function, exacerbation rate and 
ahr) albeit with a significantly higher dose of inhaled steroids as compared 
to the reference strategy group. Green and colleagues compared sputum 
eosinophils as a biomarker of asthma control versus the traditional disease 
parameters: symptoms and lung function in patients with moderate to severe 
persistent asthma (55). After 12 months it appeared that the treatment strat-
egy guided by sputum eosinophils was superior to the traditional approach, 
significantly reducing severe asthma exacerbations by over 60%. Interestingly, 
these effects were achieved at a comparable dose of inhaled corticosteroids  
as in the control arm. The development and validation of non-invasive sputum 
sampling thus enables studying and monitoring of the (kinetics of the) com-
ponents of airway inflammation. However, this technique requires multidisci-
plinary expertise and read-outs usually take several days or weeks. Therefore, 
sputum induction and analysis may be only feasible for a patient population 
regularly attending a specialized hospital and hampers its implementation 
into a primary care setting. This stresses the need of disease-related and 
treatment-responsive biomarkers, in combination with simple, non- 
invasive and reproducible, preferably online measuring capability. 
More recently, several studies in children and adults with chronic asthma  
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provided evidence for the applicability of exhaled nitric oxide (eno) mea-
surements, a still less–invasive, simple, online sampling method, as a bio-
marker of asthma control (56,57). As a result, measurements of eno have 
been implicated in the monitoring of asthma control according to current 
gina guidelines (2). These data underscore the usefulness of inflammometry 
in early clinical trials and in disease monitoring, warranting the development 
and validation of non-invasive sampling techniques such as exhaled breath 
condensate (ebc) analysis and the search for suitable biomarkers including 
the detection of smell prints (58-60).
The methodology of sampling techniques including their respective yield of 
inflammatory biomarkers from the lower airways are discussed in more detail 
in chapter 2 and evaluated in clinical trials in chapters 3-6.
Currently applied biomarkers in allergic rhinitis 
Sampling inflammatory mediators from the upper airway compartment 
may be equally valuable. Although no prospective long-term clinical trials 
for guiding anti-allergic therapy have been performed thus far, numerous 
studies have investigated the relationship between several components of 
upper airway inflammation, symptoms and response to treatment in patients 
with allergic rhinitis (61,62). Similar to asthma, in patients with seasonal 
allergic rhinitis, an increased numbers of effector cells, i.e. mainly mast cells 
and eosinophils, have been found in the nasal mucosa during pollen season 
(61). As compared with placebo, treatment with intranasal corticosteroids 
reduced the influx of these inflammatory cells together with improvement 
in symptoms. Likewise, in another study, treatment with intranasal corticos-
teroids decreased eosinophilic cationic protein (ecp), a marker of eosino-
philic degranulation, in patients with allergic rhinitis (62). This decrease was 
correlated with the decrease in symptom scores. Measuring eosinophils or 
ecp requires semi-invasive sampling techniques, like nasal lavage or nasal 
brushings. Although valuable, less-invasive sampling techniques are prefer-
able. Similar to the lower airways, no can be measured in exhaled nasal air 
in a completely non-invasive manner. So far, it has been found that nasal no 
(nno) is increased in patients with ar compared to healthy volunteers and 
is decreased following anti-inflammatory therapy (63). However, long term 
reproducibility of nno, its relationship to clinical symptoms and applicability 
in disease monitoring need to be further elucidated.
In summary, there are several non- and semi-invasive sampling techniques of 
the upper airways; many resembling the techniques used to sample the lower 
airways. However, unlike in the lower airways, many of the upper airways sam-
pling techniques still await validation. These techniques and biomarkers have 
been investigated in chapters 7, 8 and 9. 
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Aim and outlines of the present studies
Aim
The general aim of this thesis was to evaluate the feasibility and applicability 
of several non-invasive sampling methods and quantification techniques for 
the assessment of inflammatory biomarkers in allergic asthma and allergic 
rhinitis. 
Outlines
introduction
In the introduction (chapter 1), the rationale for the thesis has been provided 
in view of the current need of novel biomarkers for novel, targeted drug enti-
ties and to guide disease control. In addition, immunological and pathophysi-
ological characteristics of allergic asthma and allergic rhinitis are discussed. 
The inflammatory responses within allergic airways following allergen chal-
lenge are outlined, since this exacerbation model provides potential targets 
for (monitoring the response to) drug treatment. In addition, the advantages 
of incorporating biomarkers in early drug development and disease monitor-
ing are clarified. Chapter 2 provides an extensive overview of non-invasive 
sampling techniques (established and experimental) of inflammatory bio-
markers and quantification techniques that can be used in early clinical devel-
opment of novel drugs for asthma and potentially in disease monitoring.
clinical studies – allergic asthma
In the first clinical studies, we focus on allergic asthma to evaluate the 
feasibility and applicability of induced sputum, eno and ebc as sampling 
methods in allergic asthma. Chapter 3 is a good example of a methodologi-
cally sound approach to drug development. First, a proof of concept was 
established using the tachykinin nk1/nk2 receptor antagonist against its 
agonist, the neurokinin A challenge, in patients with mild persistent asthma. 
Subsequently, the proof of mechanism of this drug was tested in an allergen 
exacerbation model in patients with similar asthma characteristics. Apart 
from the more traditional allergen-induced airway responses (ear, lar and 
ahr), eno and sputum inflammatory markers were used to assess the effi-
cacy of the drug. In Chapters 4 and 5 the validity and applicability of eno as a 
biomarker of airway inflammation in asthma was extended. In Chapter 4, we 
investigated the effect of vigorous bronchodilation on eno levels following 
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an allergen-induced lar confirming evidence previously provided by Silkoff 
et al for the effect of airway diameter on eno (64). In chapter 5 the reliability 
and applicability of a novel hand-held device for measurement of exhaled no 
(Niox Mino®) in several subject populations was compared with a standard-
ized stationary chemoluminescence analyzer. In Chapter 6, we assessed the 
reproducibility of several novel sputum and ebc inflammatory markers from 
asthmatic patients quantified by novel processing- and detection techniques. 
Before implementation into clinical trials, novel techniques (sampling, pro-
cessing and detection) need to be tested for their validity. These validation 
steps have been summarized in a recent conference report on bioanalytical 
method validation (65). In our pilot study a first step is made towards valida-
tion of Luminex, Mesoscale and mrna quantification in sputum and ebc 
samples of asthmatics.
clinical studies – allergic rhinitis
In the second part of this thesis, the clinical studies focused on ar to evaluate 
the feasibility and applicability of nasal lavage, nasal brush and nno as sam-
pling methods in allergic rhinitis. In Chapter 7 the reproducibility of common 
markers of allergy, including serum IgE levels and skin prick test, was tested 
in combination with inflammatory markers in nasal lavage and nasal brush. 
Subsequently, the effect of a nasal allergen challenge versus the allergen’s 
diluent (=placebo) was tested on the kinetics of these biomarkers. In Chapter 
8, the applicability of nasal no measurements was evaluated for the monitor-
ing of allergic upper airway inflammation following a nasal allergen challenge 
in subjects with allergic rhinitis. 
clinical studies – allergic asthma & allergic rhinitis
Finally, Chapter 9 extends the biomarker search to Secretory Leukocyte 
Protease Inhibitor (slpi). The function of slpi is to protect tissues through its 
anti-protease properties and it may serve as a possible biomarker of chymase 
activity in allergic upper and lower airway disease.
discussion
Chapter 10 covers the discussion and conclusion sections and includes a criti-
cal evaluation of our data in relation to current literature offering a guideline 
for the selection of a relevant biomarker. In addition, speculations are made 
for future directions for biomarker research in asthma and allergic rhinitis. 
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Introduction
Asthma is a chronic disorder of the airways characterized by at least partly 
reversible airways obstruction, airway inflammation, hyperresponsiveness 
and remodeling. Furthermore, there is a systemic link to atopy, predisposing 
for IgE-related comorbidities, such as atopic dermatitis, allergic rhinitis/rhi-
nosinusitis and blood eosinophilia (1;2). Presently, asthma and related disor-
ders are considered complex and heterogeneous diseases. This has resulted 
in a paradigm-shift from a general to an individualized, and from a local to a 
systemic therapeutic approach for this ‘systemic airways disease’. 
Measurement of airway inflammation being the hallmark of asthma is crucial 
to assess the disease’s activity and severity. Although bronchial mucosal 
biopsies are still the gold standard (3), there are many disadvantages to this 
invasive and costly procedure. Therefore, an increasing number of non-
invasive sampling methods have been developed closely approaching or 
complementary to the gold standard (Figure 1) (4). Some of these methods 
have been validated and even included into clinical evaluation and therapy 
monitoring, whereas others are still in a more explorative phase. 
Airway hyperresponsiveness (ahr) has been shown to correlate with the 
degree of airway inflammation and remodeling and can be quantified by a 
direct bronchoprovocation test (5, 6). Such tests have been standardized  
and validated for the diagnosis and evaluation of asthma (7). In addition, some 
indirect bronchoprovocation tests (bpts), mimicking specific features of 
asthma, serve as disease models in early drug development trials.
With this review we aim to evaluate standardized and upcoming non-invasive 
and semi-invasive sampling methods and (in)direct bpts providing practi-
cal recommendations on their applicability for clinical monitoring or early 
clinical trials. This review provides an extension on the recommendations for 
clinical intervention trials in asthma (8).
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figure 1 Key features of asthma and possible sampling methods. eno = exhaled no, ebc = exhaled 
breath condensate, bal = bronchoalveolar lavage, amp = adenosine 5’ monophosphate,  
bpt = bronchoprovocation test.  
Sputum 
Sputum induction and processing technique 
Sputum induction has been explored since the 1990s and in 2002 the 
European Respiratory Society (ers) issued guidelines to harmonize the 
different techniques used worldwide (9). The recommended induction 
technique can be summarized as follows: prior to sputum induction, 200-
400 µg salbutamol is administered as a safety measure, followed by spirom-
etry to assess baseline Forced Expiratory Volume in one second (fev1). 
Subsequently, the entire procedure is carefully explained to the subject prior 
to commencing. The procedure has to be performed in a quiet, secluded 
environment to obtain the subject’s full cooperation. The hypertonic saline 
(NaCl 4.5%) aerosols are generated by an ultrasonic nebuliser with an aver-
age output of 1 ml/min hence producing a dose of about 5-7 ml per inhalation. 
During the procedure, subjects perform three to four inhalations by tidal 
breathing through a mouthpiece for 5-7 minutes each. According to guide-
lines, the same inhalation time should be maintained throughout the proce-
dure with a total duration of 15-20 minutes. After each induction, subjects  
are instructed to blow their nose, rinse their mouth and take a sip of water  
to minimize nasal and saliva contamination before expectoration of sputum.  
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To further minimize saliva contamination, subjects are either requested to 
spit saliva into another cup or sputum and saliva can be separated directly 
after collection but before processing. Both methods yield satisfactory 
results but are not interchangeable (10;11). During the procedure, all expec-
torations can be pooled in a pre-weighed plastic cup. After every inhalation, 
spirometry should be performed as a safety procedure. If the fev1 decreases 
by more than 20% from baseline, further induction should be discontinued 
and salbutamol administered. After the entire collection procedure, the 
obtained secretions should be processed within 2 hours according to stan-
dardized guidelines by a laboratory technician (11;12). 
Biomarkers in sputum
cellular phase
When performed according to ers guidelines, sputum cell counts can be 
performed in a reproducible and validated manner (13, 14). This applies espe-
cially for eosinophil and neutrophil counts (15). Eosinophils (and neutrophils 
in severe persistent asthma) are considered as key effector cells of the asth-
matic airway inflammation (16, 17). Increased eosinophil counts have been 
demonstrated in sputum samples both in validated models of asthma, such 
as allergen-induced late response, and in the actual disease (18). As compared 
with non-asthmatic volunteers, Louis et al showed increased sputum eosino-
phils and neutrophils in asthmatics (19). Moreover, the percentage inflam-
matory cells appeared to be related to disease severity, with further increase 
during exacerbations (20, 21). Conversely, anti-inflammatory interventions 
reduced sputum eosinophils both following allergen challenge and in ‘wild 
type’ asthma (22-27). In most studies, the reduction in sputum eosinophils 
was accompanied by an improvement in symptoms scores and lung function 
parameters. Green et al achieved superior asthma control applying a treat-
ment regimen aimed at reducing sputum eosinophils rather than aiming at 
improving symptom scores and lung function parameters (28). In general, 
sputum eosinophil count is a validated biomarker to sample airway inflamma-
tion that can be employed both in clinical setting and in early drug develop-
ment. 
fluid phase
Presently, numerous inflammatory mediators can be measured in the fluid 
phase of sputum (‘supernatant’), however the validity and reproducibility of 
several techniques has not yet been determined. Apart from the induction 
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technique, there are at least two other reasons that can account for this. First, 
processing of sputum may affect mediator measurements. Dithiothreitol 
(dtt) is added to the sputum sample, in most processing protocols, to free 
mediators by dispersing the mucus layer through cleavage of the disulphide 
bonds (11). However, dtt may also affect the disulphide bonds in the media-
tors (29). Second, varying dilutions may account for inaccurate measure-
ments among the samples and presently there is not yet a validated dilution 
factor to correct for this (12). ers guidelines recommend immunoassays as 
the method of choice to quantify mediators in sputum due to their reproduc-
ibility, specificity and improving sensitivity (12). 
granulocyte proteins
Eosinophil cationic protein (ecp) and myeloperoxidase (mpo) are granulo-
cyte proteins that can serve as activation markers of eosinophils and neutro-
phils, respectively. In sputum of asthmatics, (increased levels of) ecp have 
been found to be well-correlated with the eosinophil cell counts (30). In addi-
tion, anti-inflammatory treatment decreases both the eosinophils and ecp 
within the airways (25, 31). While measurements of ecp in sputum have been 
shown to be reproducible, mpo concentrations appear to be affected by spu-
tum induction and/or processing technique and therefore immunoassays 
are not always reproducible (29, 32, 33). 
leakage markers
Microvascular leakage is another aspect of airway inflammation that can be 
assessed by measuring the concentrations of leakage markers in the sputum 
of asthmatic patients. Based on several studies applying different induc-
tion and processing techniques, albumin and fibrinogen have been shown 
to be reproducible leakage markers correlating with the degree of airway 
inflammation. Pizzichini et al demonstrated increased levels of albumin 
and fibrinogen in sputum of asthmatics as compared with healthy controls 
(14). Two other studies found that increases in albumin and fibrinogen cor-
responded with asthma severity (20, 33). Apart from albumin and fibrinogen, 
another potential leakage marker has been studied in asthmatic subjects is 
α2-macroglobulin. Applying bptS with pro-inflammatory tachykinins in 
patients with asthma, van Rensen et al showed in patients with asthma that 
α2-macroglobulin (and albumin) appeared the best leakage markers (34). 
cytokines and chemokines 
These biomarkers are degraded by dtt. An extensive overview on cytokine 
and chemokine recovery from sputum is reported in the ers guidelines (13). 
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Several research groups have investigated modified sputum processing  
techniques to optimize recovery of these biomarkers with overall good 
results (35-37). However, these processing techniques are not fully validated 
and most of them prevented recovery of other mediators from the samples. 
As an exception, il-8, potent neutrophil chemoattractant , seems less  
affected by dtt and can be quantified by a validated immunoassay (29, 38).  
In several studies, increased reproducible levels of il-8 have been demon-
strated during asthma exacerbations and in patients with severe persistent 
asthma (38, 39). Hence, il-8 is a validated marker for the assessment of  
drug efficacy in more severe asthma and for monitoring of asthma exa- 
cerbations. 
eicosanoids 
Leukotrienes (lts) and isoprostanes are derivates of arachidonic acid. Both 
groups of inflammatory mediators are involved in the pathophysiology of 
asthma (40, 41). Cysteinyl leukotrienes (Cys-lts) are mainly released from 
activated mast cells and eosinophils. As compared to healthy controls, 
increased levels of these bronchoactive mediators have been measured 
in several body fluids of asthmatic subjects, including sputum (42, 43). 
Moreover, the concentration of Cys-lts was found to correlate with disease-
severity and was not affected by corticosteroids (57). 
F2-isoprostanes are considered specific markers of oxidative stress (44). 
These mediators are involved in the pathophysiology of inflammatory dis-
eases, including asthma and copd. 8-Isoprostane is the most extensively 
studied isoprostane, and reproducible levels have been measured in sputum 
and exhaled breath condensate (ebc) of both healthy and asthmatic subjects, 
with higher levels in those with more severe disease (45). In agreement with 
these data, increased levels of this eicosanoid have been reported during 
asthma exacerbations (45). Similar to Cys-lts, 8-isoprostane is relatively inert 
to treatment with corticosteroids (46). Hence, both Cys-lts and 8-isopros-
tane are useful markers of airway inflammation and oxidative stress in disor-
ders including asthma. 
proteases
Matrix metalloproteinases (mmps) are members of a large family consisting 
of calcium and zinc dependent enzymes. Several mmps are involved in the 
process of extracellular matrix degradation and are considered key players 
in airway remodeling occurring in e.g. asthma, copd and lung fibrosis (47). 
In the process of remodeling, there is a critical balance between mmp-9 and 
its counterpart, tissue inhibitor of metalloproteinases (timp). In asthma, 
increased levels of mmp-9 have been found in sputum, bal and bronchial 
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biopsies (48-52). In addition, several investigators reported an imbalance 
between mmp-9 and timp, resulting in a disease-severity dependent increase 
of the mmp-9/timp ratio (48, 49, 53). In agreement with these data, allergen 
challenge has been shown to induce further increase in mmp-9, without 
increasing timp levels both in sputum and bronchoalveolar lavage (bal)  
of asthmatic subjects (48, 49, 52). This mmp-9/timp imbalance may at  
least partly account for the allergen-induced airway remodeling in asthma. 
In conclusion, mmp-9/timp ratio in sputum is a potential marker for  
monitoring effects of interventions directed against airway remodeling.
Limitations of induced sputum
Only trained personnel should perform sputum inductions and careful 
patient instruction is needed prior to the procedure to ensure safety of the 
subject. Processing and analysis of the sputum samples are time-consuming 
and expensive procedures which require a well-equipped laboratory includ-
ing a technician and an experienced cytopathologist. Furthermore, the 
results are not immediately available.
Not all patients are able to expectorate sputum and not all sputum samples 
are suitable for analysis. On average, sputum induction is successful in only 
80-90% of adult patients and approximately 30% of asthmatic patients have 
normal sputum eosinophil counts (19, 28, 33, 54-56). In children (6 years and 
older) the percentage of successful inductions is significantly lower, around 
80% (57, 58). In addition, the procedure should not be performed in patients 
with unstable or severe persistent asthma and those with moderate to severe 
disease should be carefully monitored during the induction process for the 
occurrence of sudden severe bronchoconstriction (59, 60). 
Since sputum induction may affect the composition of the inflammatory 
cells and mediators within the airways, serial sputum inductions cannot be 
readily performed within a short time-interval, which may be a disadvantage 
in a clinical trial setting (61, 62). According to recommendations, a wash-out 
interval of at least 2 days should be allowed between two serial inductions 
to prevent potential carry-over effects (9, 63). Another disadvantage of the 
procedure is that most patients find the procedure strenuous and sometimes 
even embarrassing.
Summary and recommendations - sputum
Sputum is defined as secretion originating from the lower airways. Sputum 
induction by inhalations of hypertonic saline promoting expectoration is 
a validated method both for research and diagnosis. The obtained sputum 
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samples can be divided into a ‘solid’ phase consisting of cells, and a fluid 
phase containing soluble mediators. Both components can be quantified to 
assess the presence and activity of inflammatory markers. Sputum induc-
tion can be regarded as a semi-invasive procedure and is safer, cheaper and 
generally easier to perform than bronchial biopsy or bal but more trouble-
some than exhaled nitric oxide (eno) or ebc. Over the last fifteen years, a 
large amount of research has contributed to validation and standardization 
of the technique. A recent ers Task Force document has been issued relat-
ing on recommendation and guidelines for standardized induction, collec-
tion, processing and analysis of sputum (13). Although airway sputum, bal 
and bronchial mucosal biopsy provide samples from different lower airway 
compartments (64), a reasonable relationship has been found between these 
techniques providing similar information on the inflammatory airway com-
ponents (54, 65). In addition, the recommended sputum induction protocol 
can be modified to enable differentiation between inflammatory cells from 
central and distal airways (66). In conclusion, induced sputum is a validated 
tool suitable for monitoring lower airway inflammation both in patient care 
and in early drug development. The pros and cons of sputum induction are 
summarized in Table 1.  
Nitric Oxide (no)
no measurement technique 
In 2005, the American Thoracic Society (ats) issued updated recommenda-
tions for the measurements of no from the upper and lower respiratory tract 
(67). Although various methods have been reported, the online measure-
ment during a single-breath exhalation against a fixed resistance is currently 
the recommended sampling technique. This highly reproducible method 
has been standardized and is now widely used (68, 69). This technique can be 
summarized as follows: subjects are seated in front of a pc-screen while wear-
ing a nose-clip, and instructed to blow into the no-analyser with a constant 
flow rate (50 mL/s) for approximately 20 seconds. Blowing against a resis-
tance ensures soft palate closure and prevents contamination with no from 
the upper respiratory tract. A constant flow rate is important for a representa-
tive measurements, since no is markedly flow dependent (70). After several 
seconds of expiration, an no plateau is reached and the no level is measured 
online by a chemoluminescence analyser. no is expressed in parts per billion 
(ppb) and measurements are repeated until three reproducible values are 
obtained within 10%. Repeated measures do not affect the results.
31 section 1 – a critical appraisal of methods used in early clinical development   
 of novel drugs for the treatment of asthmas
table 1 overview of the most relevant advantages and disadvantages of the 
discussed techniques.
sputum induction exhaled no exhaled breath 
condensate
bronchoprovo-
cation tests
Pro’s -Multiple biomarkers 
-Reproducible cell 
differentials on cyto- 
spins
-Valid tool for  
assessment of anti-
inflammatory therapy
-Non-invasive
-Reproducible
-Inexpensive 
measurements
-Direct results
-Allows serial 
measurements
-Tool for assessment 
of anti-inflammatory 
therapy  
-Non-invasive
-Multiple biomarkers
-Allows serial 
measurements 
-Potential tool 
for assessment of 
anti-inflammatory 
therapy
-Reproducible
-Direct results
-Valid tools/models  
for assessment of 
anti-inflammatory 
therapy
Contra’s -Semi-invasive
-Expensive & time-
consuming procedure  
& analysis 
-Representative samples 
available in approx.  
80-90% of subjects
-Soluble markers 
subject to dilution
-Non-repeatable over 
short time-period 
(<48 h)
-Experienced personnel 
needed (md/cytopatho- 
logist/lab) 
-Rescue medication 
needed
-Contraindicated 
in severe persistent 
asthma/copd/active 
cardiovascular disorders
-Expensive 
equipment
-Many perturbing 
factors
-Longitudinal 
samplings within 
1 patient are 
more informative 
than single 
measurements
-Assays not fully 
reproducible
-Expensive & time-
consuming proce- 
dure/assays
-Soluble markers 
subject to dilution
-Specialized lab  
needed
-Semi-invasive
-Experienced 
personnel (md/
technician) needed
-Non-repeatable 
over short time-
period (>6h-3wk)
-Rescue medication 
needed
-Contraindicated  
in severe persis- 
tent asthma/copd/ 
active cardiovascular 
disorders
Overall 
assessment
-Validated tool for 
monitoring of anti-
inflammatory drug- 
effects 
- Lengthy, expensive 
procedure
- Not suitable for 
patients with severe 
bronchoconstric- 
tion/comorbidities 
-Validated tool for 
monitoring of anti-
inflammatory drug-
effects
- Patient & 
researcher-friendly 
method
- Procedure awaits 
further validation
- Patient & 
researcher-friendly 
method
-Validated tools 
for monitoring 
of ahr and anti-
inflammatory  
drug-effects
-Some bpts are 
standardized models 
of asthma 
- Not suitable for 
patients with severe 
bronchoconstric- 
tion/comorbidities 
Refs* (9, 11, 12, 14, 60, 208) (4, 67, 108, 209) (110, 112, 113, 148, 210) (7, 153, 154)
* Position papers and reviews/ahr: airway hyperresponsiveness/bpts: bronchoprovocation tests
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Although ambient no appears to have no effect on eno, most analyzers 
are equipped with a scrubber to ensure subjects inhale no-free air prior to 
the exhalation manoeuvre. The results can be viewed online, which allows 
incorrect manoeuvres and values to be discarded. Correct operation of the 
equipment is relatively easy and does not require extensive training. In addi-
tion, performing (serial) measurements does not impose a great burden on 
patients and can be easily explained, which is ideal for young children (appli-
cable from 4-5 years).
no as a biomarker of airway inflammation
Exhaled no is a sensitive marker of acute airway inflammation. In asthma, 
acute airway inflammation implies either loss of control or exacerbation.  
In clinical trials, this can be induced either by allergen challenge or by 
tapering off anti-inflammatory therapy (mainly corticosteroids). 
Allergen challenge, especially the late asthmatic response (lar), is a well-
known inducer of airway inflammation (71). Kharitonov et al reported a clear 
correlation between the size of the lar and allergen-induced increase in eno 
10 hours post-allergen (72). Similarly, several tapering studies have shown 
that loss of asthma control is associated with an increase in eno (21, 58, 73). In 
addition, these studies demonstrated that the change in eno is a better pre-
dictor for loss of asthma control than baseline eno per se. However, Leuppi et 
al found no increase in eno during asthma exacerbations as a result of taper-
ing off inhaled corticosteroids (ics) (74). This aberrant observation may be 
due to measuring eno offline in contrast with online measurements used in 
other studies. 
Exhaledno is very responsive to anti-inflammatory therapy. ics have been 
shown to produce a dose-dependent reduction in eno, preceding the 
decline of other disease-related parameters (75, 76). Other anti-inflammatory 
therapies for asthma, including leukotriene receptor antagonists (ltra) and 
anti-IgE, have also been shown to reduce eno both in children and adults (77, 
78). Several studies report a correlation between eno and other markers of 
airway inflammation and responsiveness in asthma which adds to its applica-
bility as a valid biomarker for clinical monitoring and early drug development. 
Jatakanon et al showed significant correlations between eno, sputum eosino-
phils and pc20 methacholine in steroid naïve patients with mild persistent 
asthma (79). These data have been confirmed and extended by Dupont et al 
who found a correlation between eno and pc20 histamine in patients with 
similar asthma characteristics (80). However in asthmatics using ics, the  
correlation between the different markers of airway inflammation and 
responsiveness is lost (81, 82). This is due to a fast decrease of eno attaining  
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a maximal response even on low dose ics therapy, resulting in almost normal 
eno levels, while airway inflammation and hyperresponsiveness are still pres-
ent. Therefore, eno should probably not be used as the sole marker of airway 
inflammation in asthmatics using corticosteroids.
table 2 reference eno values measured in clinical studies
subjects n*  
(number  
of subjects)
eno mean** 
(ppb)
interquar- 
tile range 
(ppb)
reference
Atopic asthmatic adults*** 44 58.5 30.4 – 85.5 (68, 211)
Non atopic asthmatic adults 30 18.9 14.6 - 33.4 (211, 212)
Atopic asthmatic children*** 118 25.7 11.4 – 56.2 (68, 105, 106)
Atopic non asthmatic adults 67 27.6 11.3 – 49.3 (211, 212)
Non atopic non asthmatic adults 158 15.9 11.5-21.7 (68, 211, 212)
Non atopic non asthmatic 
children
332 8.8 N.A. (213)
Cystic fibrosis 83 5.3 3.3 – 8.5 (214, 215)
Effect of corticosteroid intervention on eno levels in patients with asthma
subjects eno  
before
eno 
after
% 
change 
reference
Corticosteroid treatment 
> stable asthma 
52 75.2 34.0  -54.8% (75, 216, 217)
Tapering off corticosteroids  
> unstable asthma
67 9.8 21.8  +122.4% (21, 73)
All measurements were performed with an online chemoluminescence analyzer. 
n.a. = not applicable, eno = exhaled no. *Total number of subjects from all studies combined,  
**Median was used as mean when necessary, ***Patients with mild to moderate persistent 
asthma without maintenance therapy.
Limitations of eno
The equipment used for online measurement of eno is bulky and expen-
sive. Recently, a handheld and less costly no meter, niox mino®, has been 
introduced, yielding reproducible no measurements similar to the station-
ary chemoluminescence no-analyzer (83). The availability of smaller and 
cheaper devices will enable future no measurements to be applied at larger 
scale, including non-academic hospitals and extramural care. 
Exhaled no appears to be dependent on airway calibre. Recent studies  
have shown decreased eno on bronchoconstriction, e.g. following allergen 
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challenge, with an increase after bronchodilatation (84-87). As asthmatic 
patients often have unperceived bronchoconstriction, eno values may 
be underestimated. Applying maximal bronchodilation with short-acting 
β2-agonists before eno measurements, may be a good option to correct for 
this perturbing factor (84). 
Unlike ebc and sputum, eno depicts only one single component of the 
inflammatory response within the airways, while its origin is difficult to 
assess. Recent studies have proposed a two-compartment model to discrimi-
nate between alveolar (representing the small airways) and conducting air-
ways contribution (88, 89). Using this model, Lehtimaki et al demonstrated 
that increased eno is mainly derived from the larger airways, as in both 
steroid-naïve patients with mild-to-moderate persistent asthma and nonas-
thmatic controls comparable alveolar no levels were measured. Moreover, 
treating these patients with ics established a decrease in airway no levels 
but failed to reduce alveolar no (90, 91). Similar findings have been reported 
in patients with mild-to-moderate persistent asthma and nonasthmatic con-
trols, whereas in those with severe disease, alveolar no was increased despite 
ics and reduced by oral prednisolon (92). In this study alveolar no appeared 
to be well correlated with eosinophils in bal. Hence, these findings suggest 
that in severe persistent asthma alveolar no is a potential marker for distal 
airway inflammation that cannot be easily reached by ics. 
Many factors appear to affect eno levels including atopy status, airway cali-
ber, medication, nitrate rich food, smoking and airway infections (67, 93-96). 
Both in clinical practice and in clinical trials, these perturbing factors should 
be anticipated or corrected for to enable comparison of representative eno 
values within one subject, among subjects and across studies.
Summary and recommendations - no
Nasal no is produced in the upper respiratory compartment, while eno 
mainly comes from the lower airways following synthesis from L-arginine 
by constitutive (cnos) and inducible no (inos) synthases (97). cnos is 
expressed in neuronal, endothelial and epithelial cells under baseline con-
ditions, whereas inos is mainly expressed in inflammatory, epithelial and 
airway smooth muscle cells and can be further upregulated by inflammatory 
cytokines (98). Exhaled no can be measured in exhaled breath of several 
species, including humans (99, 100). Increased inos expression has been 
demonstrated in bronchial biopsies of asthmatic patients as compared with 
healthy controls (101). In agreement with these data, increased no levels 
occur in exhaled air from patients with asthma with further increase during 
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exacerbations (72,102). In addition, inos inhibitors, such as alcohol and  
corticosteroids, have been shown to reduce the expression of inos and 
consequently reduce eno levels in asthmatic subjects, but not in (non)
atopic, non-asthmatic controls (103, 104). Furthermore, eno concentrations 
appeared to correlate with IgE levels and the number of positive skin prick 
test wheals (105). Similarly, atopic asthmatics have been shown to produce 
higher levels of eno than non-atopic asthmatics and higher eno levels have 
been reported in atopic subjects as compared with non-atopic controls 
(Table 2) (93, 106, 107).
Taken together, upregulated inos expression accounts for high eno con-
centrations in asthma and eno levels have been shown to relate to atopy 
status and disease severity. Although increased eno is not a prerequisite 
for asthma only, measuring eno is an established tool for the assessment of 
airway inflammation and a validated marker in interventional trials with anti-
inflammatory asthma therapies. The pros and cons of eno measurements 
are summarized in Table 1.
Exhaled Breath Condensate
Collection of ebc
Several collectors and condensers are currently available (109-111). All devices 
are easy to use and both young and old subjects can easily perform the pro-
cedure (Figure 2). In most protocols, subjects have their nose clipped while 
breathing through a mouthpiece into a non-rebreathing valve connected to 
a tube of variable length for approximately 15-30 minutes (112). During the 
procedure, the exhaled breath travels through the tube that serves as a cool-
ing chamber and the thus formed condensate is collected (usually around 
2 mL/sample) in a cooled collection chamber. Cooling of the samples is 
advised to preserve “thermo-labile” markers (112). Subsequently, samples 
can be directly analysed or frozen pending analysis. The non-rebreathing 
valve ensures separation of in- and expiratory air and prevents rebreathing of 
exhaled samples. Exhalation flow affects the composition of ebc. Therefore, 
flow variations should be limited during each procedure. The long duration 
of sample collection makes fixed exhalation flow rate - commonly applied in 
eno measurements - impossible. Hence, following subject’s acclimatization, 
tidal breathing over a predefined time-interval is probably the best way to 
minimize influence of exhalation flow rate on the ebc composition. Using  
a fixed exhaled volume may be a good alternative.
36 non-invasive sampling methods of inflammatory biomarkers in asthma  
 and allergic rhinitis
figure 2 Schematic diagram of an exhaled breath condensate collecting device (reproduced and 
modified with permission from (207)
Biomarkers in ebc
hydrogen peroxide
Hydrogen peroxide (h2o2) is formed when o2- released by activated inflam-
matory cells such as neutrophils, macrophages and eosinophils, undergoes 
spontaneous or enzymatic dismutation. Hence, h2o2 is a potential marker 
of oxidative stress common in many inflammatory conditions (113). Indeed, 
reproducible increased concentrations of h2o2 have been measured in active 
smokers and patients with more severe asthma and an inverse correlation 
between fev1 and h2o2 has been found (114-117). In these patients anti-
inflammatory drugs, such as ics, have been shown to reduce exhaled h2o2 
accompanied by improvements in fev1 (114, 118). 
The stability after collection is an important advantage of measuring h2o2 
(119, 120). However, in several healthy subjects and in some asthmatics with 
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mild disease h2o2 concentrations remained below the detection limit (116, 
120). Therefore, more sensitive assays are required to study airway inflamma-
tion in these patients. 
eicosanoids
Leukotrienes and isoprostanes are involved in the pathophysiology of inflam-
matory disorders including asthma and copd. These eicosanoids can be 
measured in ebc by an enzyme immunoassay (eia) or by gas chromatogra-
phy/mass spectrometry (121). As compared with non-asthmatic controls, 
increased levels of cys-lts have been detected in asthmatic subjects. Similar 
with measurements in sputum, cys-lts levels in ebc appeared to be cor-
related with disease severity and could be reduced by anti-inflammatory 
drugs (122, 123). Leukotriene B4 (ltb4) is released by activated neutrophils; 
increased levels have been found in patients with severe persistent asthma 
and copd (122,124, 125). In these patients, sputum ltb4 levels have been 
shown to correlate with those in ebc. 
Conform with sputum, in ebc 8-isoprostane is the most extensively studied 
prostanoid for its stability and good detectability in both healthy state and 
disease (126). In asthma, 8-isoprostane ebc concentrations have been found 
to be correlated with levels of eno (127). However, 8-isoprostane levels 
appeared to correlate with asthma severity while eno does not. Unlike eno, 
8-isoprostane is not completely suppressed by corticosteroid treatment. 
Hence, 8-isoprostane is a potential indicator for ongoing airway inflammation 
despite anti-inflammatory treatment and hence may be a useful marker for 
asthma control (123, 127, 128). Moreover, recent data suggest a link between 
8-isoprostane concentration in ebc and small airways inflammation (129). 
no derived products
no within the airways can react with o2 yielding no-derived products,  
no2- and no3-. Unsurprisingly, no2- and no3- levels are increased in ebc  
of asthmatics and corticosteroids have been shown to reduce these inflam-
matory markers (130, 131). 
Nitrotyrosine is another stable end-product of no and o2-, detectable in  
ebc of healthy subjects and three-fold increased in steroid-naïve patients 
with mild persistent asthma (124). In correspondence with other no-deri-
vates, inhaled and oral corticosteroids reduced nitrotyrosine levels in asthma 
below those of healthy controls (124). Unsurprisingly, nitrotyrosine and no 
appeared to be correlated (124).
Nitrosothiol a metabolite of no and gluthatione is yet another no-derivate. 
Elevated concentrations of this biomarker have been found in ebc of patients 
with severe persistent asthma, as compared with mild asthmatics and 
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healthy, non-asthmatic controls (132). Similar to other no-derived products, 
nitrosothiol is a potential marker of asthma severity and control.
ph
Measurement of pH in ebc is relatively simple and inexpensive as compared 
with other biomarkers. Furthermore, several studies have reported that pH 
measurements are reproducible and not affected by temperature or duration 
of collection, airway obstruction, oral ammonia or storage (133, 134). Using 
different collection devices, a number of research groups have measured 
pH in ebc of healthy subjects yielding an average pH of around 7.8, whereas 
in asthma the average pH was found below 7.5 (133-137). Asthma exacerba-
tions result in further decline of pH with reversal following corticosteroid 
treatment (137). This corresponds with other studies showing a higher pH in 
steroid-treated patients as compared with steroid-naive asthma controls.  
The low costs, good reproducibility in combination with the availability 
of reference values are major advantages of pH measurements over other 
inflammatory markers in ebc. 
cytokines and chemokines
Several cytokines and chemokines including il-4, tnf-α, macrophage-
derived chemokine, and eotaxin have been detected in ebc of asthmatics 
(138, 139). The most striking ebc data so far have been reported in steroid-
naïve asthmatic children by Shahid et al showing an increase in il-4 com-
bined with a decrease of ifn-y (140). Following treatment with ics, the il-4 
and ifn-y levels returned within the ranges of healthy controls. These data 
clearly demonstrate the Th2-driven cytokine profile in human asthma and the 
modulating effects of anti-inflammatory therapy. However, in all these stud-
ies some cytokine and chemokine measurements could not be reproduced 
in all subjects and other investigators fail altogether in measuring cytokines 
in ebc (141). Hence, the methodology awaits validation and more sensitive 
assays are needed. 
Limitations of ebc and potential remedies
ebc has several limitations. Until recently there has been no consensus on 
the collection and storage techniques which complicates correct comparison 
and interpretation of data across different studies. Commercially available 
condensers in combination with a recent Task Force publication provid-
ing guidelines for standardization of collection and storage procedures are 
expected to solve most of these issues in the future (112, 142-144). The ers/
ats task force document provides a review of several protocols using differ-
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ent condensers yielding reproducible data of specific measurements in ebc. 
Using the RTube® (Respiratory Research, Inc., Charlottesville, va, usa), 
Vaughan et alshowed reproducible pH measurements in ebc of asthmatics 
(134). The Cryocond® (Boehringer Ingelheim, Burlington, Canada) has been 
used in several studies yielding reproducible h2o2 measurements in ebc 
of subjects with asthma and allergic rhinitis (77, 145). Ecoscreen® (Jaeger 
GmbH, viasys Healthcare, Hoechberg, Germany) is still another com-
mercially available condenser providing reproducible levels of sodium and 
chloride in ebc of healthy volunteers, children with asthma and cystic fibrosis 
(146). 
An even greater concern is the poor availability of sensitive assays yielding 
reproducible measurements (116, 146). Ideally, biomarkers should present 
well within the concentration range of sensitive and reproducible assays. 
Moreover, there should be a well-defined concentration range between 
healthy state and disease. However, partly due to dilution, the concentration 
of the majority of the inflammatory markers in ebc is generally in the range of 
the lower detection limit of most assays. Tufvesson et al report two potential 
processing strategies to improve measurements of several inflammatory 
markers in ebc, i.e. sample concentration and coating of collectors to mini-
mize absorption to plastic material (147). Both methods await standardiza-
tion.
Another obstacle in interpreting ebc data is the dilution factor. The airway 
lining fluid captured in ebc is variably diluted during the collection process 
(148). Extrapolation to the original concentrations within the airways is only 
possible applying a dilution factor (149, 150). Presently there is no validated 
dilution factor. 
Yet another inconsistency is the composition of an ebc sample including 
various components of different origin, coming both from different parts of 
the respiratory and from the digestive tract. Unfortunately, it is not possible 
to designate the relative contribution of these sites to the exhaled media-
tors. However, there are some devices and methods being applied to prevent 
excessive saliva contamination, such as a saliva trap or allowing the subject 
to rinse the oro-pharynx prior to collection and swallow accumulated saliva 
during collection. Furthermore, applying different flow-rates may enable dis-
crimination between central and peripheral airways (151).
Summary and recommendations – ebc
ebc is a new sampling technique for various markers of inflammation in in- 
flammatory airway diseases including asthma. ebc is a potential tool for mon-
itoring anti-inflammatory effects of novel drugs. Being a simple, non-invasive 
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procedure requiring uncomplicated and inexpensive equipment are its main 
advantages over bronchial biopsies, bal and induced sputum (134, 148).
Exhaled breath consists of two phases: the gaseous phase, containing volatile 
substances such as no and carbon dioxide (co2), and a liquid phase contain-
ing non-volatile components including water-soluble inflammatory markers 
(113). The non-volatile ions and proteins originate from the airway lining fluid. 
These entities are aerosolized due to local turbulence to become liquid con-
stituents of ebc (143). 
So far, there has been no standardization of ebc sample collection or analysis 
and this needs to be solved before results can be interpreted, compared and 
its clinical applicability can be assessed. These issues have recently been 
largely addressed by an ats/ers task force resulting in novel ebc guidelines 
(112). Overall, ebc seems a promising tool for both research and clinical moni-
toring. So far, several markers of airway inflammation have been detected in 
the ebc of asthmatics, including hydrogen peroxide, leukotrienes, isopros-
tanes, no-derived products, pH, chemokines, cytokines and adenosine (113, 
148,152). In addition, measurement of drug concentrations in ebc may allow 
studying the link between pharmacokinetic properties and pharmacody-
namic effects in the future. The pros and cons of ebc measurements are sum-
marized in Table 1.
Bronchoprovocation tests 
Methodology of bpts
The ats and ers have issued several guidelines for standardized bpts or chal-
lenges with both direct and indirect challenges. These guidelines address 
methodology, recommended equipment and preparation of pharmacologic 
agents (7, 153, 154).
Methacholine is the most common direct bronchoconstrictor stimulus 
applied for both diagnostic and research purposes (Figure 3 and Table 3). Two 
challenge methods are being recommended in the guidelines: the 2-minutes 
tidal breathing method with 2-fold concentration increases and the 5-breath 
dosimeter method with 4-fold increases (7). In the 2-min tidal breathing 
method, up to 10 consecutive doubling concentrations of methacholine 
are placed in a jet-nebulizer and aerosolized (0.13 mL/min) with a constant-
output compressor. Patients are instructed to perform tidal breathing for 2 
min through the mouth with the nose clipped. Airway response is measured 
after each concentration step over the subsequent 3-min period by fev1 and 
expressed as % fall from baseline fev1. In the 5-breath dosimeter method, 
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patients slowly inhale 5 breaths from functional residual capacity to total lung 
capacity (i.e. a slow deep breath) through a dosimeter-driven nebulizer con-
taining up to 5 fourfold concentration increases of methacholine. After each 
manoeuvre, patients are instructed to hold the breath for 3-5 seconds. Airway 
response is measured by fev1 before and 3 min after each concentration step. 
In both protocols, challenges are repeated at 5 min intervals until the fev1 
falls by at least 20% from baseline fev1. The provocative concentration caus-
ing a 20% fall in fev1 (pc20) is calculated by extrapolation and is indicative of 
the degree of ahr (range: no ahr, mild, moderate, severe ahr, respectively). 
After challenge, a short-acting β2-agonist is administered for immediate 
bronchodilation and fev1 is measured after 10 minutes to assure lung func-
tion returns within baseline values. bpts usually last up to 60-70 minutes, 
depending on the degree of ahr and the protocol used.
Although both methods are reported to be reproducible in clinically stable 
subjects, there are important differences that may affect the outcome in 
some asthma patients (7, 153). Cockcroft and co-workers found that specifi-
cally in subjects in whom mild ahr was found using the 2-min tidal breathing 
method, no measurable ahr could be detected using the 5-breaths dosim-
eter method (155). This difference can be explained by the bronchodilator 
effect of the dosimeter method, which reduces the sensitivity of the test  
specifically in patients with mild ahr.
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indirect challenges 
Indirect challenges comprise a heterogeneous group of pro-inflammatory 
stimuli. The methodologies slightly differ across the spectrum of the chal-
lenges. The majority of indirect challenges has been standardized and basical-
ly follows the same principle as a direct challenge. During these tests subjects 
are exposed to serial increasing concentrations of a pharmacological agent 
or increasing exposure to exercise resulting in a fall in fev1 as compared with 
baseline. Airway response measurements and safety precautions are similar 
to those in methacholine challenge and are described in the ers guidelines 
and a recent ers task force report (7, 154). The most commonly used indirect 
challenges have been standardized and validated (Table 3).   
Bronchoprovocation tests and their clinical relevance
pc20methacholine: marker of ahr and airway remodeling versus 
airway inflammation
Methacholine bpt is the preferential test to assess and quantify ahr by 
pc20. According to previous evidence, the wash-out period between two 
consecutive methacholine challenges varies from zero up to 24 hours in 
asthma and up to 6 hours in nonasthmatic subjects (156, 157). Two landmark 
studies investigated the relationship between methacholine-induced ahr 
and airway inflammation and/or remodeling (5, 6). In patients with mild-to-
moderate persistent asthma, Sont et al compared a treatment strategy aimed 
at improving ahr with the existing strategy aimed at improving symptoms 
and lung function (5). After 24 months, patients treated according to the 
ahr-strategy had a lower exacerbation rate corresponding with a reduced 
number of eosinophils in bronchial biopsies as compared with the reference 
strategy. Furthermore, subepithelial reticular basement membrane (rbm) 
thickness, a feature of airway remodeling, was significantly reduced in the 
ahr-group as compared with the reference group. Comparable observations 
were reported in patients with similar asthma characteristics by Ward et al 
after 12 months of treatment with high doses of ics (6). Following longterm 
anti-inflammatory therapy, the changes in pc20 methacholine and rbm-
thickness, being one of the characteristics of airway remodeling, appear to  
be interrelated (6).
In contrast with these data, the relationship between pc20 methacholine  
and markers of airway inflammation has not been unanimously demonstrat-
ed. Although several studies reported a good correlation between metha-
choline sensitivity and markers of airway inflammation (5, 28, 158, 159), other 
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studies did not find such relationship (160). These contradictive data may 
be the result of different patient characteristics, methodologies and/or 
treatment regimes and remain to be clarified.
indirect challenges: inducers of airway inflammation and models  
of asthma
In contrast with the direct stimuli, there is a variety of indirect airway chal-
lenges interfering with different pathophysiological mechanisms within the 
airways. These indirect stimuli possess varying mechanisms of action with 
a gliding scale between direct to indirect as schematically depicted in figure 
3. Depending on their (specific) mode of action, several indirect challenges 
can be applied for various purposes, including monitoring or research of 
pathophysiological mechanisms and proof of principle/concept studies in 
asthma. In the following paragraphs, the most important and validated indi-
rect challenges will be addressed (7, 153, 154).
amp challenge
Adenosine 5’ monophosphate (amp) releases inflammatory mediators 
from activated mast cells. Recent studies in asthma have shown that airway 
responsiveness to amp - expressed as pc20 amp - is a valid marker of airway 
inflammation (154). Furthermore, pc20 amp has been shown to be more 
sensitive to ics and high altitude than pc20 of other direct or indirect agents 
including methacholine or bradykinin (6, 154, 161, 162). In several intervention 
studies, there was a fast-onset, ics-dose-dependent improvement in pc20 
amp which correlated with a significant reduction in inflammatory markers 
and improvement in asthma symptom scores (163-165). Thus, amp is a sensi-
tive marker of fluctuations in airway inflammation during a relatively short 
time interval. Whether this is relevant for monitoring chronic inflammation 
remains to be established.
exercise challenge and cold, dry air challenge
Exercise and the related cold, dry air challenge have been shown to induce 
bronchoconstriction in 70-80% of asthmatics (166). Although the underlying 
mechanisms are still incompletely understood, there is evidence of mast-cell 
triggered mediator release and neural reflexes contributing to the pathophys-
iology of these airway responses (153, 167). Indeed, intervention with antileu-
kotrienes, antihistamines and neurokinin receptor antagonists have been 
shown to protect against exercise/cold dry air-induced bronchoconstriction 
in patients with asthma (168-171). Presently, these indirect challenges are 
applied as standardized models of mast-cell mediated mechanisms in asthma 
in proof of concept studies with new drugs or for diagnostic purposes (7, 154).  
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allergen challenge
Inhalation of serial increasing concentrations of a standardized allergen 
extract, the so-called allergen bpts or allergen challenge, is the most useful 
preclinical model of asthma (7). This indirect challenge can be conducted in 
two ways: inhalation of aerosolized allergen or local instillation of allergen 
into a pulmonary segment via bronchoscope. The first method allows inves-
tigation of the relation between the allergen-induced airway and inflamma-
tory responses, whereas the latter only allows to study the allergen-induced 
inflammatory response (7, 18, 172). The characteristics of the inhalational aller-
gen challenge include early asthmatic response (ear) occurring within 10 
minutes after inhalation of an effective dose of a relevant allergen, and a lar 
which is associated by allergen-induced ahr, occurring in approx. 50% of the 
subjects. The ear is a mast-cell-triggered event, resulting in acute, transient 
airway smooth muscle (asm) contraction (0-3 h), whereas the lar is charac-
terized by a chronic inflammatory response (over 24 h), in which eosinophils 
and their mediators prevail and induce the associated ahr (up to 3 weeks). 
Recent evidence has been provided that allergen challenge may induce 
features of airway remodeling in both animals and humans (173, 174). These 
characteristics render this model a suitable tool to study both the acute and 
chronic sequelae of asthma.
steroid tapering 
Steroid tapering is an exacerbation model in patients with moderate-to-
severe persistent asthma in which gradual reduction of corticosteroid 
therapy results in a gradual deterioration of fev1 and pc20 accompanied by 
an increase in symptom scores and inflammatory markers (21, 175, 176). In 
clinical trials, steroid tapering is a validated tool to test the effect of potential 
anti-inflammatory therapy on asthma control. Recent intervention studies 
applying tapering off corticosteroids have been performed with leukotriene 
receptor antagonists and anti-IgE (177-180).
rhinovirus and ozone challenges 
Rhinovirus and ozone challenge tests are still other, more experimental, 
exacerbation models of asthma. Similar to allergens, virus infections are 
important causative agents of asthma exacerbations. Rhinoviruses have been 
detected in 10-44% cases of adults and 23-86% cases of children with asthma 
exacerbations (181, 182). Grünberg et al showed that experimental rhinovirus 
infections induce airway inflammation and associated ahr in asthmatics, 
closely resembling spontaneous asthma exacerbations (183, 184). The in- 
flammatory influx caused by a rhinovirus mainly consists of eosinophils,  
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neutrophils and their respective mediators (183-186). In analogy with the 
airway inflammation in severe persistent asthma, the neutrophil component 
may – at least partly – explain why corticosteroids do not effectively protect 
against rhinovirus-induced airway inflammation (187, 188, 189). Experimental 
viral infections are exacerbation models of asthma suitable to study 
pathophysiological mechanisms and for early drug development (190). 
Ozone is another indirect, bronchoactive stimulus inducing acute neutrophil 
inflammation and oxidative stress into the airways of (non) asthmatic sub-
jects (191-193). Consequently, ozone may be a useful tool to investigate new 
drugs with anti-oxidant properties (194, 195).
Limitations of bronchoprovocation tests and models
Overall, airway challenges with direct stimuli are valuable tools to assess 
ahr, while indirect challenges are useful to study the relationship between 
a specific stimulus and the airway inflammatory response. Due to different 
modes of action, care should be taken when selecting a challenge for a spe-
cific protocol. 
If performed according to guidelines by adequately trained technicians, bpts 
are safe and generally well-tolerated (7). The most common adverse reac-
tions are transient, usually mild respiratory problems (dyspnea, chest tight-
ness, cough) and sometimes headache. The most important health-related 
contraindications for challenges are active cardiovascular diseases and 
uncontrolled or severe persistent asthma with an fev1 less than 1.2 L (7). 
In clinical trials, it should be taken into account that indirect airway challeng-
es may affect markers of inflammation, which also applies for histamine that 
has been shown to induce an airway exudative response (196). When per-
formed serially, an adequate washout period should be allowed to correct for 
these “carry-over effects”. The length of a washout period is dependent on 
the pro-inflammatory response of the indirect stimulus and varies between 
at least 6 hours for histamine and as long as 6 weeks for a rhinovirus challenge 
(197, 198).
Summary and recommendations - Bronchoprovocation tests
ahr and chronic airway inflammation are the hallmarks of asthma (199). 
Several interventional trials have demonstrated that targeting either compo-
nent resulted in better asthma control (5, 28). ahr is defined as an exagger-
ated bronchoconstrictor response to (non)specific stimuli such as cigarette 
smoke, exercise, viruses or allergens. 
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table 3 overview of direct and indirect challenges/asthma models
stimulus mode of action characteristics specific drawbacks refs
Metha-
choline
Directly on asm Gold standard to 
quantify ahr by 
pc20methacholine 
Potential marker of 
airway remodeling
Less related to 
inflammation
Not specific for asthma
(7, 153, 
155)
amp Release of mast cell-
derived mediators
Sensitive marker of 
airway inflammation
No sharp cut-off 
between atopic 
asthmatics and atopic 
controls
(7, 154, 
200)
Allergen Acute release of mast 
cell-derived mediators  
(ear), in ±50% of cases 
followed by a more 
chronic inflammatory 
response primarily 
mediated by activated 
eosinophils and their 
products (lar)
Most suitable model 
with both acute and 
chronic features of 
asthma (ear, lar and 
ahr)
Strenuous and long-
lasting procedure
Extra safety needed
Long washout period
Contraindicated in 
severe persistent 
asthma/copd/
active cardiovascular 
disorders
(7, 18, 
172)
Exercise/
cold dry air
Release of mast cell-
derived mediators
Diagnostic tool
Suitable model to test 
efficacy of therapy 
directed against 
mast cell-derived 
mechanisms
Strenuous test, not 
suitable for elderly  
or handicapped
(7, 153, 
154)
Virus/ 
Ozone
Activated eosinophils 
and neutrophils and 
their mediators
Experimental models 
to test therapy 
interfering with virus-
induced mechanisms 
of asthma, including 
airway eosinophils/
neutrophils;
unresponsive to ics 
Extra safety and 
laboratory procedures 
needed due to viral 
inoculation
(183, 
194, 218)
Steroid 
tapering
Induction of 
exacerbation by 
withdrawal of 
anti-inflammatory 
treatment and 
subsequent flare up of 
airway inflammation
Validated model to test 
efficacy of potential 
anti-inflammatory 
therapy on asthma 
control
Stepwise dose 
reduction necessitates 
lengthy trials
(175, 
176)
asm = Airway Smooth Muscle, ahr = airway hyperresponsiveness, amp = Adenosine 5’ mono-
phosphate, ear = early asthmatic response, lar = late asthmatic response, ics = inhaled cortico-
steroids
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direct and indirect stimuli
Bronchoactive stimuli can either directly or indirectly act on asm cells and 
consequently induce bronchoconstriction. Methacholine and histamine are 
direct stimuli, inducing bronchoconstriction through direct interaction with 
specific receptors on asm cells (7, 200). amp, non-isotonic aerosols, exercise 
and allergen challenges are examples of indirect stimuli causing asm con-
traction through the release of bronchoactive mediators from inflammatory 
cells and neurons (Figure 3). Challenges with methacholine, histamine and 
exercise can test the (severity of) ahr, while challenges with most indirect 
stimuli may serve as functional estimate of airway inflammation in a clinical 
or research setting. Furthermore, some of these tests have been standardized 
and have become diagnostic tools or validated models of asthma. For exam-
ple, amp challenge appeared a sensitive test to assess (the severity) of airway 
inflammation (162, 201), while challenges with exercise, allergen, ozone and 
rhinovirus can induce specific features of asthma, including a transient wors-
ening of airway inflammation and ahr. These challenges are used as validated 
models for early drug development to test specific pharmacological activity. 
The pros and cons of bpts have been summarized in Table 1 and 3.
Recommendations 
Chronic airway inflammation is the hallmark of asthma and related disor-
ders, resulting in various features including airway hyperresponsiveness 
and airway remodeling. Several studies have shown that symptoms and lung 
function parameters do not reflect the activity of the airway inflammation in 
asthma, and hence do not provide adequate information on asthma control 
(5, 28, 203, 204). Alternatively, inflammatory indices, such as sputum eosino-
phils and eno, appeared to be good indicators of asthma severity and control 
(205). Therefore, sampling of airway inflammation is becoming an integral 
part of the diagnosis, and monitoring of asthma and a valuable tool to test the 
pharmacological efficacy of anti-inflammatory therapy in early clinical trials. 
Presently, there is an increasing array of non-invasive methods aimed at sam-
pling the airway inflammation. Standardized and validated markers of airway 
inflammation include eno and sputum eosinophils, while exhaled breath 
condensate is a promising method that still awaits refinement of technique 
and more sensitive assays. In addition, there are more or less standardized 
and validated bronchial provocation tests for quantification and or assess-
ment of airway hyperresponsiveness (methacholine, histamine, exercise 
challenge), airway inflammation (adenosine monophosphate), or to mimic 
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specific pathways during a flare up of asthma – mostly applied in early clinical 
trials (exercise, allergen, rhinovirus, ozone). Although the methacholine bpts 
has been shown to be correlated with some features of airway remodeling, 
there is still a paucity of non-invasive markers for this complicated asthma 
feature, except imaging (Figure1).
The most promising future biomarker for asthma remains to be identified 
and should be disease-specific, non-invasive, reproducible, inexpensive, 
fast and simple and well- responding to the pharmacological activity of anti-
asthma therapy. The most recent developments point towards the potential 
application of so-called ‘omics’ techniques to blood, sputum and recently 
even to exhaled breath (206, 207). Such systems may drastically change the 
screening and monitoring of airway disease.
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Effect of an nk1/nk2 receptor antagonist 
on airway responses and inflammation to 
allergen in asthma
Am J Respir Crit Care Med. 2007;175(5):450-7.
J.D. Boot 1, S. de Haas 1, S. Tarasevych 1, C. Roy 3, L. Wang 4, D. Amin 4, J. Cohen 1,  
P.J. Sterk 2, B. Miller 4, A. Paccaly 4 J. Burggraaf 1, A.F. Cohen 1, Z. Diamant 1. 
1 Centre for Human Drug Research, Leiden, The Netherlands  
2 Leiden University Medical Center, Leiden, The Netherlands
3 sanofi-aventis Pharma Recherche-Developpement, France
4 sanofi-aventis U.S. Inc., Bridgewater, nj, usa
60 non-invasive sampling methods of inflammatory biomarkers in asthma  
 and allergic rhinitis
Abstract 
Rationale: The tachykinins substance P and neurokinin A (nka) are impli-
cated in the pathophysiology of asthma. 
Objective: We tested the safety, tolerability, pharmacological and biological 
efficacy of a tachykinin nk1/nk2 receptor antagonist, ave5883, in asthmatics 
in 2 double-blind, placebo-controlled, cross-over studies. 
Methods: The pharmacological efficacy of a single inhaled dose (4.8 mg) of 
ave5883 was tested against inhaled nka in 20 asthmatics. Subsequently, we 
studied the biological efficacy of the pharmacologically effective dose on 
inhaled allergen in a multiple dose trial (4.8 mg tid, 9 days) in 12 asthmatics 
with dual responses to inhaled house dust mite. On day 8, an allergen chal-
lenge was conducted and airway response was measured by fev1 until 9 h 
post-allergen. Exhaled no, pc20fev1(Methacholine) and induced sputum 
were performed on days 1,7 and 9. 
Results: ave5883 had a bad taste and transient bronchospasm occurred in 
some subjects. A single inhaled dose shifted the dose-response to nka by 1.2 
doubling doses. Unexpectedly, pretreatment with multiple doses of ave5883 
enhanced the allergen-induced early and late airway responses. However, 
there were no significant differences in the allergen-induced changes in 
exhaled no, pc20fev1(Methacholine) and sputum cell differentials between 
placebo and ave5883.
Conclusions: Despite its demonstrated pharmacological activity against 
inhaled nka, multiple doses of ave5883 increased the allergen-induced air-
way responses without affecting markers of airway hyperresponsiveness and 
airway inflammation. Our data question the prominent role of neurogenic 
inflammation in asthma and, consequently, the therapeutic potential of dual 
tachykinin antagonists. 
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Introduction
Asthma is a chronic inflammatory disease of the lower airways associated 
with various comorbidities and characterized by variable, often reversible, 
airflow obstruction (1). Pathophysiologically, airway hyperresponsiveness 
(ahr) to various bronchoconstrictor stimuli is the hallmark of asthma, which 
appears to be related to chronic airway inflammation (2). Hence, anti-inflam-
matory therapy with inhaled corticosteroids is the cornerstone of pharma-
cotherapy of persistent asthma (1). However, longterm use of (high doses of) 
inhaled corticosteroids may induce troublesome local and/or systemic side 
effects (3). Furthermore, despite a good, overall clinical efficacy, even high 
doses of inhaled corticosteroids do not fully suppress the airway inflamma-
tion in all asthmatic patients (4-6). Therefore, novel therapeutic options are 
being explored targeting various aspects of airway inflammation.
Within human airways, the tachykinins Substance P (sp) and Neurokinin 
A (nka) are the predominant neuropeptides released from the nonadren-
ergic-noncholinergic (nanc) system by mechanical, thermal, chemical or 
inflammatory stimuli (7;8). It appears, that sp exerts its pro-inflammatory 
effects mainly by stimulation of the tachykinin nk1 receptors, whereas nka 
mainly causes tachykinin nk2 receptor-mediated effects (9). Upon inhala-
tion, sp induces ahr and the so-called ‘neurogenic inflammation’ within the 
airways of both non-asthmatic and asthmatic individuals, characterized by 
microvascular leakage, mucus secretion, and inflammatory cell responses 
(9-11), whereas inhaled nka mainly causes bronchoconstriction (12,13). 
Furthermore, in contrast with non-asthmatic controls, increased tachykinin 
nk1 and nk2 receptor mrna expression has been demonstrated within 
the airways of asthmatic patients (14,15). Correspondingly, in subjects with 
allergic asthma, increased concentrations of sp have been found in sputum 
and bronchoalveolar lavage (bal) at baseline, with further increase following 
segmental allergen challenge (8,16). Similarly, in still another study in allergic 
asthma, increased nka levels have been detected 4 h following an allergen 
bronchoprovocation test (7).
These observations provided evidence that the tachykinins sp and nka 
may contribute to airway inflammation and hence may be implicated in the 
pathophysiology of asthma. Therefore, several tachykinin nk1 and/or nk2 
receptor antagonists have been developed and tested against indirect chal-
lenges including nka, adenosine monophosphate and hypertonic saline in 
patients with asthma (17-21). However, until recently, there are no published 
studies on clinical efficacy of dual tachykinin nk1/nk2 receptor antagonists 
in asthma nor on their biological efficacy in allergen challenge, being the 
most representative model of asthma.
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ave5883 is a non-peptidyl, dual tachykinin nk1/nk2 receptor antagonist 
with high specificity and affinity for tachykinin nk1 and nk2 receptors (Ki 
= 5.6 and 3.1 nM for the nk1 and nk2 receptor respectively, and >10 µM for a 
variety of other physiologically important receptors). In sensitized guinea-
pigs, intra-peritoneally administered ave5883 has been shown to reduce 
ovalbumin-induced airway hyperreactivity and eosinophil influx in the bal 
[data on file]. Similarly, intratracheally administered ave5883 protected 
against capsaicin-induced bronchoconstriction in sensitized guinea-pigs and 
aerosolised ave5883 inhibited the nka-induced increase in airway resistance 
in dogs [data on file]. 
We tested the safety and tolerability, in combination with the pharmacologi-
cal and biological efficacy and the pharmacokinetics, of inhaled ave5883 in 
clinically stable patients with mild to moderate persistent asthma not on 
maintenance anti-inflammatory therapy. In the first study, we tested the phar-
macological efficacy of a single inhaled dose of ave5883 against nka-induced 
bronchoconstriction. Subsequently, in another study in patients with similar 
asthma characteristics, we tested the biological efficacy of multiple inhaled 
doses of ave5883 against allergen-induced airway responses and markers of 
airway inflammation.
Some of the results of both studies have previously been reported in the form 
of abstracts (22,23). 
Methods
subjects
nka challenge study: 20 non-smoking, patients with clinically stable, mild to 
moderate persistent asthma participated in the nka-challenge study (Table 
1). All patients had a history of persistent asthma for at least 1 year (according 
to Global Initiative for Asthma (gina) criteria (1)), without any other clinically 
relevant disorders. Except for inhaled short-acting β2-agonists prn, no one 
was using concomitant anti-asthma or anti-allergy medication for at least 
6 weeks prior to and during the study. Patients had no history of viral infec-
tions of the lower airways for at least 6 weeks before enrollment. Caffeine-
containing beverages and short-acting inhaled β2-agonists were withheld at 
least 8 h before each visit. Baseline forced expiratory volume in one second 
(fev1) had to be >75% of predicted. Patients were hyperresponsive to both 
inhaled methacholine bromide (mbr) and inhaled nka, showing a 20% fall in 
fev1 (pc20fev1(mbr)) of lower than 19.6 mg/mL (= 16 mg/mL methacholine 
chloride, equals 80 µmol/mL) and a pc20fev1(nka) of lower than 441.2 x10-3 
µmol/mL (equals 500 µg/mL), respectively, at screening.
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Allergen challenge study: 12 patients participated in the allergen challenge 
study (Table 1). Four of them have previously participated in the nka chal-
lenge study (>6 months ago). All patients met the same aforementioned 
criteria, with a maximum pc20fev1(nka) of < 882.4 x10-6 µmol/mL (equals 
<1000 µg/mL) at screening. In addition, patients had a positive skin prick 
test to house dust mite (hdm, a positive response was defined as a mean 
wheal diameter >3mm) and a documented late asthmatic response (lar) to 
inhaled hdm extract, i.e. fall in fev1 >15% from baseline between 3 and 9 h 
post-allergen.
Both study protocols were approved by the Leiden University Medical Centre 
Ethics Committee, and all participants gave written informed consent.
table 1 patients’ baseline characteristics.
characteristics nka challenge allergen challenge
Number of patients 20a 12b
Gender Male 5 6
Female 15 6
Atopy status Yes 18 12
No 2 0
Age (years) Mean
[Range]
29.6
[19 – 47]
24.4
[20 – 39]
fev1 (L) Mean
[Range]
3.7
[2.6 – 5.7]
3.8
[3.1 – 5.9]
fev1 (% predicted) Mean
[Range]
102.4
[80.3 – 125.5]
91.6
[73.6 – 121.4c]
pc20fev1 (mbr) (mg/mL) Mean
[Range]
2.2
[0.1 – 8.5]
2.6
[0.1 – 14.4]
pc20fev1 (nka) 
(*10-3 µmol/mL)
Mean
[Range]
143.2
[5.9 – 593.8d]
357.9
[5.9 – 1115.7e]
a One subject did not complete the nka challenge study, b One subject did not complete  
the Allergen challenge study, c One subject with a lower baseline fev1 (73.6% predicted)  
was included, d One subject with a pc20fev1(nka) of 593.8 *10-3 µmol/mL was included,  
e One subject with a pc20fev1(nka) of 1115.7 *10-3 µmol/mL was included.
study design
nka challenge study: This was a single-center, randomized, double-blind, 
placebo-controlled, single-dose, cross-over study. Before entering the study, 
selection criteria were examined on 2 screening visits, 24 h apart. Fourteen 
to 28 days after screening, eligible patients were randomized into the study. 
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Each treatment period consisted of two study days, separated by a washout 
period of 12-16 days. Clinically stable subjects inhaled either ave5883 (cumu-
lative dose of 4.8 mg) or placebo, 30 minutes before an nka-challenge. Blood 
samples for pharmacokinetics were collected from a venous cannula inserted 
in a forearm vein (pre-dose, 10, 30 and 45 minutes and 1, 2, 4, 6 and 8 h post-
dose). A standardized nka challenge was performed 30 minutes after the last 
study drug inhalation. In principle, pre-challenge fev1 had to return within 
10% of baseline. However, in order to keep the time-interval between dosing 
and nka challenge constant in all patients and to allow also more hyperre-
sponsive asthmatics in the study, in the case of an unexpected drop in fev1 
following study medication, decreases in pre-nka fev1 were accepted up to 
20% from baseline, provided within a safe range (fev1 >2.3 L, allowing a safe 
pc20fev1(nka)). Ten to 14 days post-study, there was a follow-up visit. 
Allergen challenge study: This was a single-center, randomized, multiple-
dose, placebo-controlled, double-blind, cross-over study. At least 3 weeks 
before the study, selection criteria were examined. Eligible patients with a 
documented pc20fev1(nka) and a demonstrated lar to inhaled hdm at 
screening were randomized into the study. On Day 1, exhaled no (eno) 
measurement, followed by a pc20fev1(mbr), and 1 h later, a sputum induc-
tion, were performed. To ensure asthma stability, mean baseline fev1 had 
to be within 10% and the pc20fev1(mbr) had to remain within 1 doubling 
dose on Day 1 of both treatment periods. Clinically stable patients inhaled 
the first dose of study medication at 2:00 pm (± 2 h) followed by an evening 
dose at approx. 8:00 pm, followed by fev1 measurements. On Days 2-7, study 
medication was inhaled three times daily at 8:00 am, 2:00 pm and 8:00 pm 
(± 2 h). Subjects were discharged from the unit 1 h after the morning dose on 
Day 2 and returned on Day 7 (intake was monitored by telephone contact). 
On Day 8, the afternoon dose was skipped and on Day 9 patients only inhaled 
the morning dose. On Day 8, a standardized allergen bronchoprovocation 
test was conducted approximately 45 min post-dosing (provided pre-allergen 
fev1 returned within 10% of the predose value), and the airway response was 
recorded by fev1 until 9 h post-allergen. Blood samples were collected for 
pharmacokinetics from a venous cannula inserted in a forearm vein on Day 8 
(pre-dose, 15 and 30 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8 and 9 h post-dose) and 
on Day 7 and 9 (pre-dose, and 1, 2, 4, and 6 h post-dose). The pro-inflammato-
ry effects of inhaled allergen were monitored by eno, sputum cell differen-
tials and pc20fev1(mbr) on Days 7 and 9, 24 h pre- and post-allergen, respec-
tively. Ten to 14 days post-study, a follow-up visit was scheduled (Figure 1). 
Throughout the study, patients recorded any symptoms and signs of asthma, 
medication use, and adverse events into a diary.  
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All bronchoprovocation tests were performed at the same time of the day  
(±2 h). After all bronchoprovocation tests, patients received salbutamol 
>2x100 µg through Volumatic (GlaxoSmithKline, Zeist, The Netherlands), 
until the fev1 returned within 10% from baseline.
figure 1 Study flowchart - allergen challenge study. there was at least a one-week washout  
between screening visit 1 and 2. scr = screening, pc20fev1(nka) = provocative 
concentration of neurokinin a causing a 20% fall in fev1, pc20fev1(mbr) = provocative 
concentration of methacholine bromide causing a 20% fall in fev1, sputum = sputum 
induction, allergen = allergen challenge. 
study medication 
For both study protocols ave5883 ([4-(1-{2-3-(3,4-Dichloro-phenyl)-1-
(3,4,5-trimethoxy-benzoyl)-pyrrolidin-3-yl]-ethyl}-4-phenyl-piperidine-4-
carbonyl)-piperazin-1-yl]-acetic acid) was supplied by sanofi-aventis phar-
maceuticals Inc. (Cheshire, uk) as a sterile solution or matching placebo in 
an alcohol/propellant (HFA-227) mixture, both delivered in a pressurized 
metered dose inhaler (pMDI; 300 µg/actuation). Each administration con-
sisted of 16 actuations in 8 min yielding a cumulative dose of 4.8 mg ave5883. 
Post-dosing subjects were required to rinse their mouth. 
inhalation challenges & response measurements
The airway response to the inhaled aerosols was measured by fev1 according 
to standardized lung function techniques and recorded by a spirometer con-
nected to a personal computer (Vmax Spectra, Sensor Medics, Bilthoven,  
The Netherlands) (24). mbr, nka and allergen bronchoprovocation chal-
lenge tests were performed by tidal breathing method according to validated 
techniques as described previously (25-27). A detailed description of methods 
used is presented in the online supplement. 
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sputum induction and analysis
Sputum induction and analysis were performed according to the entire 
expectorate (‘full sample’) method, that has been previously validated (26). 
Hypertonic saline aerosols (NaCl 4.5%) were generated at room temperature 
by a DeVilbiss Ultraneb 2000 ultrasonic nebulizer (Tefa Portanje, Woerden, 
The Netherlands) and inhaled for 3x5 min at 15 min intervals (26). Sputum 
samples were processed according to a previously validated method after 
adding dtt 0.1% (28). Subsequently, cytospins were made (50 µL/cytospin; 
Shandon Cytospin 4, Thermon Electron Corporation, Runcorn, uk) and dif-
ferential cell counts performed on May-Grünwald-Giemsa-stained cytospins; 
cells were expressed as a percentage of 500 nucleated cells excluding 
squamous cells as described previously (26). Samples with > 80% squamous 
cells were excluded from analysis. A detailed description of methods used is 
presented in the online supplement.
exhaled nitric oxide 
Exhaled no measurements were performed in triplicate within 10% at a exha-
lation flow of 50 mL/s according to current ats recommendations (29), by a 
chemoluminescence analyzer (Ecomedics cld88sp, Duernten, Switzerland). 
A detailed description of methods used is presented in the online supplement.
plasma concentration of ave5883
Blood samples (7 mL) were collected into sodium heparinate vacutainers 
and centrifuged at 3000 rpm for 10 minutes at 4 °C. ave5883 was determined 
in plasma samples of subjects treated with ave5883 by Bioanalytics, dmpk, 
sanofi-aventis pharmaceuticals Inc, Bridgewater, NJ, using a validated lc/
ms/ms method with a lower limit of quantification of 0.1 ng/mL. 
analysis
nka challenge study: The protective effect of ave5883 against nka-induced 
bronchoconstriction was assessed by comparison of the pc20fev1(nka) 
(log10 transformed) after ave5883 and placebo pre-treatment. 
pc20fev1(nka) was calculated by linear interpolation of the inhaled dose 
of nka below and above a 20% fall in fev1 (27). If no fall in fev1 >20% was 
reached after inhalation of the highest nka-dose, pc20fev1 (nka) was set 
at 1.76 µmol/mL (=2000 µg/mL; i.e. one doubling dose higher than the high-
est dose tested) (27). The difference in pc20fev1 (nka) between ave5883 
and placebo was tested using an analysis of variance with sequence, subject 
(within sequence), and treatment as factors. The safety and tolerability was 
primarily assessed through examination of treatment-emergent adverse 
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events. Treatment-emergent adverse events consisted of all on-treatment 
adverse events and any pre-treatment adverse events that worsened in inten-
sity (severity or frequency) after the start of study medication. Descriptive 
statistics were provided for plasma concentration-time data and plasma  
pharmacokinetic parameters.
Allergen challenge study: The effect of ave5883 on the allergen-induced 
airway responses was determined by comparing the absolute corresponding 
area under the time-response curve (auc) for both the ear (0-3 h post-aller-
gen), and the lar (3-9 h post-allergen) between ave5883 and placebo. The 
trapezoidal rule was applied for the calculation of the aucs (30). Similarly,  
the differences in the maximal percent fall in fev1 during the ear and lar 
were compared between the two treatments.  
In addition, the differences in allergen-induced changes in eno, pc20fev1 
(mbr) and the sputum differential cell counts (mast cells, eosinophils, neu-
trophils, lymphocytes, macrophages, epithelial and squamous cells) were 
assessed by comparing the (changes of the) corresponding values 24 h before 
and 24 h after allergen challenge between the two treatments. pc20fev1 
(mbr) was calculated by linear interpolation of the airway responses below 
and above a 20% fall in fev1 (27). The airway responses to inhaled allergen 
were expressed as percentage fall in fev1 from post-diluent baseline and 
plotted as time-response curves during both treatment periods. For the 
assessment of treatment differences (ave5883 vs placebo) in these outcome 
parameters, an analysis of variance (anova) appropriate to the 2-period, 
2-sequence, 2-treatment cross-over design was used. The anova model con-
tained factors of treatment, sequence, and subject within sequence. Carry-
over effects were examined for the lar auc analysis. P-values <0.05 were 
considered statistically significant.
The sample size of 12 evaluable patients for this study was based upon the 
simplifying assumption for a comparison of the two treatments using a paired 
t-test. Given this assumption, the calculated sample size required to detect 
a 30% mean difference in the lar was 10 subjects (α = 0.05 (two-tailed), β = 
0.10 (one-tailed), power = 90%; within subject standard deviation = 25%) (31). 
Results
safety & tolerability
nka challenge study: A total of 20 patients were randomized and 19 patients 
completed the study. One subject was withdrawn after the first study day 
because of a moderate bronchoconstriction (i.e. a fall in fev1 of 34% from 
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baseline) within 5 min of inhalation of ave5883. Overall, the study medica-
tion was well-tolerated, although all patients on ave5883 vs. none on placebo 
(p) reported bad taste. The most commonly occurring adverse event was 
transient, self-limiting bronchospasm starting within 12 minutes after study 
drug inhalation reported by 8 patients on ave5883 and 4 on P. Other reported 
adverse events were headache (5 patients on ave5883 and 3 on P) and self-
limiting dyspnoea (2 patients on ave5883 and 5 on P). 
Allergen challenge study: A total of 12 patients were randomized and 11 
patients completed the study. One subject was withdrawn because of a viral 
exacerbation requiring oral prednisone between treatment period I and II. 
Similar to the nka challenge study, ave5883 was generally well-tolerated 
although all patients reported a bad taste after ave5883 inhalation. The most 
common adverse event was self-limiting dyspnoea occuring within 30 min-
utes of study drug inhalation (in 5 patients on ave5883 vs. 2 on P). However,  
in all patients pre-allergen fev1 was within 10% of predose value (see table  
E2 of individual pre-dose and pre-allergen fev1 in online supplement). In 
addition, headache was reported by 3 patients on ave5883 vs. 3 on P. Based  
on observations in the unit, diaries and canisters’ weight, all patients were 
compliant with the dosing regime. There was no difference in asthma control, 
including short-acting β2-agonist usage and pef-measurements between the 
two treatment periods. 
In both studies, no serious adverse events occurred and there were no clini-
cally significant changes in physical examination, vital signs, laboratory 
parameters and baseline spirometry values. 
pharmacokinetics
The pharmacokinetics of ave5883 after single dose (nka challenge study) 
and multiple dose (allergen challenge study) administration are shown in 
Table 2. ave5883 plasma concentrations showed considerable inter-subject 
variability and were similar in the two studies.
effect of ave5883 on airway caliber
In the nka challenge study, pre-nka fev1 was between 80% and 90% of 
baseline in 5 out of 19 patients. However, in the allergen challenge study 
multiple drug dosings did not significantly affect the pre-allergen airway 
caliber. In both studies, pre-challenge fev1 was not significantly different 
between the two treatments (nka study: (mean ± sem) 3.40 ± 0.23 L 
(ave5883); 3.46 ± 0.20 L (p); p=0.40) and allergen challenge study: (mean 
± sem): 3.82 ± 0.3 L (ave5883); 3.76 ± 0.3 L (p); p=0.52). Individual pre-dose 
and pre-challenge fev1 data for both studies are provided in the online 
supplement (Table E1 and E2).
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table 2 main pharmacokinetic parameters of inhaled ave5883 
parameter nka challenge study allergen challenge study
Dose (mg) 4.8 single dose 4.8 three times a day
Number of patients 19 11
auclast (ng x h/mL) 11.1 ± 6.0* 9.8 ± 4.9*
Cmax (ng/mL) 5.4 ± 3.7* 3.6 ± 1.8*
Tmax (h) 0.30 [0.28 – 1.12]** 0.35 [0.25 - 1.00]**
T 1/2 (h) nd 6.93 ± 2.11 *
nd = Not determined, auclast = auc from time zero to time of last measured concentration, 8 h in 
the nka challenge study and 9 h in the allergen challenge study (*mean ±sd, **median [range])
effect of ave5883 on nka-challenge
A single inhaled dose of ave5883 reduced the nka-induced bronchocon-
striction in 16 out of 19 patients. In 5 of these 16 patients there was an increase 
in pc20fev1(nka) of at least 2 doubling doses. In addition, 7 patients did not 
reach a pc20fev1 (nka) following inhalation of the highest dose of nka ver-
sus 2 subjects in the placebo group. 
On average, ave5883 caused a rightward shift of the dose-response curve 
to inhaled nka of at least 1.2 doubling doses as compared to P pretreatment 
(mean difference in log10 pc20fev1 (nka) ± sd: 0.35 ± 0.10; 90% CI: 0.17-
0.53; p=0.004). Excluding those 5 subjects with pre-nka fev1 fev1 between 
80-90% of baseline, a subgroup analysis still showed a significant effect of 
ave5883 compared to P (see online supplement, Table E3).
effect of ave5883 on allergen-induced airway responses
In all patients, inhaled hdm induced an ear and a lar at screening. Pretreat- 
ment with ave5883 (4.8 mg tid, 9 days) did not protect against the allergen-
induced airway responses (Figure 2). Conversely, as compared with P, there 
was a slightly greater fall in fev1 from baseline following ave5883 inhalations 
in terms of area under the curve (auc) during both the ear: mean auc (0-3 
h) ± sem (%fall*h): 23.7 ± 3.0 (ave5883) and 18.0 ± 3.0 (p) (p=0.02); and the 
lar: mean auc (3-9 h) ± sem (%fall*h): 145.5 ± 11.7 (ave5883) and 116.2 ± 11.7 
(p), (p=0.01). Although the maximal percentage fall (max%fall) from baseline 
fev1 during ear was comparable between the two treatments: max%fall 
± sem: -19.9 ± 2.2 (ave5883) and -18.0 ± 2.2 (p), (p=0.29), during lar it was 
more pronounced following ave5883: (max %fall ± sem) -38.7 ± 2.9 as com-
pared to -33.6 ± 2.9 (p); (p<0.01). At 24 h post-allergen (Day 9), allergen chal-
lenge caused a significant decrease in baseline fev1 in both treatment groups. 
However, the changes in fev1 were not significantly different between the 
two treatments (p=0.77).
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figure 2 Allergen-induced airway responses in percentage change from pre-allergen fev1  
(mean ± sem) 0-9 h following allergen challenge during ave5883 (closed circles)  
and p (open squares) treatment. There was a significant difference in both the ear  
(auc 0-3 h) and lar (auc 3-9 h) between the two treatments, ‡ = p<0.05.
effect of ave5883 on allergen-induced changes in airway 
responsiveness to methacholine 
Allergen challenge caused a significant increase in ahr to methacholine 
(24 h pre- vs. 24 h post-challenge) during ave5883 treatment (mean change 
in pc20fev1(mbr) ± sem: -0.23 ± 0.08 mg/mL; doubling concentrations; 
p=0.02). Similarly, there was an allergen-induced decrease in pc20fev1 
(mbr) following placebo (mean change in pc20fev1 (mbr) ± sem: -0.32 ± 
0.08 mg/mL; doubling concentrations; p=0.003). However, these allergen-
induced changes in airway responsiveness to mbr were not significantly dif-
ferent between the two treatments (p=0.21) (Figure 3).
effect of ave5883 on allergen-induced changes in eno 
Multiple doses of ave5883 did not affect baseline eno values as compared to 
placebo treatment (Day 1 vs Day 7, p=0.28). The allergen challenge induced 
a significant increase in eno (Day 7 vs Day 9) in both treatment periods 
(p <0.001). However, the changes in eno were not statistically different 
between the two treatments (mean change ± sem (Day 7 vs Day 9) 37.64 ± 
6.40 ppb (ave5883) and 43.44 ± 6.57 ppb (p), p=0.32) (Figure 4). 
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figure 3 Airway responsiveness to mbr expressed as pc20fev1(mbr) on days 1, 7 and 9 during both 
ave5883 (filled bars) and p (striped bars) treatment period. Allergen challenge decreased 
pc20fev1(mbr) during both treatment periods (day 7 vs. 9), ‡ = p<0.05. However, there was 
no significant difference in the changes in allergen-induced airway responsiveness to mbr 
between the two treatments (p=0.21).
 
effect of ave5883 on allergen-induced changes in sputum cell 
differentials 
On pre-allergen Day 7, there was no difference in the % sputum eosinophils 
between both treatment periods (mean ± sem: 4.86 ± 1.75 % (ave5883) and 
3.33 ± 1.58 % (p)). The allergen challenge induced a rise in sputum eosinophils 
during both treatment periods (Day 7 vs. Day 9; mean change ± sem 8.09 
± 3.018; (ave5883)) and mean change ± sem 7.08 ± 2.972; (p)). Since only 3 
patients managed to expectorate evaluable sputum samples on both Days 
7 and 9 of the two treatment periods, no adequate power analysis could be 
performed on the allergen-induced changes in sputum cell count between 
the two treatments. However, based on evaluable samples, there was a 
clear trend towards increase in sputum eosinophils following allergen chal-
lenge. This is in agreement with the allergen-induced changes in eno and 
pc20fev1(mbr).
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figure 4 Exhaled no as mean (± sem) on days 1, 7 and 9 during both ave5883 (filled bars) and  
p (striped bars) treatment period. As compared with pre-allergen (day 7), there was  
a significant increase in eno 24 h post-allergen (day 9) during both treatments, ‡ = (p<0.05). 
However, the changes in eno were not significantly different between the two treatments 
(p=0.32).
Discussion
We report combined study data on the safety, tolerability, pharmacological 
and biological efficacy and pharmacokinetics of a single and multiple inhaled 
doses of ave5883, a novel dual tachykinin nk1/nk2 receptor antagonist, in 
patients with mild to moderate persistent asthma. In all patients, both dos-
ing regimens of inhaled ave5883 were safe and generally well-tolerated. 
and no clinically relevant adverse effects occurred. However, the substantial 
number of 16 actuations in combination with repeated deep inhalations from 
the pMDI device may have induced self-limiting dyspnoea accompanied by a 
transient drop in fev1 in some patients. As dyspnoea and fev1 were recorded 
at 12 minutes post-dosing in the single dose study and at 30 minutes in the 
multiple dose study, respectively, this may explain the higher occurrence 
of dyspnoea and/or drop in fev1 in the single dose (nka-challenge) study. 
Despite pharmacological activity of a single inhaled dose (4.8 mg) against 
nka-induced bronchoconstriction, multiple inhaled doses of ave5883 (4.8 
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mg tid for 7 days) increased the allergen-induced airway responses and 
failed to reduce allergen-induced markers of airway inflammation and airway 
hyperresponsiveness in patients with similar asthma characteristics.
In a comparable proof of concept study in patients with similar asthma 
characteristics, a single inhaled dose of a less specific tachykinin nk1/nk2 
receptor antagonist, FK224, failed to protect against nka-induced bronchoc-
onstriction (32). In contrast, a single oral dose of another dual tachykinin nk1/
nk2 receptor antagonist, dnk333, provided significant protection against 
nka-induced bronchoconstriction in patients with mild persistent asthma, 
causing a rightward shift of the dose-response curve to inhaled nka by on 
mean 4.08 doubling doses (18). Moreover, in patients with similar asthma 
characteristics, an oral triple tachykinin receptor antagonist, CS-003, has 
been shown to produce a potent and long-lasting rightward shift of the 
nka-dose-response curve (21). Our study results confirm and extend previ-
ous findings, showing that an inhaled dual tachykinin nk1/nk2 receptor 
antagonist is also capable of inhibiting nka-induced bronchoconstriction in 
asthma, albeit to a lesser extent than the more potent oral compounds (18;21). 
Alternatively, an inhaled formula may offer the benefit of targeted therapy 
with possibly fewer systemic side effects. 
In correspondence with several animal studies with other tachykinin nk1/
nk2 receptor antagonists (33-35), aerosolized ave5883 not only provided 
protection against both nka-induced bronchoconstriction, but also against 
other (tachykinin-driven) bronchoconstrictor stimuli, including capsaicin 
and ovalbumin in sensitized guinea-pigs and dogs [data on file]. To our 
knowledge, this is the first study reporting on the effects of a dual tachykinin 
nk1/nk2 receptor antagonist on allergen-induced airway responses and 
markers of ahr/inflammation in asthmatic subjects in vivo. Despite a partial 
antagonistic effect of a single inhaled dose (4.8 mg) against exogenous nka 
in patients with asthma, unexpectedly, pretreatment with multiple inhaled 
doses of ave5883 (4.8 mg tid for 9 days) enhanced the allergen-induced 
airway responses without affecting the markers of airway ahr/inflamma-
tion. Furthermore, since ave5883 did not affect baseline fev1 throughout 
the treatment period and since pre-allergen fev1 was not different between 
both treatments, this argues against a clear-cut mechanistic explanation for 
this phenomenon. In conclusion, while animal studies have produced a large 
body of evidence warranting efficacy of dual tachykinin nk1/nk2 receptor 
antagonists in asthmatic patients in vivo, we were unable to substantiate this 
hypothesis in the present study. 
We do not believe that the lack of efficacy of ave5883 against allergen-
induced airway and inflammatory responses has been caused by method-
ological or dosing errors. First, we applied previously validated methods 
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and all participating patients had both an airway responsiveness to inhaled 
nka and an allergen-induced late asthmatic response (25;26). In addition, 
pre-allergen fev1, recorded at approx. 1 h post-dosing, was not affected by 
inhalation of the study medication, nor were there any significant differences 
in baseline data between both treatment groups. Second, we based our dos-
ing regimen on the same dose and mode of administration that effectively 
reduced the nka-induced bronchoconstriction in the first part of the study in 
patients with similar asthma characteristics. Since a steady state plasma con-
centration was expected within three days, 7 days treatment with ave5883 
pre-allergen was deemed sufficient to demonstrate biological efficacy. In a 
similar study protocol, inhaled corticosteroids have been shown to provide 
a significant reduction of allergen-induced airway responses and markers of 
airway inflammation following 7 to 8 days pretreatment (36;37). 
What could possibly account for the lack of effect of ave5883 against allergen 
challenge? First, it may be possible that while nka and sp play an important 
role in the allergen-driven airway inflammation in several animal models of 
asthma (38), this may not similarly apply to asthmatic patients due to species-
related differences. For instance, Bowden et al (39) reported that in guinea-
pigs, the most commonly applied laboratory species, approximately 60% of 
intra-epithelial fibres within the trachea constitute of sp nerve fibres, while in 
humans this is only 1% (40). Furthermore, in asthmatic airways the number 
of the sp fibres was not found to be increased as compared to nonasthmatic 
controls (41). Correspondingly, up to now reported (single) tachykinin nk1 or 
nk2 receptor antagonists have shown little if any efficacy against (tachykinin-
driven) bronchoconstrictor stimuli in asthmatic subjects, despite previously 
shown pharmacological efficacy against the respective agonist (nka or sp) 
(20;42). In the first study, multiple oral doses of the specific nk2 receptor 
antagonist, sr 48968, failed to protect against adenosine-induced bronchoc-
onstriction in subjects with allergic asthma (20). In another study, CP-99,994, 
an nk1 receptor antagonist, did not inhibit hypertonic saline-induced bron-
choconstriction and cough in patients with mild persistent asthma (42). 
Still another possibility could be that sp, being a major pro-inflammatory 
tachykinin (8), is likely to play a more important role in allergen-induced 
airway inflammation than nka, which appears to possess more direct bron-
choconstrictor properties (13). And although ave5883, being a dual nk1/nk2 
antagonist was expected to inhibit the effects of both tachykinins, we only 
tested its protective properties against nka, and are hence not fully informed 
about its pharmacological efficacy against inhaled sp in asthma in vivo. In line 
with this and based on its modest antagonistic properties against inhaled 
nka, it may be that ave5883 is not potent enough to offer protection against 
allergen-induced airway response and inflammation. Comparable findings 
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were reported in clinical trials with early leukotriene (lt) receptor antago-
nists in asthma. Despite a 3.8-fold rightward shift in the dose response curve 
to inhaled ltd4 in mild asthmatics, the oral lt receptor antagonist L-649,923 
failed to protect against allergen-induced bronchoconstriction. However, 
the more potent lt antagonist zafirlukast, causing an approx. 10-fold shift 
in the dose-response curve to inhaled ltd4, significantly protected against 
allergen-induced airway responses and the associated ahr (43-46). Finally, 
although similar plasma concentrations of ave5883 were observed in both 
studies, higher and longer lasting plasma exposure of ave5883 may have been 
required to warrant adequate drug concentrations within the airways, before 
and during the allergen-induced late asthmatic response. Therefore, consid-
ering the relatively short terminal elimination half-life of the drug (T1/2 = 6.93 
h), higher doses and/or a more frequent dosing of ave5883 may have been 
required to achieve any protective effect. 
In conclusion, a single inhaled dose of ave5883 provided a modest protection 
against nka-induced bronchoconstriction in patients with mild to moderate 
persistent asthma, whereas 7 days pretreatment with multiple daily doses of 
this dual tachykinin nk1/nk2 receptor antagonist paradoxically enhanced 
the allergen-induced airway responses without affecting the markers of air-
way inflammation/hyperrresponsiveness in a patient population with similar 
asthma characteristics. Therefore, these findings question the prominent 
role of neurogenic inflammation in asthma and consequently, the therapeu-
tic potential of dual tachykinin antagonists. Hence, more research is required 
to determine the precise role of tachykinins and their receptors in the allergic 
airway inflammation that will help to establish the position of potent com-
bined tachykinin receptor antagonists in the treatment of asthma. 
76 non-invasive sampling methods of inflammatory biomarkers in asthma  
 and allergic rhinitis
references
1 Global Initiative for Asthma (gina). Global strategy 
for asthma management and prevention. Bethersda/
Martyland: NHLBI/WHO workshop report. Last 
updated: 2006. 1-1-1995. 
2 Ward C, Reid DW, Orsida BE, Feltis B, Ryan VA,  
Johns DP et al. Inter-relationships between 
airway inflammation, reticular basement 
membrane thickening and bronchial hyper-
reactivity to methacholine in asthma; a systematic 
bronchoalveolar lavage and airway biopsy analysis. 
Clinical & Experimental Allergy 2005; 35(12) 
:1565-1571.
3 Tattersfield AE, Harrison TW, Hubbard RB, Mortimer 
K. Safety of inhaled corticosteroids. Proc Am Thorac 
Soc 2004; 1(3):171-175.
4 Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker 
M, Djukanovic R. The relationship between airways 
inflammation and asthma severity. Am J Respir Crit 
Care Med 2000; 161(1):9-16.
5 Sont JK, Han J, van Krieken JM, Evertse CE, Hooijer 
R, Willems LN et al. Relationship between the 
inflammatory infiltrate in bronchial biopsy specimens 
and clinical severity of asthma in patients treated with 
inhaled steroids. Thorax 1996; 51(5):496-502.
6 Bateman ED, Boushey HA, Bousquet J, Busse WW, 
Clark TJH, Pauwels RA et al. Can Guideline-defined 
Asthma Control Be Achieved?: The Gaining Optimal 
Asthma ControL Study. Am J Respir Crit Care Med 
2004; 170(8):836-844.
7 Heaney LG, Cross LJ, McGarvey LP, Buchanan KD, 
Ennis M, Shaw C. Neurokinin A is the predominant 
tachykinin in human bronchoalveolar lavage fluid 
in normal and asthmatic subjects. Thorax 1998; 
53(5):357-362.
8 Nieber K, Baumgarten CR, Rathsack R, Furkert J, 
Oehme P, Kunkel G. Substance P and beta-endorphin-
like immunoreactivity in lavage fluids of subjects with 
and without allergic asthma. J Allergy Clin Immunol 
1992; 90(4 Pt 1):646-652.
9 Advenier C, Lagente V, Boichot E. The role of 
tachykinin receptor antagonists in the prevention of 
bronchial hyperresponsiveness, airway inflammation 
and cough. Eur Respir J 1997; 10(8):1892-1906.
10 Van Rensen EL, Hiemstra PS, Rabe KF, Sterk PJ. 
Assessment of microvascular leakage via sputum 
induction: the role of substance P and neurokinin A 
in patients with asthma. Am J Respir Crit Care Med 
2002; 165(9):1275-1279.
11 Cheung D, van der Veen H, Den Hartigh J, Dijkman 
JH, Sterk PJ. Effects of inhaled substance P on airway 
responsiveness to methacholine in 
 asthmatic subjects in vivo. J Appl Physiol 1994; 
 77(3):1325-1332.
12 Cheung D, Bel EH, Den Hartigh J, Dijkman JH, Sterk 
PJ. The effect of an inhaled neutral endopeptidase 
inhibitor, thiorphan, on airway responses to 
neurokinin A in normal humans in vivo. Am Rev 
Respir Dis 1992; 145(6):1275-1280.
13 Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, 
Cohen AF, Diamant Z. Relationship between airway 
responsiveness to neurokinin A and methacholine in 
asthma. Pulm Pharmacol Ther 2005; 18(3):171-176.
14 Adcock IM, Peters M, Gelder C, Shirasaki H, Brown 
CR, Barnes PJ. Increased tachykinin receptor gene 
expression in asthmatic lung and its modulation by 
steroids. J Mol Endocrinol 1993; 11(1):1-7.
15 Bai TR, Zhou D, Weir T, Walker B, Hegele R,  
Hayashi S et al. Substance P (nk1)- and neurokinin 
A (nk2)-receptor gene expression in inflammatory 
airway diseases. Am J Physiol 1995; 269 
(3 Pt 1):L309-L317.
16 Tomaki M, Ichinose M, Miura M, Hirayama Y, 
Yamauchi H, Nakajima N et al. Elevated substance 
P content in induced sputum from patients with 
asthma and patients with chronic bronchitis. Am J 
Respir Crit Care Med 1995; 151(3):613-617.
17 Ichinose M, Nakajima N, Takahashi T, Yamauchi H, 
Inoue H, Takishima T. Protection against bradykinin-
induced bronchoconstriction in asthmatic patients 
by neurokinin receptor antagonist. Lancet 1992; 
340(8830):1248-1251.
18 Joos GF, Vincken W, Louis R, Schelfhout VJ, Wang 
JH, Shaw MJ et al. Dual tachykinin nk1/nk2 
antagonist dnk333 inhibits neurokinin A-induced 
bronchoconstriction in asthma patients. Eur Respir J 
2004; 23(1):76-81.
19 Van Schoor J, Joos GF, Chasson BL, Brouard RJ, 
Pauwels RA. The effect of the nk2 tachykinin receptor 
antagonist SR 48968 (saredutant) on neurokinin 
A-induced bronchoconstriction in asthmatics. Eur 
Respir J 1998; 12(1):17-23.
20 Kraan J, Vink-Klooster H, Postma DS. The NK-2 
receptor antagonist SR 48968C does not improve 
adenosine hyperresponsiveness and airway 
obstruction in allergic asthma. Clin Exp Allergy 2001; 
31(2):274-278.
21 Schelfhout V, Louis R, Lenz W, Heyrman R, 
Pauwels R, Joos G. The triple neurokinin-receptor 
antagonist CS-003 inhibits neurokinin A-induced 
bronchoconstriction in patients with asthma. 
Pulmonary Pharmacology & Therapeutics 2006; 
19(6):413-418.
22 Boot J, Tarasevych S, Wang L, Sterk PJ, Miller B, Amin 
D et al. Effect of ave5883, a Dual nk1/nk2 Receptor 
Antagonist, on Allergen-Induced Airway Responses 
and Inflammation in Asthma. Proc Am Thorac Soc 
3[A80]. 2006. 
23 Diamant Z, De Haas S, Cohen J, Burggraaf J, 
Schoemaker RC, Sterk PJ et al. Effect of inhaled 
ave5883, a dual nk1/nk2 receptor antagonist, on 
airway responsiveness to neurokinin A in asthma. 
European Respiratory Journal 24[P1384]. 2004. 
24 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen 
OF, Peslin R, Yernault JC. Lung volumes and 
forced ventilatory flows. Report Working Party 
Standardization of Lung Function Tests, European 
Community for Steel and Coal. Official Statement of 
the European Respiratory Society. Eur Respir J Suppl 
1993; 16:5-40.
77 section 2 – effect of an nk1/nk2 receptor antagonist on airway responses and  
 inflammation to allergen in asthma
25 Cheung D, Timmers MC, Zwinderman 
AH, Den Hartigh J, Dijkman JH, Sterk PJ. 
Neutral endopeptidase activity and airway 
hyperresponsiveness to neurokinin A in asthmatic 
subjects in vivo. Am Rev Respir Dis 1993; 148(6 Pt 
1):1467-1473.
26 Diamant Z, Kuperus J, Baan R, Nietzmann K, Millet S, 
Mendes P et al. Effect of a very late antigen-4 receptor 
antagonist on allergen-induced airway responses 
and inflammation in asthma. Clin Exp Allergy 2005; 
35(8):1080-1087.
27 Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft 
DW, O’Byrne PM, Anderson sd et al. Airway 
responsiveness. Standardized challenge testing with 
pharmacological, physical and sensitizing stimuli in 
adults. Report Working Party Standardization of Lung 
Function Tests, European Community for Steel and 
Coal. Official Statement of the European Respiratory 
Society. Eur Respir J Suppl 1993; 16:53-83.
28 Leader of the Working Group:, Members of the 
Working Group:, Hamid Q, Kelly MM, Linden M, Louis 
R et al. Methods of sputum processing for cell counts, 
immunocytochemistry and in situ hybridisation. Eur 
Respir J 2002; 20(37_suppl):19S-23.
29 ats/ers Recommendations for Standardized 
Procedures for the Online and Offline Measurement 
of Exhaled Lower Respiratory Nitric Oxide and Nasal 
Nitric Oxide, 2005. Am J Respir Crit Care Med 2005; 
171(8):912-930.
30 Aalbers R, Kauffman HF, Koeter GH, Postma DS, De 
Vries K, De Monchy JG. Dissimilarity in methacholine 
and adenosine 5’-monophosphate responsiveness 3 
and 24 h after allergen challenge. Am Rev Respir Dis 
1991; 144(2):352-357.
31 Inman MD, Watson R, Cockcroft DW, Wong BJ, 
Hargreave FE, O’Byrne PM. Reproducibility of 
allergen-induced early and late asthmatic responses. J 
Allergy Clin Immunol 1995; 95(6):1191-1195.
32 Joos GF, Van Schoor J, Kips JC, Pauwels RA. The 
effect of inhaled FK224, a tachykinin NK-1 and NK-2 
receptor antagonist, on neurokinin A-induced 
bronchoconstriction in asthmatics. Am J Respir Crit 
Care Med 1996; 153(6 Pt 1):1781-1784.
33 Schuiling M, Zuidhof AB, Zaagsma J, Meurs H. Role 
of tachykinin nk1 and nk2 receptors in allergen-
induced early and late asthmatic reactions, airway 
hyperresponsiveness, and airway inflammation in 
conscious, unrestrained guinea pigs. Clin Exp Allergy 
1999; 29 Suppl 2:48-52.
34 Schuiling M, Zuidhof AB, Zaagsma J, Meurs 
H. Involvement of tachykinin nk1 receptor in 
the development of allergen-induced airway 
hyperreactivity and airway inflammation in conscious, 
unrestrained guinea pigs. Am J Respir Crit Care Med 
1999; 159(2):423-430.
35 Schuiling M, Zuidhof AB, Meurs H, Zaagsma J. 
Role of tachykinin nk2-receptor activation in the 
allergen-induced late asthmatic reaction, airway 
hyperreactivity and airway inflammatory cell influx in 
conscious, unrestrained guinea-pigs. Br J Pharmacol 
1999; 127(4):1030-1038.
36 Gauvreau GM, Doctor J, Watson RM, Jordana M, 
O’Byrne PM. Effects of inhaled budesonide on 
allergen-induced airway responses and airway 
inflammation. Am J Respir Crit Care Med 1996; 
154(5):1267-1271.
37 Larsen BB, Nielsen LP, Engelstatter R, Steinijans V, 
Dahl R. Effect of ciclesonide on allergen challenge 
in subjects with bronchial asthma. Allergy 2003; 
58(3):207-212.
38 Joos GF, Germonpre PR, Pauwels RA. Role of 
tachykinins in asthma. Allergy 2000; 55(4):321-337.
39 Bowden J, Gibbins IL. Relative density of substance 
P-immunoreactive nerve fibres in the tracheal 
epithelium of a range of species. faseb J A1276. 1992. 
40 Groneberg DA, Quarcoo D, Frossard N, Fischer A. 
Neurogenic mechanisms in bronchial inflammatory 
diseases. Allergy 2004; 59(11):1139-1152.
41 Howarth PH, Djukanovic R, Wilson JW, Holgate 
ST, Springall DR, Polak JM. Mucosal nerves in 
endobronchial biopsies in asthma and non-asthma. 
Int Arch Allergy Appl Immunol 1991; 94(1-4):330-333.
42 Fahy JV, Wong HH, Geppetti P, Reis JM, Harris 
SC, Maclean DB et al. Effect of an nk1 receptor 
antagonist (CP-99,994) on hypertonic saline-induced 
bronchoconstriction and cough in male asthmatic 
subjects. Am J Respir Crit Care Med 1995; 152(3):879-
884.
43 Barnes N, Piper PJ, Costello J. The effect of an oral 
leukotriene antagonist L-649,923 on histamine and 
leukotriene D4-induced bronchoconstriction in 
normal man. J Allergy Clin Immunol 1987; 79(5):816-
821.
44 Britton JR, Hanley SP, Tattersfield AE. The effect of 
an oral leukotriene D4 antagonist L-649,923 on the 
response to inhaled antigen in asthma. J Allergy Clin 
Immunol 1987; 79(5):811-816.
45 Smith LJ, Glass M, Minkwitz MC. Inhibition of 
leukotriene D4-induced bronchoconstriction in 
subjects with asthma: a concentration-effect study of 
ICI 204,219. Clin Pharmacol Ther 1993; 54(4):430-436.
46 Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT. 
Effect of cysteinyl-leukotriene receptor antagonist ICI 
204.219 on allergen-induced bronchoconstriction and 
airway hyperreactivity in atopic subjects. Lancet 1991; 
337(8743):690-694.
78 non-invasive sampling methods of inflammatory biomarkers in asthma  
 and allergic rhinitis
chapter 4
Reversal of the late asthmatic response increases  
exhaled nitric oxide
Respir Med. 2005;99(12):1591-4.
J.D. Boot1, S. Tarasevych1, P.J. Sterk 2, R.C. Schoemaker1, L. Wang 3, D. Amin 3, 
A.F. Cohen1 and Z. Diamant1. 
1  Centre for Human Drug Research, Leiden, Netherlands
2  Leiden University Medical Center, Leiden, Netherlands 
3  Aventis Pharma Inc, Bridgewater, nj, United States
80 non-invasive sampling methods of inflammatory biomarkers in asthma  
 and allergic rhinitis
Introduction
Exhaled nitric oxide (eno) is indicative of the severity of the airway inflam-
mation in asthma (1,2). Consequently, this non-invasive, patient-friendly 
methodology has recently been introduced into clinical practice as a diag-
nostic and monitoring tool especially for children (3-5). However, despite 
standardization of the eno protocol (6), there are still some issues that need 
to be addressed. For example, whether there does or does not exist a relation-
ship between the airway calibre and the eno levels. A clear-cut relationship 
of eno and the airway calibre may have implications for the measurements 
(7-10).
Late asthmatic airway response (lar) to inhaled allergen, defined as a fall in 
forced expiratory volume in 1 second (fev1) of at least 15% from pre-allergen 
baseline (11), have been shown to be associated with airway inflammation, 
including increased levels of eno (12). We hypothesized that eno levels dur-
ing lar are related to the degree of airway narrowing. Therefore, we studied 
the effect of vigorous bronchodilation with inhaled salbutamol during lar 
on eno levels.
Subjects and methods
subjects
Data from 12 asthmatics (6m/6f, 21-40 y) pc20fev1 methacholine<8 mg/
mL) with mild to moderate persistent asthma (fev1 73.6-121.4 % predicted) 
and dual responses to inhaled house-dust mite (hdm) extract participating 
in an intervention study were used. All subjects had a history of persistent 
asthma for at least 1 year (according to criteria by gina 2002), without any 
other clinically relevant disorders. None of the subjects had smoked tobacco 
during the past year. None was using concomitant anti-asthma or anti-allergy 
medication for at least 6 weeks prior to and during the study, except for 
inhaled short-acting β2-agonists prn. There was no history of viral infections 
of the lower airways for at least 4 weeks. The study was approved by the Ethics 
Committee of the Leiden University Medical Center and all participants gave 
written consent.
study design
The allergen-induced airway response during the lar was measured 
at 1-hourly intervals until 9-h post-allergen. To reverse the lar, 600 µg 
salbutamol was administered through an aerochamber (Volumatic, 
GlaxoSmithKline, Zeist, The Netherlands), and the fev1 was repeated 15 min 
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later. Exhaled no was measured before and approximately 30 minutes post-
salbutamol. For ethical reasons, no placebo-arm was included in this study.
Methods
allergen bronchoprovocation test
The allergen bronchoprovocation test was performed using the standard-
ized 2-minutes tidal breathing method according to Cockcroft (11). Purified 
aqueous allergen extract of Dermatophagoides Pterinyssinus (sq503, 
alk-bpt, alk-Abelló, Nieuwegein, The Netherlands), with 0.5% phenol as a 
preservative was used for the bronchoprovocation tests (bpt). Preparation 
of the hdm extract dilutions was performed according a previously validated 
protocol (13). The allergen aerosols were generated by a DeVilbiss 646 nebu-
lizer (output 0.13 mL/min) connected to an in-and expiratory valve box with 
an expiratory aerosol filter (Pall Ultipor bb50T, Medica bv, Den Bosch, The 
Netherlands). Subjects first inhaled the allergen diluent, and provided the 
subsequent fall in fev1 remained <10% of baseline, they subsequently inhaled 
a total of 3 doubling concentrations of hdm extract at 12 min intervals that 
previously caused a lar. The airway response during the lar was measured 
at 1-hourly intervals until 9 h post-allergen or earlier if subjects experienced 
unbearable discomfort or the fev1 fell below 1.4 L.
airway response
The airway response to the inhaled aerosols was measured by fev1 according 
to standardized lung function techniques and recorded by a spirometer con-
nected to a pc (Vmax Spectra, Sensor Medics, Bilthoven, The Netherlands) 
(14). At each specified timepoint, the fev1 was measured in duplicate, and the 
highest, technically satisfactory fev1 was implicated in the analysis. The airway 
response was quantified as percentage change from pre-allergen baseline fev1.
exhaled no measurements
Exhaled no levels were measured in triplicate (within 10%) by a chemolu-
minescence analyzer (Ecomedics cld88sp, Duernten, Switzerland) at the 
specified timepoints. The mean ppb-value was implicated in the analysis; the 
response was quantified as percentage change from pre- to post-salbutamol 
value. 
analysis
fev1 and eno responses were correlated using a Spearman Rank Order 
Correlation Coefficient.
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Results 
All subjects had a lar. As compared to pre-allergen baseline, the mean fall in 
fev1 at the time of reversal was 33.3% (range 15.1-57.7%). Salbutamol increased 
fev1 on average by 43% (sd: 16%) as compared to pre-salbutamol fev1.
At the end of the allergen challenge, the mean eno pre-salbutamol was 60.2 
ppb (30.6-108.1 ppb). Salbutamol increased eno on average by 30% (range: 
39.06 – 140.6 ppb; sd:17%). The Spearman Rank Order Correlation between 
the % change in fev1 and the % change in eno (pre- versus post-salbutamol) 
was 0.51 (p<0.02) (Figure).
figure 1 There was a significant correlation between the % change in fev1 and the % change in eno 
(pre- versus post-salbutamol); the spearman rank order correlation was 0.51 (p<0.02).
Discussion
We found a raised eno level following reversal of airways obstruction with 
inhaled salbutamol during the lar at 9 hours post-allergen. Our data under-
score and extend earlier findings.
First, late asthmatic responses (lar) are associated with increased airway 
inflammation and accordingly, Kharitonov et al found increased eno levels 10 
hours post-allergen in asthmatic subjects, corresponding with the magnitude 
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of the lar at 9 h post-allergen (12). Second, eno levels have been found to 
relate to the airway diameter. Various studies in asthma showed decreases 
in eno levels following bronchoconstrictor stimuli including methacholine, 
histamine, hypertonic saline, adenosine monophosphate (amp) and exer-
cise-induced bronchoconstriction (7,9,10). Alternatively, following inhalation 
of salbutamol, Silkoff et al found increased levels of eno corresponding with 
increases in fev1 in asthmatic subjects in absence of allergen challenge (8).  
The present study combines all abovementioned observations: in agreement 
with Kharitonov’s data (12), we found similar pre-bronchodilator eno values 
during the lar at 9 h post-allergen. And, according to the observations of 
Silkoff et al in the absence of allergen, there was a 30% raise in eno levels fol-
lowing bronchodilation (8). 
Our data imply that as a result of allergen-induced bronchoconstriction, 
the eno level during the lar is usually underestimated. Although eno has 
been shown to reflect the degree of airway inflammation in asthma (15,16), 
Ricciardolo et al have demonstrated that the allergen-induced eno may 
also act as an endogenous bronchoprotective mechanism (17). Therefore, 
using a bronchodilator following allergen challenge may not only relieve the 
bronchoconstriction, but may also support this endogenous bronchoprotec-
tive mechanism. Another implication of our study may be that for a correct 
non-invasive assessment of airway inflammation in asthma, eno should be 
measured after (appropriate) bronchodilatation. To enable comparison with 
other studies or measurements in individuals, we suggest that both the bron-
chodilator dose and timepoint of post-bronchodilator eno measurements 
should be standardized. 
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Abstract
Background: Exhaled nitric oxide (eno) is an established, noninvasive bio-
marker of active airway inflammation in (atopic) asthma. Treatment with anti-
inflammatory therapy, such as inhaled corticosteroids, effectively decreases 
eno levels. The niox mino® (mino) is a hand-held, relatively inexpensive, 
electrochemical device that has been shown to yield comparable eno mea-
surements to the niox stationary unit.
Aim: To compare measurements of mino with another widely used and vali-
dated stationary chemoluminescence analyzer, the Ecomedics (eco). 
Methods: We performed subsequent eno measurements on eco and mino 
in 50 subjects (19 healthy volunteers, 18 healthy smokers and 13 non-smoking, 
atopic asthmatics, not on controller therapy) on two visits 4-10 days apart. 
The mean of three acceptable measurements by eco and the first acceptable 
measurement with the mino were used for analysis.
Results: Both devices yielded reproducible eno values for all subjects on both 
visits, with an overall cv of 22.7% (eco) and 18.3% (mino). A significant cor-
relation was found between both devices (r = 0.97, p < 0.0001). Bland Altman 
plots showed a high degree of agreement for the entire study population 
(mean difference mino vs. eco = -10%; 95% limit of agreement =  -36% and 
+28%) and in the three individual subgroups. 
Conclusions: Exhaled no values measured with the mino are reproducible 
and in agreement with the eco. Our results add further evidence to the reli-
ability of the mino and warrant its applicability in research and clinical prac-
tice.
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Introduction
Asthma is a chronic inflammatory disease presenting with variable symp-
toms and mostly reversible airway obstruction within the lower airways. 
According to international guidelines, modern asthma management is aimed 
at the suppression of airway inflammation by avoidance of allergens and 
anti-inflammatory, ‘controller’ therapy (1). For optimal guidance of disease 
control, measuring biomarkers of airway inflammation has become increas-
ingly important (1). To this aim, several non- and semi-invasive sampling tech-
niques have been developed and validated (2). 
Exhaled nitric oxide (no) is an established biomarker of airway inflamma-
tion that may serve to monitor the response to (novel) controller therapy. 
In asthma, elevated levels of eno have been shown to correlate with disease 
severity, showing increases prior and during an asthma exacerbation and 
decreases following anti-inflammatory treatment (2). In addition, using eno 
measurements to guide individual doses of inhaled corticosteroids resulted 
in reduced airway hyperresponsiveness along with an overall lower dose of 
inhaled corticosteroids without compromising asthma control (3,4).
Stationary chemoluminescence no analyzers are validated devices for  
online measurement of no levels in exhaled air (5). However, their usage  
is largely hampered by their bulkiness and high costs. More recently, mino 
has been marketed for portable, online eno measurements. This hand-held 
and relatively inexpensive device is simple to use and yields reproducible 
measurements, even when performed by children at home (6). In addition,  
a recent economic evaluation revealed that the use of mino in the treatment 
of asthma offers cost savings compared to asthma management based on 
standard guidelines, while both methods result in comparable health ben-
efits (7). These properties warrant its potential applicability in both primary 
health care setting and in clinical trials. However, its reliability needs to be 
fully assessed. So far, mino has been compared with the niox stationary 
unit but, to our knowledge, not with the other validated and widely used 
chemoluminescence analyzer, eco (8-10). In this study we compared eno 
measurements by mino with the previously validated eco in healthy volun-
teers, healthy smokers and atopic asthmatics.
Methods
 
subjects 
The study population consisted of three subgroups: 19 healthy volunteers, 18 
healthy smokers and 13 non-smoking, atopic asthmatics (Table 1).
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The healthy volunteers were non-smokers for at least 12 months with less 
than 5 pack years (1 pack year = 20 cigarettes or equivalent smoked per day 
for 1 year). The healthy smokers were current smokers (last cigarette was 
smoked 1-2 hours before the study procedures) with a smoking history of at 
least 10 pack years. The asthmatic-subgroup only used inhaled short-acting 
β2-agonists as needed and had no controller medication for at least 1 month 
prior to the study. All had intermittent to mild persistent asthma and clinical 
stability was assessed by stable lung function (fev1 within 10% on both study 
visits), absence of symptoms and stable, infrequent use of rescue medication 
in the last 3 months. Atopy was demonstrated by a positive skin prick test 
for at least 1 of 10 airborne allergens. None of the participants had a history 
of airway infection in the previous 4 weeks prior and during the study. All 
subjects gave written informed consent and the study was approved by the 
Ethics Committee of Leiden University Medical Centre.
study design
Exhaled no measurements were performed in all subjects on eco and mino 
on 2 study visits, 4-10 days apart. All the measurements were performed 
during the same time of the day (±2 hours).
exhaled no measurements
All eno measurements were performed according to current guidelines 
(11). Briefly, subjects were sitting in upright position and wearing a nose clip 
during the eno measurements with both devices. They inhaled no-free air 
through the device and subsequently exhaled at 50 ml/s for approximately 
10 seconds. The mean of the first three technically acceptable measurements 
within 10% performed with the eco (Ecomedics cld88sp; Ecomedics, 
Duernten, Switzerland) were implicated into analysis. For measurements 
by the mino (Aerocrine ab, Solna, Sweden), the first technically acceptable 
measurement was used for analysis (10).
spirometry
Following eno measurements, spirometry (forced expiratory volume in 1 
second (fev1), forced vital capacity (fvc) and peak expiratory flow (pef)) 
was performed according to standardized lung function techniques by a 
calibrated spirometer connected to a personal computer (Vmax Spectra 
Sensor Medics; Cardinal Health, Houten, The Netherlands) (12).
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analysis
As eno values were not normally distributed, data were log transformed 
prior to analysis. Comparisons between healthy volunteers and the other 
subgroups were made using an unpaired t-test. The reproducibility of both 
devices was assessed by the within subject variation between visits and 
expressed as a coefficient of variation (cv = the standard deviation expressed 
as percentage of the mean). In order to compare both devices, data were 
plotted in a scattergraph and the Pearson correlation was calculated on 
log-transformed data. Bland Altman plots were made with the difference 
(eco - mino) of measurements of both methods on the y-axis and the mean 
of the two methods on the x-axis, along with an estimation of the upper and 
lower limit of agreement, being 1.96 times the standard deviation (sd). The 
presented Bland-Altman plots incorporated all data and were constructed 
as if every pair of measurements was independent. Analysis of the first and 
second visit independently yielded similar results.
All calculations were performed using sas for windows V9.1.2 (sas Institute, 
Inc., Cary, nc, usa).
table 1 patients’ characteristics at baseline
healthy 
volunteers
healthy 
smokers
atopic 
asthmatics
p-value
Total number 19 18 13
Female : Male 10 : 9 9 : 9 8 : 5
Age
(years)
41
(30-53)
40
(32-52)
29
(21-54)
fev1
(% predicted)
104.4
(87.5-119.5)
103.6
(82.1-121.1)
91.8
(61.0-122.0)
Exhaled no
Ecomedics (ppb)
18.0
(7.4-35.5)
11.1
(4.7-20.5)
60.8
(10.9-184.6)
<0.01*
Exhaled no
niox mino (ppb)
20.3
(8.0-39.0)
12.2
(5-23)
63.8
(13-172)
<0.01*
All values are given as mean (range). *Healthy volunteers compared to healthy smokers and 
compared to asthmatics.
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Results
One subject from the healthy non-smokers’ group produced eno values <5 
ppb on both occasions. Two subjects (one healthy volunteer and one atopic 
asthmatic) failed to perform acceptable eno measurements on the eco. 
These measures were excluded from analysis. All other subjects completed 
the study and performed technically acceptable manoeuvres on both study 
visits. Overall, healthy smokers had significantly lower and asthmatics signifi-
cantly higher eno values compared to healthy volunteers (Table 1). Exhaled 
no values by mino were slightly, but not significantly, higher than the eco 
values in all three subgroups (Table 1). 
Both devices yielded reproducible eno values for all subjects on both visits, 
with an overall cv of 22.7% (eco) and 18.3% (mino). The Pearson correlation 
analysis yielded an r of 0.975 (p<0.0001) between eno values measured by 
mino and eco (Figure 1). 
In addition, Bland-Altman plots demonstrate agreement between both 
devices in the entire study population and the three subgroups (Figure 2) for 
both low and high values of eno.
Discussion
In recent years, eno has become widely accepted as a biomarker of airway 
inflammation in asthma. The availability of simple and reliable eno-measure-
ments is of major importance in the diagnosis and monitoring of day-to-day 
asthma. Hence, we compared the hand-held mino to the widely used sta-
tionary eco analyzer in a study population consisting of 3 subgroups: healthy 
volunteers, healthy smokers and atopic asthmatics not on controller therapy. 
Apart from a good reproducibility of eno values on both study visits, a sig-
nificant correlation and a high degree of agreement was observed between 
eno measurements yielded by both devices. Subgroup analysis revealed a 
superior agreement in the high eno ranges (atopic asthmatics) compared 
to the low eno ranges (healthy smokers). However, with respect to the latter 
the group sizes were too small to draw definitive conclusions. Our results are 
in agreement with previous data comparing the mino to the stationary niox 
unit and extend the findings to another widely used and validated chemolu-
minescence analyzer, (Ecomedics) (8-10).    
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figure 1 Pearson correlation between exhaled no levels measured with the Ecomedics (x-axis)  
and the niox mino (y-axis) analyzer. Healthy volunteers (=open squares), healthy smokers 
(=open circles) and atopic asthmatics (closed circles).
figure 2 Bland Altman plot of exhaled no measurements using the Ecomedics vs niox mino for 
the entire study population, healthy volunteers (=open squares), healthy smokers (=open 
circles) and atopic asthmatics (closed circles).
Correlation= 0.975, p -value=<.0001
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Exhaled no values are not normally distributed and require log-transforma-
tion prior to analysis (10). Therefore, in the current paper the upper and lower 
limits of agreement are presented in percentages difference which may not 
be suitable for clinical interpretation. However, if we use the mean value of 
eno for the entire study population (26.4 ppb for the eco) and back-translate 
to an arithmetic scale the upper and lower limit of agreement are +7.4 ppb 
and -9.5 ppb, respectively. In our study, both devices yielded comparable 
eno measurements in individual subjects, while mino systematically pro-
duced slightly higher values. Although similar with other studies comparing 
mino with the niox stationary unit, this may impact clinical interpretation 
if patients are assessed on both devices alternately (3,4,10,13). Hence, the cut-
off eno values should be adjusted for mino. In a previously conducted study 
comparing chemoluminescence analyzers, the eco produced overall lower 
eno values than the other stationary analyzers (14,15). In conclusion, it is clear 
that eno analyzers yield comparable, but not interchangeable eno values. 
This implicates that, ideally, in an individual patient, all eno measurements 
should be performed on the same analyzer. 
A potential issue may be the difference in lower detection limits between 
the eco (0.1 ppb) and the mino (5 ppb). Indeed, in this study one subject 
(smoker) had to be excluded from analysis because his eno values on the 
eco were under the detection limit of the mino. From a clinical perspective, 
this may not have consequences since very low eno values are not clinically 
relevant in asthma. However, should the device need to be employed in the 
lower detection range, this issue will have to be resolved. This may explain the 
larger variance between both devices in the smoker group, although the sub-
ject numbers were too small to show a significant difference in variances in 
the lower detection ranges between study groups. Other studies comparing 
the mino device with chemoluminescence analyzers did not find any differ-
ence between the lower and higher eno values (8,10). 
In conclusion, eno values measured with mino are reproducible and gener-
ally in agreement with the eco. Its simplicity, relatively low costs and small 
size make the mino device more suitable than the stationary chemolumines-
cence analyzers for primary healthcare and large clinical trials. Conversely, it 
cannot be used in research settings requiring more sophisticated measure-
ments including nasal no, very high or low eno values or samplings at differ-
ent flow rates. Our results add further evidence to the reliability of mino and 
warrant its applicability in clinical practice and research.
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Abstract
Rationale Traditional biomarker quantification methods in exhaled breath 
condensate (ebc) and sputum have yielded conflicting data due to the lack 
of standardization of the collection technique (ebc), denaturant effects of 
sputum processing (dithiothreitol (dtt)), and the limited sensitivity of most 
detection assays.
Aim We aimed to improve the recovery of inflammatory biomarkers 
from sputum and ebc from atopic asthmatics. To this end, we applied 
two alternative processing methods to sputum and sensitive detection 
techniques in both sputum and ebc.
Methods On two separate visits, ebc and NaCl 4.5%-induced sputum 
was obtained from 10 non-smoking, clinically stable, atopic asthmatics 
(4M/6f, 21-54 y, fev1 70-122% predicted, pc20fev1 methacholine<8 mg/
mL, SABA prn only). ebc was analyzed with antibody based flow-cytometry 
using Luminex Multi-Analyte Profiling beads. The sputum was processed 
conventionally, by treatment with dtt to solubilize mucins followed by 
dialysis to remove dtt (dtt-dialysis) and analyzed with antibody based 
electrochemiluminescence using Mesoscale multi-array microplates. 
Subsequently, sputum was obtained from 4 of these patients on two extra 
occasions: the sample was split manually and half of each sample was 
processed conventionally and the cell pellet was used as a quality check; 
the other half was ultracentrifuged (35,000rpm, Ultra) and analyzed with 
Mesoscale and Luminex. 
Results All subjects expectorated analyzable sputum. In dtt-dialysis-
processed sputum, spiking experiments with exogenously added cytokines 
and chemokines showed a poor recovery and almost all biomarkers remained 
under detection level. After Ultra-processing, several biomarkers were 
measurable with Mesoscale yielding similar levels on two separate occasions. 
Hence, Luminex platform analysis was applied allowing detection of a large 
array of biomarkers. Applying Luminex in ebc, many biomarkers remained 
below detection limit. In the sputum samples we were able to isolate rna and 
perform rna profiling in the majority of collected samples. Gene expression 
profiling appeared similar on both visits within subjects. 
Conclusion In this exploratory pilot study, we found that recovery of 
biomarkers was superior in Ultra-processed sputum as compared with dtt-
dialysis treated samples, when measured with Mesoscale. Luminex allowed 
the detection of similar and other biomarkers. In ebc most biomarkers 
remained below detection limit despite a sensitive detection technology 
(Luminex). rna isolation from sputum cells was highly successful and 
appeared repeatable. 
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Introduction
Non-invasive sampling methods, including the collection of exhaled breath 
and sputum analysis, are increasingly applied for assessments of the airway 
inflammation in clinical monitoring and research in asthma and copd (1). 
However, traditional biomarker quantification methods in exhaled breath 
condensate (ebc) and sputum have yielded conflicting data, due to the lack of 
standardization of the collection technique (ebc) or to denaturant effects of 
sputum processing with dithiothreitol (dtt), or to limited sensitivity of most 
detection assays (2-4).
Quantification of inflammatory mediators in sputum supernatant requires 
homogenization of the sputum sample with subsequent release of cells and 
mediators from the mucous bonds. Therefore, dtt is added to the sample 
to reduce disulphide bonds which cross-link mucinous glycoproteins (5). 
However, this activity also interferes with the essential disulphide bonds in 
cytokines and chemokines and hampers the immunological detection of 
these mediators (5) Recently, Erin et al, introduced a dialysis technique to 
dtt-processed sputum samples, removing dtt after homogenisation and 
restoring the disulphide bonds, and hence substantially increasing the recov-
ery of cytokines and chemokines (6). Significant differences in cytokine and 
chemokine levels in supernatant were detected between healthy volunteers 
and asthmatics, whilst these differences could not be established with the 
standardized processing. 
Ultrasonification or ultracentrifugation is another technique for releasing 
cells and mediators by physical homogenization which does not require the 
addition of dtt (7,8). Ultracentrifugation of the entire sample, immediately 
after collection, yields a homogenous supernatant, devoid of cell debris and 
mucous. Hadjicharalambous et al showed that eotaxin could readily be mea-
sured by enzyme linked immunosorbent assay (elisa) in induced sputum 
samples from both asthmatics and healthy volunteers following ultracen-
trifugation whilst this was not feasible in samples (from the same subjects) 
treated with dithioerythritol (dte; i.e. an isomer of dtt) (9). A drawback of 
this technique concerns the disruption of cells and spilling of intracellular 
content in the homogenate – which of course, can partly account for higher 
biomarker concentrations (8). 
Following adequate sample processing, mediators are mostly measured 
with immunoassays (3,8). However, several authors failed to demonstrate 
most of the soluble inflammatory components due to limited sensitivity of 
these assays (10). Multiplex platforms may offer an advantage due to their 
capability of simultaneous measurements of up to 100 analytes in small and 
diluted sample volumes (25-50 ml), such as sputum supernatant and ebc. 
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The Luminex platforms combine a sandwich immunoassay with fluorescent 
bead–based detection increasing the specificity and sensitivity of a measure-
ment (11). Gessner et al were able to detect a wide range of cytokines in the 
exhaled breath condensate of copd patients using a Luminex immunoassay 
(12). So far, this has been difficult using traditional immunoassays. Mesoscale 
is another multi-array technology based on chemiluminesence detection for 
increased sensitivity.
Inflammatory mediators can also be detected at the rna level in induced 
sputum after the cells have been lysed (13). Reverse transcriptase polymerase 
chain reaction (rt-pcr) is a sensitive and specific method for the detection 
of messenger rna (mrna) concentrations even in samples with a low total 
cell count (14).
In this pilot study we have collected ebc and sputum from a limited number 
of atopic asthmatic subjects. We aimed to recover rna from the sputum 
cells and using microarray analysis conduct gene expression profiling and 
investigate, via 2-dimensional clustering, the reproducibility of this technique 
in sputum samples collected on two separate visits in the same subject. The 
collected sputum supernatant underwent new and optimized processing 
methods (dialysis and ultracentrifugation) and was analyzed with more sensi-
tive detection techniques (Mesoscale platform, Luminex immunoassay) on 
two visits to investigate which inflammatory mediators can be measured and 
assess the reproducibility. In addition, ebc collected in these same subjects 
also underwent a Luminex immunoassay analysis. With these results the 
most suitable processing and detection techniques will be selected for a sub-
sequent allergen challenge study in a similar patient population. 
Methods
subjects
Ten non-smoking subjects with clinically stable, mild to moderate persistent 
allergic asthma were recruited. All patients had a history of persistent asthma 
for at least 1 year (according to Global Initiative for Asthma (gina) criteria 
15), without any other clinically relevant disorders. Atopy was established by 
a positive skin prick test to Dermatophagoides Pteronyssinus (alk-Abello, 
Nieuwegein, The Netherlands) at screening. Except for stable, infrequent 
use of inhaled short-acting β2-agonists as required, no one was using con-
comitant anti-asthma or anti-allergy medication for at least 6 weeks prior to 
and during the study. Patients had no history of viral infections of the lower 
airways for at least 3 weeks before enrollment. Caffeine-containing bever-
ages and short-acting inhaled β2-agonists were withheld at least 8 h before 
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each visit. The study protocol was approved by the Leiden University Medical 
Centre Ethics Committee, and all participants gave written informed consent.
design
The study was performed in a single-center setting in two parts (figure 1).  
In the first part, ebc and subsequently, sputum samples were obtained from 
10 eligible, asthmatic subjects on two separate study visits. The sputum was 
processed according to a novel dialysis technique described by Erin et al (6). 
Following analysis of the sputum samples from the first part, the second 
part of the study was initiated. Four asthmatic subjects (from the initial 10) 
returned for two extra sputum inductions (visit 3 and 4). These sputum sam-
ples were split in two equal parts by a forceps: one part was processed accor- 
ding to standard procedures and cell differentials were counted as a quality 
check, while the other part was ultracentrifuged and analyzed, as described 
below. All the samplings were performed during the same time of the day  
(±2 hours) on all study visits – and all study visits were separated by 4-10 days.
figure 1 Study flowchart
Collection techniques
exhaled breath condensate collection
After an acclimatization period of approximately 30 minutes and before 
sputum induction, each subject was asked to inhale and exhale calmly, while 
wearing a nose clip, through a mouthpiece and two-way nonrebreathing 
sample collection on visit 1 and 2
from 10 asthmatics
sample collection on visit 3 and 4
from 4 asthmatics
M
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th
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d
s
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Cell Pellet   Supernatant                1/2 sample             1/2 sample
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Luminex 
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all samples
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Cell count
all samples
Mesoscale
all samples
Spiking
Cell count
all samples
Mesoscale
6 samples
Luminex
all samples
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valve connected with the EcoScreen condenser (Jaeger, Cardinal Healthcare, 
Houten, The Netherlands) during a fixed period of 20 minutes (3). 
Immediately after collection, condensate samples were aliquoted and stored 
at -80°C pending analysis.
sputum induction
Sputum induction was performed according to a validated method. 
Hypertonic saline aerosols (NaCl 4.5%) were generated at room temperature 
by a DeVilbiss Ultraneb 2000 ultrasonic nebulizer (Tefa Portanje, Woerden, 
The Netherlands) and inhaled for 3x5 min at 15 min intervals (16). After each 
inhalation, or as soon as the subjects experienced cough, they were asked to 
blow their nose, to rinse their mouth and throat with water, and to expecto-
rate sputum into a clean plastic container by coughing. 
Sputum processing techniques
dialysis technique (dtt dialysis) 
On study visits 1 and 2 whole sputum samples were processed according to 
a previously validated protocol by Fahy et al (17), with modifications (18,19). 
Briefly, the volume of the induced sputum samples was determined and 
mixed with an equal volume of 0.1% sputolysin (Dithiothreitol, Calbiochem, 
La Jolla, ca, usa). Prior to addition to the sputum, a protease inhibitor tablet 
(Complete Protease Inhibitor Cocktail tablets, Roche Applied Science #11 
697 498 001) was added to 0.1% dtt solution (1 tablet per 50 mL of solution). 
To ensure adequate homogenization, the samples were placed in a shaking 
water bath at 37°C for 15 min, once interrupted by gently mixing the sample 
with a plastic pipette. The homogenized sputum was centrifuged at 1400 
r.p.m. at 4°C for 10 min. The sputum supernatant was collected and stored at 
-80°C until further processing. 
After thawing the sputum supernatant 2 µL of 0.5M edta and 50 µL of 20% 
bsa was added per 1 mL of sputum supernatant. Prepared samples were 
transferred into equilibrated 3,500 MWCO dialysis cassettes (Thermo 
Scientific cat. no. 66330; 0.5-3.0 mL capacity) with the use of a syringe 
(Pierce cat. no. 66494). The dialysis cassettes containing prepared samples 
were placed in a 4 L beaker filled with prechilled Dialysis Buffer 1 and were 
incubated stirring overnight at 40°C. On the next day, the dialysis cassettes 
were transferred into a 4 L beaker containing prechilled Dialysis Buffer 2 
and were incubated stirring overnight at 40°C. After the double dialysis the 
sputum supernatants were collected using a syringe and stored at -80°C until 
Mesoscale and Luminex analysis.
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rna analysis 
After centrifugation and removing the supernatant, the sputum cell pellets 
were resuspended in pbs to a final volume of 2 mL, followed by filtration 
through a gauze (pore size 1 mm) to remove clumps. Subsequently, 360 µl 
was taken for differential cell count. The remaining cell suspension was cen-
trifuged at 4°C for 10 minutes at 390 G (1500 rpm). The supernatant was care-
fully collected to prevent disrupting of the cells and discarded. The cell pellet 
was immediately re-suspended in 1ml of cold TRIzol reagent (Invitrogen, Cat. 
# 15596-018). 1.5 mL of TRIzol was added if the total cell count is > 5 x 106 cells 
to ensure complete lysis. The solution was mixed by pipetting up and down 
with a 1 ml pipette, and vortexing. The resulting lysate was stored at -80°C 
pending rna analysis.
ultracentrifuge (ultra)
Four subjects were asked to expectorate sputum on two additional study 
visits. The sputum samples were carefully divided manually into two por-
tions of equal weight. One part was processed using dtt (as described 
above) and only the cell pellet was used for cell differentials (as quality 
control). The other part of the sample was weighed into an ultracentrifuge 
container (Beckman Coulter 1.5 mL polyallomer microfuge tube; cat. no. 
357448 or 3.2 mL glass tube; cat. no. 362333) and 50 µL of a protease inhibitor 
cocktail was added per 200 mg of weighed sputum. The protease inhibitor 
cocktail was prepared by dissolving one protease cocktail tablet into 50 mL 
of 1X pbs (Invitrogen cat. no. 14040). Prepared samples were subsequently 
ultracentrifuged for 90 minutes in a high-speed ultracentrifuge (Beckman 
Coulter Inc. Optima Max Ultracentrifuge 130,000 rpm; Fullerton, California) 
at 35,000rpm (53,500 x g) at 4°C. Sputum supernatants were then col-
lected without disrupting the pellet and stored at -80°C until Mesoscale and 
Luminex analysis. The pellet was discarded.
Analysis techniques
exhaled breath condensate analysis
Biomarkers were measured using the Luminex Human Multi-Analyte Profiles 
(map) immunoassay platform of Rules Based Medicine (Austin, tx, usa) 
according to manufacturer’s directions.
sputum analysis – soluble phase
To determine the effects of both processing methods on sputum mediators, 
a recovery analysis was performed by spiking 500 pg of two cytokines, il-13 
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(msd il-13 Calibrator for Ultrasensitive kit (msd cat. no. k111acs-2)) and tnf-
alpha (r&d Systems cat. no. 210-ta-050) per 1 mL of sputum prior to incuba-
tion at 37°C in the procedure in three randomly selected samples. The spiked 
analyte levels were within the detection range of the assays. The Mesoscale 
assays (tnf-α, il-13, tarc and eotaxin) were performed by electrochemilu-
minescence (msd Clinical Development Laboratory, nj, usa) according to 
manufacturer’s directions. 
In samples where biomarkers could be measured using Mesoscale, additional 
analyses were performed using the Luminex Humanmap antigen platform of 
Rules Based Medicine according to manufacturer’s directions.
sputum analysis – cellular phase
Cell counts were performed in a haemacytometer (Novex Microscope, The 
Netherlands), to obtain an estimate of the total number of cells per sample. 
Subsequently, the samples were diluted with pbs to a final concentration of  
± 0.4 x 106 cells/mL which was used for preparation of cytocentrifuge slides 
(50 µL/cytospin; Shandon Cytospin 4, Thermon Electron Corporation,  
Runcorn, uk). Differential cell counts of eosinophils, neutrophils, lym- 
phocytes, macrophages, epithelial and squamous cells were performed  
on May-Grünwald-Giemsa-stained cytospins by a certified cytopathologist. 
In addition, mast cells were counted on Toluidine blue-stained cytospins. 
In each sputum sample, at least 500 nucleated cells, excluding squamous 
cells, were counted twice and the average percentage of each cell type was 
calculated and expressed as percentage nonsquamous cells. If > 80% of the 
cell count consisted of squamous cells, the quality of the sputum sample was 
judged unsatisfactory and the entire sample (including the supernatant) was 
excluded from analysis.
sputum analysis - gene expression
rna was isolated from the cell lysate collected on visit 1 and 2 following 
standard rna extraction procedures. Total rna quality (sample integrity) 
was evaluated utilizing 28S/18S ratio and rna Integrity Number (rin) scores 
obtained from the Agilent Bioanalyzer capillary electrophoresis system. 
Sample concentration was assessed utilizing the RiboGreen® (Invitrogen) 
fluorescent dye system. Established pass/fail criteria were then used to iden-
tify samples of sufficient quality and concentration for expression profiling. 
Only specimens that passed the two qc steps were amplified and profiled. 
These samples were amplified using the nugen Ovation amplification tech-
nology and profiled on Affymetrix arrays. After scanning, the array data were 
normalized by multiarray average (rma) of background-adjusted, normal-
ized, and log-transformed perfect match (PM) values. A profiling qc step was 
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performed, assessing in particular the percentage of present calls, scale fac-
tor, gapdh and Actin mrna 5’ to 3’ ratios for each hybridization, in order to 
identify potential outliers. Based on this quality check outliers were excluded 
from subsequent data analysis. The remaining samples were analyzed by 2D 
unsupervised hierarchical clustering.
analysis
Only sputum samples with an adequate quality (<80% squamous cells and 
500 nucleated cells counted) were included into analysis. The least detect-
able dose (ldd) was determined as the mean + 3 standard deviations of 20 
blank readings. Group sizes in this pilot study were too small for statistical 
analysis, hence, descriptive statistics was used to describe the results. 
Results
ebc andsputum quality assessment
ebc was obtained from all subjects. All ten subjects were able to expectorate 
adequate (<80% squamous cells and 500 nucleated cells counted) sputum 
samples on all visits.
sputum supernatant and ebc
Spiking showed a poor recovery for the sputum samples obtained on the 
first two study visits and processed with the dtt-Dialysis technique (Table 
1). Therefore, Mesoscale analysis was randomly performed in 6 samples only. 
Almost all cytokines and chemokines appeared below the least detectable 
dose (ldd) (Table 2) and hence, the remaining samples were not analyzed.  
In the second part of the study, we collected sputum samples from 4 of the 10 
asthmatics on two extra visits. Following processing with the Ultra technique, 
these samples showed a much higher recovery in the spiking experiments 
(Table 1). Subsequently, these samples were analyzed with the Mesoscale 
platform (Table 2). The positive results provided support to additional analy-
sis with Luminex. The relevant detectable mediators for inflammatory airway 
disease are summarized in Table 3. In the same subjects ebc (collected on 
Visit 1) was also analyzed with Luminex (Table 3).
rna recovery from sputum cells
In part 1 of the study, from 17 out of 20 collected sputum samples (10 sub-
jects; 2 visits) sufficient rna could be extracted from the cell pellet lysate. 
Specimens collected from the same patient at different times were co-
clustered in a dendogram as presented in Figure 2. These data show that total 
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rna extraction and profiling of samples obtained on both study visits (visit 1 
and 2) were reproducible with variation in the gene expression profiles being 
smallest within the individual patient.
table 1 percentage recovery of spiked il-13 and tnf-α measured by mesoscale
procedure il-13 (pg/ml) tnf-α (pg/ml)
dtt-Dialysis technique (n=3) 27.9 % (± 11.6) 51.6 % (± 4.3)
Ultra technique (n=3) 110.6 % (± 11.3) 62.4 % (± 6.2)
Values are presented as mean (± sd)
table 2 levels of inflammatory mediators in sputum supernatant following  
dtt-dialysis and ultra-processing measured by mesoscale 
procedure subject eotaxin-3 
(pg/ml)
tarc 
(pg/ml)
il-13 
(pg/ml)
tnf-α 
(pg/ml)
dtt-Dialysis 
technique
Nr 1 - Visit 1 <ldd <ldd <ldd <ldd
Nr 1 - Visit 2 <ldd <ldd <ldd <ldd
Nr 4 - Visit 1 147 <ldd <ldd <ldd
Nr 5 - Visit 1 <ldd <ldd <ldd <ldd
Nr 5 - Visit 2 <ldd <ldd <ldd <ldd
Nr 8 -Visit 1 129 12.2 <ldd <ldd
Sputum 
Ultra  
technique
Nr 7 - Visit 3 14.5 <ldd <ldd 1.74
Nr 8 - Visit 3 216 20.5 <ldd 5.89
 Nr 9- Visit 3 641 14.3 0.79 25.8
Nr 10 - Visit 3 37.9 <ldd <ldd <ldd
Sputum 
Ultra  
technique
Nr 7 - Visit 4 <ldd <ldd <ldd 1.57
Nr 8 - Visit 4 24.4 10.5 <ldd 1.91
Nr 9 - Visit 4 4892 59.5 3.2 40
Nr 10 - Visit 4 71.2 <ldd <ldd <ldd
<ldd 9.6 9.6 .59 1.52
Mesoscale analysis was randomly performed in 6 samples only on Visit 1 and 2. Four asthmatics 
returned for Visit 3 and 4 for an extra sputum induction. ldd = Least detectable dose
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figure 2 Two-dimensional clustering of mrna collected from asthmatic subjects on study visit 1  
and 2.
Discussion
This pilot study was aimed to improve the recovery of inflammatory bio-
markers obtained with non-invasive airway sampling techniques, ebc and 
induced sputum – both from the soluble and the solid phase. To this end we 
tested two alternative sputum processing methods and applied novel sensi-
tive detection techniques to both the sputum and ebc samples. Applying 
Mesoscale analysis on sputum samples, processed by the dialysis technique 
previously introduced by Erin et al, we were unable to measure relevant 
cytokines and chemokines (6). Therefore, this processing technique was not 
pursued any further, and we processed sputum supernatant with the dtt-
free Ultracentrifuge technique described previously (9). In these samples 
we found a good recovery of spiked cytokines and chemokines, and we were 
able to quantify several cytokines and chemokines. In addition, in these 
samples we were able to measure multiple inflammatory mediators with the 
Nr 1Visit 1
Nr 10Visit 2
Visit 1
Nr 2
Visit 2
Visit 2
Nr 7
Visit 1
Visit 1
Nr 4
Visit 2
Nr 3Visit 1
Visit 1
Nr 5
Visit 2
Visit 1
Nr 6
Visit 2
Visit 1
Nr 9
Visit 2
Visit 2
Nr 8
Visit 1
[corr] > 0,5 = 11,98%
1000            2000            3000            4000            5000            6000
Experiments clustered
Induced Sputum Pilot combined 12 june 2008
-0,3           0               0,3
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
1 chip
107 section 2 –combining alternative sputum processing methods & sensitive   
 detection techniques for biomarker analysis: a feasibility study
Luminex analysis. In contrast, applying Luminex analysis to the ebc samples 
of these subjects, most mediators remained under ldd. Regarding the solid 
phase-biomarkers: rna isolation from sputum cells was highly successful. 
Seventeen out of 20 collected samples passed the quality control tests and 
the gene expression profiling appeared similar on both visits within subjects.
 In contrast to the dtt-Dialysis, applying the Ultra technique, we were 
able to quantify several inflammatory mediators in sputum samples. We 
decided to specifically measure eotaxin-3 with the Mesoscale, since a study 
by Berkman et al reported that eotaxin-3 - and not eotaxin - was upregulated 
in bronchial biopsies and bronchoalveolar lavage fluid in atopic asthmatics 
following inhaled allergen challenge (20). We found similar levels of eotaxin-3 
measured with Mesoscale and eotaxin measured with Luminex as previously 
reported by Hadjicharalambous following ultracentrifugation of sputum 
samples of patients with mild to moderate persistent asthma (9). The authors 
applied this technique because in their study spiked sputum samples showed 
low recovery following treatment with dte without any increase following 
ultrafiltration. These findings are comparable to our results applying the 
dtt-Dialysis technique. Interestingly, in the same study, eotaxin levels were 
not higher following ultracentrifugation (13,000g) compared to regular 
speed centrifugation (400 g). However, it is unlikely that the Ultra technique 
yields similar data as the dtt processing technique, since ultracentrifugation 
causes intracellular contents to spill into the supernatant and consequently 
may increase the levels of the inflammatory markers. In addition, applying 
this technique, cell counts cannot be performed due to the cellular disrup-
tion by the high speed centrifugation. This can be overcome by splitting 
the samples, so in one part cell counts can be performed, for the purpose 
of quality control of the entire sample, while the remaining part is used to 
investigate the presence of dtt-sensitive biomarkers. Although the numbers 
were small in the second part of the study, the techniques appeared to yield 
reproducible results. Patients with the highest biomarker levels on visit 3, 
presented with the highest levels on visit 4 and in the same range for several 
detectable mediators (Table 2). A similar pattern was seen in the Luminex 
analysis (Table 3). Obviously, more precise data on the reproducibility of 
these detection techniques need to be obtained in larger patient and sample 
numbers in a more standardized manner. In this setting, the Ultra technique 
should also be compared to the standardized sputum processing methods 
(including dtt), and not only to the dtt-Dialysis technique. 
Despite the sensitive detection technique employed, a wide range of bio-
markers remained below the ldd in the Ultra samples and even more so in 
the ebc. In agreement with the results by Bayley et al in a population with 
copd, we were also unable to measure α-antitrypsin, il-8 and myeloper-
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oxidase in ebc (21). Possibly, these biomarkers are present in higher con-
centrations in other asthma-phenotypes or under different conditions, e.g. 
in a more severe disease or following an exacerbation, rather than in stable 
disease. For example, Csoma et al found higher levels of leukotrienes in ebc 
in patients with severe asthma than in patients with moderate persistent 
asthma, while levels in mild asthmatics were similar to healthy controls (22). 
In addition, several studies reported increased levels of leukotrienes follow-
ing an asthma exacerbation as compared to stable disease (22,23). 
The large array of mediators in the Luminex platform is ideal to provide an 
impression of which inflammatory mediators are present in a sample and 
hence, can help to decide on what biomarkers to focus. Subsequently, the 
Mesoscale platform that was specifically developed at a collaborating labora-
tory to measure mediators in sputum can reliably quantify these mediators. 
 Most studies have employed rt-pcr to focus on the expression of sev-
eral genes of interest (13,24). In this pilot study, we are amongst the first to 
perform global genes expression profiling in sputum cells. We were able to 
recover suitable rna in the majority of samples and the profiles were fairly 
similar on visit 1 and 2 in the same subjects. Again, rna expression profiling is 
probably more valuable in an intervention study whereby the profiles before 
and after the intervention (e.g. allergen challenge or drug administration) can 
be compared. For example, a recent study reported a clear enhancement of 
expression patterns involved in airway inflammation following an endotoxin 
challenge in allergic individuals compared to pre-challenge expression levels 
(25). 
 In conclusion, we compared two alternative processing techniques of 
induced sputum in combination with two sensitive biomarker detection 
techniques to improve biomarker quantification from non-invasive sampling 
techniques. The dtt-dialysis technique did not yield measurable levels of 
inflammatory mediators in sputum samples. Applying the Ultra technique, 
we were able to measure several cytokines and chemokines in sputum and 
also in ebc employing the broad Luminex platform and sensitive Mesoscale 
analysis. However, many mediators still remained below the ldd. In the same 
sputum samples we were able to isolate rna and perform expression profil-
ing. This technology provides a viable platform for identification of specific 
signatures between patients. These techniques will be applied and further 
validated in an interventional allergen challenge study in our institute. These 
findings may open a pathway to identify a magnitude of potential biomarkers 
even in small volume-samples.
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chapter 7
Applicability and Reproducibility of Biomarkers 
for the Evaluation of Anti-Inflammatory Therapy 
in Allergic Rhinitis
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Abstract 
Background: We aimed to study the reproducibility of several biomarkers of 
allergic rhinitis to investigate their potential as outcome measures in clinical 
intervention trials. Furthermore, we investigated the kinetics of the biomark-
ers studied in nasal lavage and brush material following a placebo-controlled 
nasal allergen challenge. 
Methods: We performed a skin prick test and measured serum specific 
immunoglobulin (Ig) E levels and inflammatory biomarkers in nasal lavage 
and brush material in 20 patients with allergic rhinitis on 2 separate days 
(washout, 14-21 days). The patients were then randomly assigned to undergo 
an intranasal challenge with a relevant allergen (n = 10) or diluent (n = 10) in 
order to assess the kinetics of several biomarkers of allergic airway inflamma-
tion in nasal lavage and brush samples.
Results: Baseline serum IgE levels and skin wheal sizes were highly repro-
ducible measurements, with a coefficient of variation (cv) of 13.4% and 
18.2%, respectively. This was not the case with the majority of inflammatory 
biomarkers, whose cv varied considerably (range, 6.1%-224.1%). The nasal 
allergen challenge induced an increase in composite symptom scores in all 
patients. Compared to placebo, tryptase (p = .004), eosinophilic cationic pro-
tein (ecp) (p = .03) and α2-macroglobulin (p = .002) were increased in nasal 
lavage at 20 minutes post-allergen. Nasal lavage ecp levels and nasal brush 
eosinophils were still significantly increased at 7 hours (p = .03 and p = .04), 
but all statistical significance had been lost at 24 hours post challenge.
Conclusion: Serum specific IgE assays and skin prick tests exhibited good 
reproducibility in patients with clinically stable allergic rhinitis. We were also 
able to investigate the kinetics of allergen-induced upper airway inflamma-
tory markers in nasal lavage and brush material. Hence, nasal allergen chal-
lenge, when used in combination with nasal lavage and brush sampling, is a 
suitable research tool for early drug development.
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Introduction
Allergic rhinitis is a chronic inflammatory disorder of the upper airways 
that produces characteristic signs and symptoms in sensitized individuals 
exposed to relevant allergens (1). Allergic airway inflammation is character-
ized by immunoglobulin (Ig) E-triggered mast cells and activated eosino-
phils, which release proinflammatory mediators such as histamine and leu-
kotrienes (2). Furthermore, allergic rhinitis is associated with elevated serum 
IgE levels and a positive skin prick test (spt) to corresponding allergens (1, 3).
In addition to their diagnostic value, serum specific IgE levels and spt results 
may serve as biomarkers to monitor disease activity in response to anti-
allergic therapy (4). In allergic rhinitis, interventional studies with antihista-
mines and immunotherapy have shown decreases in allergic symptoms and 
reduced wheal and flare responses to intradermal allergens (5, 6). Similarly, 
in patients with allergic rhinitis and asthma, treatment with the anti-IgE 
antibody omalizumab substantially lowered free serum IgE levels with subse-
quent improvements in symptoms (7, 8). 
Nasal allergen challenge is a validated, reproducible clinical model for inves-
tigating the pathophysiology of allergic rhinitis that also permits the study 
of the kinetics of nasal inflammatory responses (9). As such, it may serve 
as a tool to study the effects of anti-allergic interventions targeting specific 
inflammatory mechanisms in relationship to upper airway response (10). 
Although nasal biopsies are the golden standard for studying cellular inflam-
matory response, there are some limitations to this invasive technique: it 
can only be performed by an experienced ear, nose, and throat physician; it 
provides information on just a limited part of the upper airways; and it does 
not allow repeated samplings within short time intervals (11, 12). Nasal brush-
ing, in contrast, is a less invasive method that has emerged as a possible viable 
alternative for interventional trials requiring repeated sampling. In patients 
with allergic rhinitis, Jacobson et al showed that seasonal changes in the 
number of mast cells and eosinophils in nasal brush samples correlated well 
with those found in nasal biopsies (12). Likewise, intranasal fluticasone pro-
duced a similar degree of reduction in these inflammatory cells in both brush 
and biopsy samples. Nasal lavage is another relatively noninvasive sampling 
technique which allows serial assessments of the effects of anti-inflammatory 
therapy on soluble components of upper airway inflammation (13). 
The aim of this study was to analyze the reproducibility of various biomark-
ers associated with allergic rhinitis to assess their potential use as outcome 
measures in clinical trials testing novel anti-inflammatory therapies. To this 
end, in a group of clinically stable patients with untreated allergic rhinitis, we 
combined several semi-invasive (sampling) techniques and analyzed serum 
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specific IgE levels, spt results, and various cellular and soluble biomarkers 
of upper airway inflammation identified in nasal lavage and brush material. 
In addition, we tested the effect of nasal allergen challenge on the kinetics of 
these inflammatory biomarkers in a randomized study design. 
Methods
subjects
Twenty multisensitized subjects (10 females, 10 males; age, 19-51 years) with 
nonsymptomatic allergic rhinitis participated in the study. All the subjects 
had a history of intermittent or persistent allergic rhinitis for at least 1 year 
prior to enrollment (1). Maintenance anti-allergy or anti-asthma medication 
was discontinued at least 6 weeks prior to the study. Atopy was confirmed 
by a positive spt for at least 2 of 6 common airborne allergens (grass pollen, 
tree pollen, Dermatophagoides pteronyssinus [hdm], Dermatophagoides 
farinae, and cat and dog dander) (alk Abelló, Nieuwegein, The Netherlands). 
Subjects with any other clinically relevant disorders were excluded. Eligible 
subjects were sensitized to at least 1 of the allergens used for nasal provoca-
tion (grass pollen, hdm, or cat dander extracts) (alk Abelló). Symptomatic 
subjects with mite or pollen allergy were tested outside the relevant season 
(October-February for hdm and May-August for pollen in the Netherlands). 
In the case of subjects with concomitant allergy to pets, only those with 
no close contact with pets during the study were included. Allergic rhinitis 
symptoms were monitored throughout the study using a composite symp-
tom score validated by Lebel et al and subjects with a baseline score of more 
than 2 on the allergen challenge day (visit 2) were excluded (14). Respiratory 
tract infections were excluded by confirming the absence of relevant 
symptoms in the 3 weeks prior to and during the study and each nostril was 
inspected for accessibility using a nasal speculum. All subjects were non-
smokers or ex-smokers who had quit at least 12 months prior to the study with 
a smoking history of under 10 pack years. The study protocol was approved by 
the Leiden University Medical Centre Ethics Committee and all the subjects 
gave their written informed consent prior to enrollment in the study. 
study design
We used a combined study design (Figure 1). In the first part of the study, we 
tested the reproducibility of serum specific IgE measurements, spt results, 
and baseline inflammatory marker measurements using nasal lavage and 
brush material. In the second part of the study, we tested the kinetics of the 
inflammatory markers analyzed in the first part of the study following a nasal 
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challenge with an allergen or diluent. Eligible subjects were included in the 
study and specific serum IgE levels, spt, and nasal lavage and brush inflam-
matory markers were measured during visit 1 and repeated 14 to 21 days later 
during visit 2. Subsequently, subjects were allocated to an allergen group 
(n = 10) or a placebo (diluent) group (n = 10) in a randomized, double-blind, 
parallel fashion. Nasal lavage measurements were repeated 20 minutes 
and 7 hours post challenge (i.e., after the last placebo/allergen dose), and 
nasal brush measurements were repeated 7 hours post challenge. Symptom 
scores were recorded before the challenge, after the administration of the 
diluent, 10 minutes after each challenge dose, and hourly until 7 hours post 
challenge (14). Clinically stable subjects were dismissed from the unit 8 to 
9 hours post challenge and asked to return 24 hours later (visit 3) for record-
ing of symptom scores and nasal lavage and brush measurements and again 
7 days later (visit 4) for the final lavage and brush measurements. The occur-
rence of adverse events was monitored throughout the study. As a safety 
check, airway response was measured in all patients by forced expiratory 
volume in 1 second (fev1) (Vmax Spectra; Sensor Medics, Bilthoven, The 
Netherlands) in accordance with standardized lung function techniques. 
This check was performed during screening, pre allergen, and 7 hours post 
allergen (15).
figure 1 Study flowchart. The biomarkers studied were inflammatory markers in nasal brush and 
nasal lavage material. spt indicates skin prick test; ige, immunoglobulin e; n, number  
of subjects. 
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Five mL of venous blood were collected and stored at –80ºC for subsequent 
analysis of total and specific serum IgE levels. Total and specific IgE levels for 
hdm, grass pollen, tree pollen, and cat and dog dander were determined by 
fluorescence enzyme immunoassay (feia) using the Immuno cap system 
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skin prick test
spts were performed in duplicate at the volar site of each forearm by the 
same experienced technician by application of 1 drop of each allergen extract 
to the skin, at least 3 cm apart, according to a previously validated protocol (3). 
Histamine chloride (10 mg/mL) was used as a positive control and a diluent 
of each allergen (alk Abelló) as a negative control. Subsequently, the dermis 
was punctured once with an alk lancet (alk Abelló); a clean lancet was used 
for each solution. Fifteen minutes later, the results were read by the same 
technician, who marked the edges of the wheal responses (excluding pseu-
dopods) with a special thin-tipped pen. The mark was transferred to trans-
parent tape and attached to the result form. The mean value of the 2 largest 
perpendicular diameters of wheal responses was included in the analysis. For 
the reproducibility analysis, we compared wheal sizes (visit 1 vs visit 2) for the 
allergen yielding the largest wheal response during visit 1. 
nasal allergen challenge
Nasal allergen challenges were performed according to a previously validated 
protocol (13). The procedure is briefly described as follows: to select the intra-
nasal allergen (hdm, grass pollen, or cat dander) for each patient, account was 
taken of the allergen that had caused the largest wheal in the spt in combina-
tion with the patient’s history of clinical symptoms and the season. Pre chal-
lenge, subjects were acclimatized for 30 minutes in the test room and then 
administered 1 puff of xylometazoline 0.1% in each nostril. Approximately 
20 minutes later, a puff of allergen diluent (phosphate buffered saline [pbs] 
containing human serum albumin 0.03% in benzoalkonium chloride 0.05%) 
(alk Abelló) was sprayed into each nostril; this was followed by the admin-
istration of 1 puff of intranasal allergen (at 3 increasing concentrations of 100, 
1000 and 10 000 biological units [bu]/mL) into each nostril at 10-minute 
intervals. Subjects in the placebo group received the allergen diluent intrana-
sally 4 times using the same time intervals. The puffs were delivered as distally 
as possible into the nasal cavity using a nasal pump that delivered a fixed dose 
of 0.125 mL solution per puff (nasal pump 1013463; alk Abelló). Subjects were 
instructed to inhale gently to prevent the solution from entering the lower air-
ways. The nasal response at the respective time points was quantified by a vali-
dated composite symptom score system (14). Symptoms were recorded using 
the following scoring system: sneezes < 2 = 0, sneezes 3-4 = 1 point, sneezes 
> 5 = 3 points, anterior rhinorrhoea = 1 point, posterior rhinorrhoea = 1 point, 
difficult breathing = 1 point, 1 blocked nostril = 2 points, 2 blocked nos-
trils = 3 points, pruritus in the nose = 1 point, pruritus of palate or ear = 1 point, 
conjunctivitis = 1 point (total possible score, 0-11 points). Composite symptom 
scores were recorded 10 minutes after each dose and dosing was discontinued 
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when a total score of 6 or more was reached or after the administration of the 
highest dose (10 000 bu/mL or diluent).
nasal lavage
The nasal lavage was performed in the same nostril throughout the study 
using a modified protocol of the technique described by De Graaf-In ’t Veld et 
al (13). Briefly, the subjects, in a seated position, were instructed to flex their 
neck approximately 30° from the vertical and to not breathe through their 
nose. A nasal olive was inserted into the corresponding nostril and 8 mL 
of pbs (37°C) was gently instilled using a 10 mL preweighed syringe with a 
dwelling time of approximately 10 seconds. This procedure was performed 
twice. The lavage fluid was then collected, kept on ice, weighed, and pro-
cessed within 1 hour (centrifugation for 10 minutes at 400 g and storage of 
supernatant at –80°C pending analysis). The following soluble inflammatory 
markers, listed below with their respective assay kits and detection limits, 
were determined in the nasal lavage samples according to the manufacturers’ 
directions: interleukin (il)-8, enzyme-linked immunossorbent assay (elisa) 
(clb, Amsterdam, The Netherlands), 30 pg/mL; il-13, elisa (r&d systems, 
Minneapolis, Minnesota, usa), 600 pg/mL; eotaxin, elisa (r&d systems), 
10 pg/mL; thymus and activation-regulated chemokine (tarc), elisa (r&d 
systems), 75 pg/mL; eosinophilic cationic protein (ecp), feia (Phadia AB), 
2 µg/L; tryptase, feia (Phadia AB), 1 µg/L; IgE, feia (Phadia AB), 1 kU/L; 
α2-macroglobulin, elisa (r&d systems), 10 ng/mL; mucin 5AC (muc5ac), 
immunoblotting using apical secretions obtained from bronchial epithelial 
cells cultured at the air-liquid interface as standard (Neomarkers antibody; 
Lab Vision Corporation, Fremont, California, usa), 1 arbitrary unit (au)/mL. 
Samples were not concentrated before analysis.
nasal brushings
All nasal brushings were performed in the nostril not used for the lavage 
throughout the study according to a modified version of the original tech-
nique described by Jacobson et al (12). Briefly, the brush (Buccal Swab Brush; 
biozymtc, Landgraaf, The Netherlands) was introduced between the nasal 
septum and the inferior turbinate and gently rotated 90º to 180°. Immediately 
after sampling, the brush was placed in a 3 mL plastic tube containing 2 mL of 
pbs at room temperature, carefully shaken, and brushed off gently against the 
wall of the tube. Aliquots (100 µL) containing the cell suspension were loaded 
into a cytocentrifuge for the preparation of slides, spun for 7 minutes at 400 g 
(Shandon Cytospin 4; Thermon Electron Corporation, Runcorn, uk), and 
dried prior to storage at 7°C. Differential cell counts of eosinophils, neutro-
phils, lymphocytes, macrophages, nasal epithelial cells, and squamous cells 
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were performed on coded May-Grünwald-Giemsa-stained cytospins. The cell 
differentials were expressed as a percentage of 250 nucleated nonsquamous 
cells; cytospins containing fewer cells were deemed unsuitable for analysis.
statistical analysis 
Reproducibility of serum IgE results (highest level), spt measurements (larg-
est diameter), and inflammatory biomarker measurements was assessed by 
analyzing intrasubject variation between visits, expressed as a coefficient of 
variation (cv, standard deviation expressed as percentage of the mean). The 
necessary change in these measurements for the detection of an interven-
tion effect in future studies was calculated using a power calculation program 
(nQuery advisor 3.0; Dixon Statistical Associates, Los Angeles, California, 
usa). The within-subject cv was used to estimate the standard deviation 
of the difference and the calculation was based on a crossover study of 
12 patients, a power of 80%, and an α-risk of 5% in a 2-tailed comparison. 
The effect of each challenge was analyzed with a mixed-model analysis of 
covariance (ancova) using intervention, time, and intervention by time as 
fixed factors, the subject as a random factor, and the prechallenge measure-
ment as a covariate. Where necessary, variables were log-transformed to 
meet analysis requirements. Contrasts between the placebo and allergen 
challenge were calculated at various time points. When results fell below the 
detection limit, levels were set at 50% of this limit. When ancova was not 
possible (in the placebo group, for example, due to a lack of variance), the first 
postchallenge measurements were analysed using the t test (null hypoth-
esis: mean = 50% of detection limit). An intervention effect with a P value of 
less than .05 was considered statistically significant. Sample size estimation 
was based on previous work examining the reproducibility of most of the 
biomarkers we aimed to evaluate and their response following allergen chal-
lenge (16, 17). All the calculations were performed using sas for Windows, 
version 9.1.2 (sas Institute, Cary, North Carolina, usa).
Results
patient characteristics atbaseline
None of the subjects had symptomatic allergic rhinitis on either of the 2 study 
visits; the maximum baseline symptom scores were 2. 
reproducibility of serum specific ige levels and spt wheal sizes
Both specific serum IgE levels and spt wheal sizes were found to be repro-
ducible parameters in patients with allergic rhinitis over an observational 
121 section 3 – applicability and reproducibility of biomarkers for the evaluation   
 of anti-inflammatory therapy in allergic rhinitis
period of 14 to 21 days. In all cases, total and maximal serum specific IgE levels 
and histamine-induced and maximal wheal sizes remained fairly constant 
between visits 1 and 2 (Figure 1 and Table 2).
reproducibility of baseline inflammatory markers in nasal lavage 
and brush material 
The reproducibility of inflammatory markers in nasal lavage and brush mate-
rial varied considerably. While nasal IgE remained fairly constant between 
visit 1 and 2, ecp and α2-macroglobulin levels differed greatly (Table 1). In 
addition, levels of il-8, il-13, eotaxin, tarc, and tryptase in the nasal lavage 
fluid were below the detection limit in most samples and hence could not 
be included in the reproducibility analysis. The changes in serum IgE levels, 
wheal size, and inflammatory marker measurements needed to detect a 
significant intervention effect (eg, drug treatment) was calculated using the 
within-subject cv in a crossover study design with 12 patients (Table 1).
table 1 inflammatory marker measurements on visit 1 and 2 with corresponding 
coefficient of variation (cv) and required effect size*  
visit 1 visit 2 cv within 
subjects, %
required  
effect size
Serum Immunoglobulin (Ig) E Levels
Maximal specific IgE, iu/mL 29.3 ± 5.7 27.5 ± 5.3 13.4 18.3%**
Total IgE, iu/mL 266.2 ± 54.3 249.5 ± 51.4 18.4 25.9%
Skin Prick Test 
Histamine wheal size, mm 5.7 ± 0.2 6.3 ± 0.2 11.7 0.9 mm
Maximal wheal size for allergen, mm 6.9 ± 0.5 7.1 ± 0.4 18.2 1.6 mm
Nasal Lavage
Nasal IgE, iu/mL 5.4 ± 0.2 5.5 ± 0.1 6.1  7.9%
Mucin 5AC, au/mL 44.2 ± 6.5 37.9 ± 7.7 224.1 436%
α2-macroglobulin, ng/mL 377.5 ± 115.5 296.1 ± 91.2 219.7 436%
ecp, ng/mL 3.9 ± 0.9 8.1 ± 4.2 123.3 234%
Nasal Brushing
Eosinophil count, % 12.4 ± 5.5 12.7 ± 3.7 99.5 183.8%
Neutrophil count, % 76.6  ± 6.7 79.8 ± 5.2 39.9 63.3%
Abbreviations: au, arbitraty units; ecp, eosinophil cationic protein. * Results are expressed as mean 
(± sem) unless otherwise indicated. ** For example, in a crossover study with 12 patients, a real 
change in serum specific IgE of 18.3% or more can be related to the treatment effect and not the 
natural variation of this biomarker in 80% of experiments.
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figure 2 a, individual maximal serum specific immunoglobulin (ige) levels at visits 1 and 2. b, 
individual maximal wheal sizes at visits 1 and 2. + shows mean levels.
nasal allergen challenge
Intranasal interventions (allergen and diluent) were well tolerated by 
all subjects and no clinically significant adverse events were recorded. 
Furthermore, there was no significant fall in fev1 from baseline in any of the 
patients at 7 hours post challenge. The number of patients with concomitant 
allergic rhinitis and asthma was equal in the allergen and diluent group. 
As compared with placebo (p), intranasal allergen (a) induced a nasal 
early allergic response (ear) in all subjects with a mean symptom score 
(mean ± sem, 7.25 ±  0.56 [A] vs 0.70 ±  0.26 [P]) at 10 minutes post challenge 
(Figure 3). The allergen-induced nasal ear was accompanied by significantly 
increased levels of tryptase, α2-macroglobulin and ecp (4.39 ±  2.0 [A] 
vs 0.5 ±  0.0 ng/mL [P]; 6630.7 ±  4240.23 [A] vs 51.7 ±  28.58 ng/mL [P]; 
24.19 ±  18.33 [A] vs 1.17 ±  0.17 ng/mL [P], respectively), but not nasal IgE or 
muc5ac (5.20 ±  0.14 [A] vs 5.33 ±  0.25 IU/mL [P] and 72.60 ±  23.35 [A] vs 
33.8 ±  6.69 au/mL [P], respectively) in the nasal lavage fluid at 20 minutes 
post challenge (Figure 3). In addition, all subjects had a nasal late allergic 
response (lar), defined as a composite symptom score above baseline on 
2 consecutive time points between 3 to7 hours post allergen (1.3 ±  0.31 [A] 
vs 0.24 ±  0.21 [P] (Figure 3) in combination with a significant increase in 
nasal eosinophil count and its degranulation marker ecp (20.9 ±  4.75 [A] vs 
12.1 ±  3.79% [P] and 25.19 ±  19.18 [A] vs 1.72 ±  0.39 ng/mL [P], respectively) 
(Figure 3) (13). Contrasts between allergen and placebo challenges were 
calculated at selected time points as shown in Table 2. The inflammatory 
markers described above had all returned to baseline levels by visit 4 (7 days 
post challenge). Levels of the other inflammatory markers (il-8, il-13, eotaxin, 
and tarc) remained below detection limits in most nasal lavage samples  
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and were not affected by either challenge, and hence could not be included  
in the analysis. The overall sample recovery rate for nasal lavage samples 
during the study was 72% (mean ±  sem, 5.7 ±  0.9 mL). Eighty seven percent  
of all the nasal brush samples were suitable for analysis.
figure 3 Mean change (± sem) in symptom scores, tryptase, α2-macro-globulin, and eosinophilic 
cationic protein (ecp) levels in nasal lavage and eosinophil count in nasal brush material 
following allergen challenge (open square) and placebo challenge (filled circle).
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table 2 inflammatory marker kinetics following allergen and placebo challenges
parameter 
(time point)
lsm -  
allergen
lsm -  
placebo
lsm  
difference, %
(95% ci)
p value
Overall symptom score, 
points
2.21 0.28 1.9
(2.4-1.4)
< .001
IgE, iu/mL 
(20 min post challenge)
5.25 5.22 0.5
(–12.5-15.5)
.93
Mucin 5AC, au/mL 
(20 min post challenge)
33.52 39.58 –36.2
(–82.4-131.9)
.64
Tryptase, ng/mL
(20 min post challenge)
na* na* 2.21
(0.9-5.3)*
.004*
α2-macroglobulin, ng/mL 
(20 min post challenge)
815.24 28.75 2735.2
(334-18425)
.002
α2-macroglobulin, ng/mL 
(7 h post challenge)
121.4 50.1 142.2
(–30.1-741.1)
.15
ecp, ng/mL 
(20 min post challenge)
4.30 1.11 287.8
(11.3-1251.4)
.03
ecp, ng/mL 
(7 h post challenge)
5.69 1.44 295.4
(24.9-1151.9)
.02
Eosinophil count, % 
(7 h post challenge)
25.25 10.45 144.4
(13.8-424.8)
.04
Eosinophil count, % 
(24 h post challenge)
21.98 9.73 125.8
(-31.0-639.1)
.16
Abbreviations: ci, confidence interval; ecp, eosinophilic cationic protein; lsm, least square means; 
na, not applicable. * Tryptase under challenge was tested against the null hypothesis mean = 50% 
of detection limit. 
Discussion
In the present study of patients with allergic rhinitis, we tested the reproduc-
ibility of several inflammatory biomarkers obtained by semi-invasive sam-
pling techniques in combination with their kinetics in nasal lavage and brush 
material following a nasal challenge involving allergens and placebo. We 
found that, in clinically stable patients with untreated allergic rhinitis, both 
specific serum IgE levels and spt wheal sizes proved to be reproducible mea-
sures over a period of 14 to 21 days, indicating that these parameters may be 
reliable outcome measures for interventional trials on anti-allergic therapy. 
In agreement with previously published data, measurements of soluble and 
cellular inflammatory biomarkers in nasal lavage and brush samples showed 
marked variability at baseline (11, 13, 16). Nonetheless, on analyzing these 
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measurements in a nasal allergen challenge, we observed a clear increase in 
several upper airway inflammation biomarkers up to 24 hours post allergen, 
together with an increase in nasal symptoms following the allergen challenge 
but not the placebo challenge. Our data confirm and extend previous obser-
vations. Taken together, repeated nasal lavage and brush samplings are a use-
ful extension of the nasal allergen challenge model and offer additional infor-
mation in interventional trials with therapy targeting allergic mechanisms.
Serum IgE levels showed a low cv in patients with clinically stable allergic 
rhinitis. Similarly, low intrasubject variation has been observed in other trials 
involving patients with allergic disease (7, 18). Indeed, due to their correla-
tion with symptoms and other allergic markers (nasal eosinophils) serum 
IgE levels may be used as outcome parameters for anti-allergic medication (7, 
19). However, because there is a substantial variation in precision and accu-
racy between commercial IgE assays, similar assay techniques should be 
employed throughout a study (20). In the present study, spt was performed 
according to recommendations issued by the Global Allergy and Asthma 
European Network (ga2len) with an alk lancet (21). Employing a similar 
spt technique in a study in allergic children, the cv over 1 week was found to 
be 24.3% for hdm and 17.3% for histamine (22). Our data thus extend earlier 
observations as we found a cv over 2 to 3 weeks of under 20% for the largest 
dermal wheal size and of 11.7% for the histamine-induced wheal size. When 
applying spt serially, it is essential to use the same standardized techniques 
and allergen extracts and to limit confounding factors such as drug intake, 
changes in circadian rhythm, and an excessive number of investigators (23). 
Similarly to IgE levels, a decreased spt response following anti-allergic treat-
ment has been shown to accompany a reduction in disease-related features 
both in patients with allergic rhinitis and allergic asthma (5, 6, 24).
 Even though the patients in our study were clinically stable, defined by an 
absence of symptomatic disease, all of the nasal inflammatory markers, with 
the exception of IgE levels, showed marked baseline variability over time. 
Our findings therefore, call into question the applicability of nasal lavage 
and brushing in longitudinal studies with a limited number of patients. In 
the present study, we applied a slightly modified version of the nasal lavage 
technique previously reported by Naclerio et al; nasal lavage fluid recovery 
was similar to that reported in other studies (65% to 82%) (13, 16, 25). Based 
on the low variability of nasal IgE levels throughout the study, it may be con-
cluded that nasal lavage, in combination with other semi-invasive sampling 
techniques such as nasal brushing, can yield representative serial measure-
ments in a relatively short time interval (eg, during the ear). However, the 
limited dwelling time used in the present study could explain why certain 
soluble mediators varied while others remained below the detection limit. 
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Employing a similar washing technique, other researchers also found low or 
undetectable levels of several mediators (13, 16, 26). 
 How could these issues be resolved? A more sensitive assay technique, 
such as Luminex technology, with a lower limit of detection for a variety 
of inflammatory mediators, could be used (27). Alternatively, the method 
described by Greiff and Grundberg, which involves applying an inflated bal-
loon into either nostril, allows an increased dwelling time, which is associated 
with the recovery of higher levels of soluble markers from nasal lavage fluid 
(28). However, we anticipated that the allergen-induced swelling in combina-
tion with multiple other procedures conducted in the present study would 
not be compatible with this technique. Although nasal biopsies are currently 
considered the most suitable tool for investigating the kinetics of inflamma-
tory cells in nasal mucosa, nasal brushing, which is a less invasive sampling 
method, has been shown to yield comparable results in terms of inflam-
matory cell differentials (11, 12). However, comparing changes in eosinophil 
counts in nasal brush and biopsy samples from patients with allergic rhinitis 
following exposure to grass pollen for 2 weeks out of season, Godthelp et al 
found similar variability in brush cellular counts whereas biopsies yielded less 
variable data (11). Our overall findings show that simpler, less invasive sam-
pling techniques such as nasal lavage and brushing allow greater flexibility 
and repeatability, but at the expense of increased variability, especially over 
longer time intervals. 
 In a nasal allergen challenge study by Braga et al, allergen-induced com-
posite symptom scores were shown to be associated with an increase in total 
nasal resistance, measured by anterior active rhinomanometry (29). Based on 
the increase in composite symptoms scores, the nasal allergen challenge pro-
duced both an early- and late-phase response in all patients with allergic rhin-
itis. These events corresponded to increased levels of several upper airway 
inflammatory markers. In contrast to placebo, the allergen caused a signifi-
cant increase in nasal lavage tryptase levels, an indicator of mast cell degranu-
lation, at 20 minutes post challenge; these levels were undetectable during 
later samplings. Measuring tryptase in nasal lavage fluid without a relevant 
stimulus, therefore, does not seem useful. A similar, short-lived increase in 
nasal lavage tryptase levels has been observed in other nasal allergen chal-
lenge studies (13, 26). α2-macroglobulin was also increased in nasal lavage 
fluid at 20 minutes post allergen challenge but not at 7 hours. Another nasal 
allergen study, however, reported increased concentrations of albumin, also 
a leakage marker, at both 20 minutes and 7 hours post allergen challenge (17). 
This different finding could be the result of a more pronounced lar in the 
latter study or because the level of albumin, being a smaller molecule than 
α2-macroglobulin, may also be determined by passive diffusion and secre-
127 section 3 – applicability and reproducibility of biomarkers for the evaluation   
 of anti-inflammatory therapy in allergic rhinitis
tion. We specifically measured α2-macroglobulin since it is one of the largest 
plasma solutes and may be more specific for the exudation process (30). In 
agreement with previous studies, intranasal allergen challenge also induced 
a rise in ecp, which reached significant levels at 20 minutes and 7 hours post 
challenge (13, 26). This corresponds to an increase in eosinophilic degranula-
tion, also observed in another study following an allergic stimulus (31). In 
addition, we were able to demonstrate the presence of muc5ac, the principal 
airway mucin, in nasal lavage fluid both at baseline and throughout the chal-
lenges (32). However, due to the large variation within and between subjects, 
no difference in muc5ac levels could be found between the allergen chal-
lenge and the placebo group at any of the time points analyzed. Whether 
this large variation (high sd) is caused by interindividual differences in 
the disease process and whether levels are higher than in healthy controls 
remain to be established. In contrast to the placebo challenge, the allergen 
challenge induced a significant increase in nasal brush eosinophil counts at 
7 hours; these counts were still increased at 24 hours, albeit not significantly. 
Hence, our data confirm and extend the results reported by Juliusson et al, 
who investigated the kinetics of the allergen-induced changes in nasal brush 
eosinophils at 2-hourly intervals until 12 hours post allergen (33). Overall, our 
data support the validity of repeated nasal brush samplings as a method for 
analyzing allergen-induced changes in nasal eosinophils. In addition, eosino-
phils have been shown to be responsive to anti-inflammatory therapy (12). 
Nonetheless, based on the large variation in eosinophil count within and 
between subjects, large numbers of patients need to be included in a prefer-
entially crossover study design to ensure optimal statistical power.
In conclusion, in untreated patients with clinically stable allergic rhinitis, we 
demonstrated that serum specific IgE levels and spt wheal responses are 
reproducible parameters, characterized by low intrasubject variation (=cv) 
over a period of 14 to 21 days. Compared to well established nasal biopsies, 
nasal lavage and brushing are less invasive techniques that allow greater flex-
ibility and repeatability but at the expense of greater intrasubject variation. 
On implementing these sampling techniques in a standardized nasal allergen 
challenge study, we found significantly increased levels of several inflamma-
tory biomarkers following the allergen challenge but not the placebo chal-
lenge. We believe that nasal challenge with a relevant allergen conducted in 
conjunction with semi-invasive sampling techniques such as nasal lavage or 
brushing is a suitable method for exploring novel anti-allergic therapies. The 
drawbacks of large intrasubject variation could be resolved by using a cross-
over design and more sensitive detection techniques. 
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Abstract
Background: Exhaled no (eno) is a validated non-invasive marker of airway 
inflammation in asthma. In patients with allergic rhinitis (ar), increased lev-
els of nasal no (nno) have also been measured. However, the applicability of 
nno as a marker of upper airway inflammation awaits validation. 
Aim: To test the longitudinal reproducibility of standardized nno measure-
ments in patients with ar and the effects of nasal allergen challenge. 
Methods: 20 patients with clinically stable, untreated ar participated in a 
combined study design. First, reproducibility of nno was tested over 1, 7, and 
14-21 days. Subsequently, the effect of nasal allergen challenge on nno was 
studied in a placebo-controlled, parallel design. nno was measured with a 
chemoluminescence analyzer. Ten subjects randomly underwent a standard-
ized nasal allergen challenge; 10 subjects received placebo. Response to nasal 
challenge was monitored by composite symptom scores.
Results: There was a good reproducibility of nno up to 7 days (Coefficient of 
Variation (cv) over 1 (16.45%) and 7 days (21.5%)), decreasing over time (cv 
(14-21 days): 38.3%). As compared with placebo, allergen challenge caused 
a significant increase in symptom scores (p<0.001), accompanied by a 
decrease in nno at 20 min post-challenge (p=0.001). Furthermore, there was 
a gradual increase in nno at 7 h, reaching significance at 24 h post-allergen 
(p=0.04).
Conclusions: Similarly to eno in asthma, nno is a non-invasive marker, poten-
tially suitable to monitor upper airway inflammation following allergen-
induced late response. Present data show a good reproducibility of nno 
measurements, decreasing over time, probably due to subclinical seasonal 
influences. 
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Introduction 
Allergic rhinitis is an IgE-triggered chronic inflammatory disorder of the 
upper airways with pathophysiological and immunological links to allergic 
asthma (1). Recent studies providing evidence of systemic cross-talk between 
upper and lower airway compartments, have resulted in the concepts of 
“allergic airway disease” or ‘combined allergic rhinitis and asthma syndrome’ 
(caras) (2). The hallmark of caras is chronic airway inflammation, mainly 
characterized by mast cells, eosinophils and their pro-inflammatory products 
(3). Historically, airway biopsies have been regarded as the gold standard for 
the sampling of the allergic airway inflammation. However, the applicability 
of invasive methods is limited for repeated sampling, such as in clinical moni-
toring or intervention trials. In addition, biopsies are limited to a very small 
part of the airways. Therefore, several less or non-invasive methodologies are 
being developed, some of which have been validated (4). Nitric oxide (no) is 
a gaseous molecule synthesized in the respiratory compartment by no-syn-
thases and can be detected in exhaled air of various species (5,6). Increased 
levels of eno – originating from the lower airways - have been measured 
in asthmatic patients (7), with overall higher levels in allergic asthma (4). In 
patients with untreated asthma, levels of eno appeared to correlate with 
the numbers of eosinophils within the airways (8,9). Likewise, both airway 
eosinophils and eno can be reduced by anti-inflammatory therapy (10,11). 
Alternatively, increased eno levels following tapering off inhaled corticoster-
oids (ics) have been shown to predict asthma exacerbations (12). Hence, eno 
measurement is presently a validated tool for non-invasive repeated assess-
ment of the airway inflammation in asthma, both for intervention trials and 
clinical practice (4,13,14). In patients with ar, nasal eosinophilia and increased 
nno levels have been demonstrated (15,16). These increased nno levels may 
be the result of enhanced inos expression within the nasal epithelium due to 
persistent mucosal inflammation (17). In the upper airways, paranasal sinuses 
are major contributors to no production: direct samplings from paranasal 
sinuses show substantially higher nno-levels than nasal samplings (18). The 
applicability of nno as a marker of upper airway inflammation, however 
awaits validation (17). With this study, we wished to test the applicability of 
nno as a potential outcome parameter for clinical intervention trials. First, 
we studied the longitudinal reproducibility of standardized nno measure-
ments in clinically stable patients with untreated ar (5). Second, the effect 
of intranasal xylometazoline, a commonly used decongestant, on nno was 
assessed. And finally, we performed a nasal allergen challenge in a random-
ized, placebo-controlled, parallel design, in the same group of patients. Some 
results have previously been reported in the form of an abstract (19). 
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Methods
subjects
Twenty multi- sensitized subjects with clinically stable allergic rhinitis 
participated in the study (Table 1). All subjects had a history of ar (intermit-
tent or persistent) for at least 1 year prior to enrollment (1). Subjects with 
concomitant stable, intermittent or mild persistent asthma, using inhaled 
short-acting β2-agonists on demand only, were allowed to participate. During 
the study, they were asked to withhold the β2-agonists at least 6 hours before 
each visit. Concomitant maintenance anti-asthma or anti-allergy medication 
was discontinued at least 6 weeks prior to the study. Atopy was confirmed by 
a positive skin prick test for at least 2 of 6 common airborne allergens (grass, 
trees, Dermatophagoides pteronyssinus (hdm), Dermatophagoides farinae, 
cat-, and dog-dander, alk Abelló, Nieuwegein, The Netherlands). Potential 
subjects with any other clinically relevant chronic or acute disorders were 
excluded. All eligible subjects were sensitized to at least one of the allergens 
used for nasal provocation, i.e. grasspollen, hdm- or cat-dander extracts. 
Symptomatic subjects with pollen allergy were tested outside the relevant 
pollen season (in the Netherlands outside the period May – August) and 
those with concomitant allergy to pets were only included, provided they had 
no close contact with pets (e.g. in their homes) during the study. ar symp-
toms were monitored throughout the study by a composite symptom score 
validated by Lebel, and subjects with a baseline symptom score of more than 
2 on the allergen challenge day (Visit 2) were excluded (20). Furthermore, 
respiratory tract infections were excluded by patients’ history at least 3 weeks 
prior and during the study. All subjects were non-smokers or ex-smokers 
(stopped at least 12 months prior to the study with less than 10 pack years). 
Starting the day before a study visit, all participants had to refrain from stren-
uous exercise and nitrate rich foods. The study protocol was approved by the 
Leiden University Medical Centre Ethics Committee and all subjects gave 
their written informed consent prior to enrolment into the study. 
study design
The study consisted of two parts (Figure 1). First we examined the reproduc-
ibility of nno measurements over 1, 7, and 14-21 days. Second, we studied the 
effect of intranasal xylometazoline and allergen versus placebo on nno levels. 
Before entering the study, the inclusion criteria were examined. Eligible sub-
jects were included into the study and baseline nno levels were measured 
(Visit 1). Fourteen to 21 days later (Visit 2), baseline nno levels were repeated, 
and all subjects received intranasal xylometazoline (0.1%; Pharmachemie, 
Haarlem, The Netherlands). Nasal no levels were recorded 30 min post-xylo-
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metazoline. Subsequently, subjects randomly underwent a nasal challenge 
with either a relevant allergen (n=10) or its diluent (n=10) in a double-blind, 
parallel fashion. nno measurements were repeated 20 min and 7 hours 
post-challenge. Symptom scores were recorded pre-challenge, post-diluent, 
10 min after each subsequent challenge dose and hourly, until 7 hours post-
challenge (20). Clinically stable subjects were dismissed from the unit 8-9 h 
post-challenge and returned 24 hours later (Visit 3) for nno measurements 
and recording of symptom scores and 7 days later (Visit 4) for a final nno 
measurement (Figure 1). The occurrence of adverse events was monitored 
throughout the study. In order to exclude an allergen-induced late phase 
bronchoconstriction, the airway response was measured by fev1 according 
to standardized lung function techniques at screening, pre- and 7 h post-aller-
gen (Vmax Spectra, Sensor Medics, Bilthoven, The Netherlands) (21).
figure 1 Study flowchart. nno = nasal no, n = number of subjects, Xylo = xylometazoline 
administration.
nasal no measurements 
Nasal no measurements were performed according to current ats recom-
mendations (5), using a chemoluminescence analyzer (Ecomedics cld88sp, 
Duernten, Switzerland) with a nasal sampling tube. Briefly, subjects seated in 
an upright position were instructed to inhale “no free” air (<1 ppb) through 
their mouth to total lung capacity and subsequently exhale through their 
mouth with a constant expiratory flow of 50 mL/s using online visual moni-
toring. An expiratory resistance was applied to ensure soft palate closure to 
exclude no originating from the lower airways (eno). During exhalation a 
Teflon tube connected to the no analyzer aspirated nasal air with a constant 
flow rate of 0.3 L/min. During the study, nno was measured in the same nos-
tril, which was completely occluded with a foam plug (containing the Teflon 
tube) to prevent leakage of air. The contralateral nostril remained unob-
structed. To minimize diurnal variation, all measurements were performed at 
the same time of the day (±2 hours). During each measurement, plateau nno 
levels were determined and expressed as parts per billion (ppb). nno levels 
were measured until three acceptable measures were obtained (within 10%) 
and the mean ppb-value was implicated into the analysis.
visit 1 visit 2 visit 3 visit 4
nno
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table 1 subjects’ characteristics 
subject 
nr
age  
(yrs)
gender 
(m/f)
atopy asthma 
(+/-)
1 21 m Cat, hdm, grass, trees, dog, d. Far +
2 21 m hdm, d. Far, dog +
3 24 f Grass, trees, Dog -
4 24 f Cat, hdm, trees, grass, d. Far +
5 21 m hdm, d. Far, dog -
6 22 m Grass, cat, dog, d. Far., trees, hdm +
7 19 f hdm, d. Far, trees, cat, dog -
8 27 f Cat, hdm, dog, d. Far +
9 27 m Cat, hdm, d. Far, grass, dog +
10 50 f Cat, dog, grass, trees +
11 35 f hdm, d. Far -
12 32 m hdm, d. Far -
13 20 m D. Far, hdm, grass, trees, cat, dog +
14 22 f Cat, hdm, d. Far, grass, dog +
15 24 m Grass, hdm, d. Far, cat, dog +
16 21 m hdm, d. Far, grass, trees, cat, dog -
17 21 f Grass, dog -
18 19 f Cat, hdm, d. Far, dog -
19 43 f D. Far, hdm, cat, dog -
20 23 m Grass, trees, dog -
hdm = Dermatophagoides pteronyssinus, d. Far = Dermatophagoides farinae.
nasal allergen challenge
Nasal allergen challenges were performed according to the previously vali-
dated protocol by de Graaf-in’t Veld et al (22). Briefly, the procedure can be 
described as follows: selection of the relevant allergen was based on which-
ever allergen caused the largest wheal in the spt in combination with clinical 
symptoms and depending on the season. Pre-challenge, subjects acclima-
tized for 30 minutes in the ‘challenge’ room and each nostril was inspected 
for accessibility using a nasal speculum. Subsequently, subjects received 1 
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puff of xylometazoline 0.1% in each nostril. Approximately 20 min later, the 
allergen’s diluent (phosphate-buffered saline containing hsa 0.03% in ben-
zoalkonium chloride 0.05%, alk Abelló, Nieuwegein, The Netherlands) was 
sprayed in both nostrils (1 puff/nostril), followed by the allergen in 3 increas-
ing concentrations of 100, 1,000 and 10,000 bu/mL (1 puff/nostril) each at 
10 minutes intervals. Subjects were challenged with hdm, grasspollen or cat 
dander (alk Abelló, Nieuwegein, The Netherlands). During placebo chal-
lenge, subjects received 4 times the allergen’s diluent intranasally. The puffs 
were delivered as distally as possible into the nasal cavity using a nasal pump, 
delivering a fixed dose of 0.125 mL solution per puff (alk Abelló, Nieuwegein, 
The Netherlands). Subjects were instructed not to inhale too deeply to pre-
vent the solution to enter the lower airways. The nasal response at the respec-
tive time points was quantified by composite symptom scores validated by 
Lebel et al (20). Symptoms were recorded using the following scoring system: 
sneezes <2 = 0, sneezes 3-4 = 1 point, sneezes >5 = 3 points, anterior rhinor-
rhoea = 1 point, posterior rhinorrhoea = 1 point, difficult breathing = 1 point, 
one blocked nostril = 2 point, two blocked nostrils = 3 points, pruritus in the 
nose = 1 point, pruritus of palate or ear = 1 point, conjunctivitis = 1 point (total 
score 0-11). Symptom scores were recorded 10 min after each allergen dose 
and further dosing was discontinued at a total score of 6 or more, or after the 
highest dose was given (10,000 bu/mL) (22). 
analysis
Prior to analysis, nno data were tested for normal distribution using several 
tests, including the Kolmogorov-Smirnov test. These tests showed no signifi-
cant deviation of normal distribution; hence, data were not log transformed. 
To assess the reproducibility of nno measurements the within subject varia-
tion between visits was calculated and expressed as a cv (= the standard 
deviation expressed as percentage of the mean). The necessary change in 
nno for the detection of an intervention effect was calculated with a power 
calculation program nQuery (nQuery advisor 3.0) using the within subject 
cv to estimate the standard deviation of the difference and based on a cross-
over study with power = 80% and α=0.05, two-sided. The data were analyzed 
with a mixed model analysis of covariance (ancova) with intervention, time, 
and intervention by time as fixed factors, the subject as a random factor and 
the measurement before challenge/placebo but after xylometazoline as 
covariate. Contrasts between placebo and allergen challenge were calculated 
at various timepoints. A treatment effect or contrast with a p-value less than 
0.05 was considered statistically significant. All calculations were performed 
using sas for windows V9.1.2 (sas Institute Inc., Cary, nc, usa).
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Results 
reproducibility of nno
All subjects were able to perform the nno maneuvers. On average (mean ± 
sd) 6.1 ± 2.4 maneuvers during maximally 7 minutes were needed to obtain 
three acceptable measurements (good plateau response and within 10%).
Although comparable mean nno levels were measured on visits 1 and 2 
(mean ± sd 1017 ± 477 ppb and 1104 ± 496 ppb, respectively), there was a sub-
stantial within subject variability (cv = 38.3%; Figure 2, Table 2). Better repro-
ducibility was found over shorter time intervals: 1 day and up to 7 days later, i.e. 
between Visit 2 and 3; and between Visit 2 and 4 (Table 2). To exclude potential 
influence of nasal allergen challenge, the reproducibility of nno over 1 and 7 
days was analyzed in the placebo group only. 
The necessary change in nno for the detection of a significant intervention 
effect (e.g. following drug treatment) was calculated using the within subject 
cv for several sample sizes in a cross-over study design (Table 3).
table 2 reproducibility of nasal no over various time points  (mean ± sd). 
number of 
subjects
first 
measurement
second 
measurement
cv (%) within 
subjects
Δ 14-21 days
(Visit 1 - 2)
20 1017 ± 477 ppb 1104 ± 496 ppb 38.3
Δ 14-21 days
(Visit 1 - 2)
10* 874 ± 310 ppb 977  ± 531 ppb 33.5
Δ 7 days
(Visit 2 - 4)
10* 977  ± 531 ppb 1038 ± 285 ppb 21.5
Δ 1 day
(Visit 2 –3)
10* 977 ± 531 ppb 968 ± 373 ppb 16.5
*n=10 subjects in the placebo challenge group only. cv = coefficient of variation.
table 3 change in nasal no for detection of a significant intervention effect
no. of subjects  Δ 7 days Δ 14-21 days
12 subjects 261 ppb 510 ppb
16 subjects 220 ppb 430 ppb
20 subjects 194 ppb 379 ppb
Calculations based on a cross-over study with power = 80% and α=0.05, two-sided.
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figure 2 Individual baseline values of nasal no on visit 1 and 2 (Δ 14-21 days) for all subjects (n=20).  
+ = mean nasal no level.
effects of intranasal xylometazoline and nasal challenges
All intranasal interventions (xylometazoline, allergen and the allergen’s 
diluent) were well-tolerated by all subjects and no clinically significant 
adverse events occurred. Pre-challenge, none of the subjects had lower 
airway complaints and all fev1 values were similar to screening. At 7 h post-
challenge, there was no significant fall in baseline fev1 following either 
intervention (mean ± sd: -0.03 ± 0.13 L (Allergen (a)); p=0.43; -0.03 ± 0.09 L 
(Placebo (p)); p=0.39). Neither were the changes in fev1 significantly differ-
ent between the two challenges (p=0.88).
As compared with baseline measurements, 30 min post-administration, xylo-
metazoline significantly decreased nno levels in all patients by on average 
24% (265 ppb; p=0.001).
For evaluation of the effect of nasal allergen challenge, post-xylometazoline 
symptom scores and nno levels were used as baseline measurements in 
the analysis. Ten patients were randomized to intranasal allergen (2 subjects 
received cat-allergen; 2 grass-pollen; 6 hdm) and ten to placebo. As com-
pared with placebo, intranasal allergen induced a nasal early allergic response 
(nasal ear) in all subjects with a mean symptom score ± sd: 0.70 ± 0.82 (p) 
and 7.25 ± 1.58 (a) at 10 min post-challenge (Figure 3). In addition, all subjects 
had a nasal late allergic response (nasal lar), defined as a symptom score 
above baseline on two consecutive timepoints between 3-7 h post-allergen 
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(mean ± sd: 0.24 ± 0.66 (p) and 1.3 ± 1.0 (a) (Figure 3) (22). The changes in 
symptom scores between allergen and placebo were significantly different 
(p<0.001). 
As compared with placebo, nasal allergen challenge induced a significant 
decrease in nno at 20 min post-challenge (estimated difference –514 ppb, 
95% confidence interval (CI) -780 to -247 ppb; p=0.001). Seven hours post-
allergen, both nno levels and symptom scores were slightly increased 
as compared to placebo. At 24 hours post-challenge, there was a further 
increase in nno levels following allergen as compared with placebo (esti-
mated difference 344 ppb, 95% CI 24 to 664 ppb; p=0.04) (Table 4). Mean 
changes (± 95% CI) in symptom scores and nno levels following allergen  
and placebo are shown in Figures 3 and 4. 
figure 3 Mean change (± 95% confidence interval) in composite symptom scores following nasal 
allergen versus placebo challenge. Open squares: relevant allergen, closed dots: placebo.
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figure 4 Mean change (± 95% confidence interval) in nasal no concentrations (ppb) following nasal 
allergen versus placebo challenge. Baseline was set after xylometazoline administration in 
all subjects. Open squares: relevant allergen, closed dots: placebo. *Indicates a significant 
difference between allergen and placebo at 20 min post-challenge (p=0.001), #indicates a 
significant difference between allergen and placebo at 24 hours post-challenge (p=0.04).
table 4 effect of nasal allergen/placebo challenge on nasal no levels (mean ± sd). 
pre-
challenge
20 min
post-
challenge
7 h
post-
challenge
24 h
post-
challenge
7 days
post-
challenge
Allergen
Nasal no 980 ± 345 ppb 336 ± 287 ppb 946 ± 267 ppb 1393 ± 307 ppb 1272  ± 294 ppb
Placebo
Nasal no 717 ± 358 ppb 682 ± 258 ppb 752 ± 220 ppb 968 ± 373 ppb 1038 ± 285 ppb
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Discussion
We have demonstrated that nno is a reproducible parameter over short 
time intervals in clinically stable patients with untreated ar. A potential 
explanation for the increased variability over time in our study could be due 
to (subclinical) seasonal effects. Moreover, we showed that unlike placebo  
challenge, intranasal decongestant and allergen challenge significantly 
affected nno levels. Overall, our data suggest that nno may be a potential 
outcome parameter in clinical intervention trials in patients with ar. 
Our findings confirm and extend data from previous studies in both healthy 
subjects and patients with ar applying different nno sampling methods 
(23,24). While in these studies recordings were made during breath holding, 
we measured nno according to ats recommendations (5,23,24). This meth-
od holds sampling of nno during oral exhalation against a fixed resistance for 
optimal closure of the velum to prevent mixing from other (airway) compart-
ments. Applying this technique, baseline nno levels on both visits 1 and 2 
were higher to those reported in two other studies in patients with untreated 
ar (25,26). This discrepancy can be ascribed to the higher sampling flow 
rate applied in our study, as comparable nno levels have been measured in 
another study in patients with ar applying a similar flow rate (0.25 L/min 
compared to our 0.3 L/min) (27).
We found good reproducibility of nno levels in patients with untreated ar 
up to 7 days. Comparable data have been reported in healthy subjects over 
a similar time period (23). The decay in reproducibility over time (14 to 21 
days) may be caused by subclinical seasonal or weather influences and hence, 
should be taken into account when calculating the necessary sample size. 
Based on our findings, it can be anticipated that in clinical intervention tri-
als outside pollen season, a change in nno levels beyond baseline variation 
will be needed to detect a potential drug effect. So far, there are few data on 
nno as an outcome parameter in clinical intervention trials. In a comparative 
study mean nno levels were approximately 55% lower (mean difference of 
846 ppb) in patients with ar treated with nasal corticosteroids as compared 
to nno measured in patients with untreated ar (16). Although this was not 
a placebo-controlled study, it provides further evidence on potential appli-
cability of nno as a biomarker of upper airway allergic inflammation, even 
over longer (treatment)-periods. Finally, in accordance with other studies, 
we found marked inter-individual differences in nno (Figure 2) (27). In order 
to minimize the effect of between-subject variability, a cross-over design is 
recommended. 
Since xylometazoline is often incorporated in a nasal allergen challenge 
protocol when measurements of pro-inflammatory biomarkers (e.g. in nasal 
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lavage) are performed, we wished to evaluate its effect on pre-allergen nno 
levels as part of the analysis (28,29). We found a 24% mean fall in nno from 
baseline levels, at 30 min following intranasal xylometazoline. In correspon-
dence with our findings, previous studies in healthy volunteers and patients 
with ar showed a mean decrease in nno levels by 12-14% and 20-25%, respec-
tively, 10 minutes following administration of intranasal decongestants with 
comparable pharmacological properties as xylometazoline (25). Moreover, 
a comparable fall in nno has been encountered in subjects with an upper 
respiratory tract infection following intranasal oxymetazoline (30). The 
reduction in nno is possibly caused by the xylometazoline-induced vaso-
constriction, decreasing no-diffusion (25). In addition, evidence from in vitro 
animal studies suggests additional anti-inflammatory effects through inhibi-
tion of the no-producing enzymes (31). However, prolonged use of nasal 
decongestants in humans is associated with unwanted side effects, surpass-
ing these potentially beneficial properties (32). 
In contrast to sham challenge, nasal allergen challenge (irrespective of the 
relevant allergen applied) caused similar symptoms and signs of acute rhi-
noconjunctivitis in all subjects, consistent with a nasal ear (22). In agreement 
with previous studies in allergic rhinitis, we found a significant fall in nno at 
20 minutes post-allergen (16). At least one possible explanation for this phe-
nomenon may be the allergen-induced swelling of the nasal mucosa during 
the nasal ear – not occurring after placebo – resulting in hampered no diffu-
sion (33). Our data are consistent with findings by Colantonio et al in patients 
with allergic rhinitis and polyposis nasi, in whom - despite inos-upregulation 
– decreased nno levels have been found (34). In this study, nno levels 
appeared to be inversely correlated to the polyp size and raised following 
treatment of the polyps; suggestive of a mechanic blockade of no diffusion 
from the sinuses. In addition, similar observations have been reported for the 
lower airways, measuring eno following bronchial allergen challenge in asth-
ma (35,36). In these studies, there was an (albeit statistically non-significant) 
decrease in eno accompanied by allergen-induced bronchial obstruction 
during the early asthmatic response
In agreement with previous data on eno following allergen-induced bron-
chial lar, we found a (gradual) increase in nno at 7 h (i.e. during the nasal 
lar), reaching statistical significance at 24 h post-allergen (35,37). However, 
it should be noted that pre-challenge administration of intranasal xylometa-
zoline in the present study protocol, may account for potentially underesti-
mated values of both the symptom scores and nno up to 7 h post-allergen 
(38). Indeed, at 24 h post-challenge when the xylometazoline effect had worn 
off, the increase in nno became statistically significant. Similarly, Hanazawa 
et al found increased nno levels in patients with ar at 24 h following intrana-
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sal administration of eotaxin (39). In addition, an increase in nasal eosinophils 
was measured at 8 h post-eotaxin; accompanied by maximal levels of nno 
(no pretreatment with nasal decongestant) (39). Likewise, during allergen-
induced lar in asthma, increases in eno appeared to be accompanied by 
sputum eosinophilia (37). Based on these data, nno may be a useful outcome 
parameter for allergen-induced airway inflammation during the lar in 
patients with ar, preferably not pre-treated with nasal decongestant. 
Based on the link between the upper and lower airways, it could be anticipat-
ed that nasal allergen challenge may affect lung function especially in patients 
with allergic rhinitis and asthma (40). Although in the present study there 
were no significant changes in fev1, this does not entirely rule out co-existent 
pro-inflammatory events within the lower airways induced by nasal allergen. 
However, assessments of the lower airway inflammation were kept outside 
the scope of this study. Moreover, including a limited number of ar patients 
in combination with different phenotypes (with and without concomitant 
asthma) precludes a heterogeneous lower airway response to nasal allergen. 
In conclusion, nno measurement is a quick and non-invasive tool in patients 
with allergic rhinitis. Based on our data and previous other findings in ar 
patients, nno may potentially serve as a biomarker of (allergen-induced) 
nasal inflammatory response during ‘’the stable phase’’, such as the nasal 
lar (27,39). However, confounding factors such as acute allergen-induced 
nasal response resulting in massive rhinorrhea and occlusion of the paranasal 
sinuses or pretreatment with nasal decongestants or corticosteroids may 
limit the applicability of nno during the nasal ear. 
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Abstract 
Background: Secretory leukocyte protease inhibitor (slpi), which is present 
in many physiological fluids including saliva, sputum and nasal discharge, is 
the most effective inhibitor of chymase. Previously, we demonstrated that 
chymase is able to cleave slpi and that the cleaved portion, cslpi, is a bio-
marker of chymase activity. 
Objective: We investigated the potential of cslpi as a biomarker of chymase 
activity in subjects with allergic rhinitis and asthmatic airway disease. 
Methods: Baseline sputum samples were collected from atopic asthmatics 
and healthy controls. Nasal lavages (nal) were performed in subjects with 
allergic rhinitis (ar) both at baseline and following a nasal challenge with 
allergen or placebo. Levels of cslpi and chymase were determined by west-
ern analysis and tryptase and α2-macroglobulin were measured by immuno-
assay.
Results: As compared with healthy controls, asthmatics showed a signifi-
cant increase in baseline cslpi/total slpi ratios and an increase in chymase 
levels. There was a high correlation of cslpi/slpi ratios to chymase levels 
in normal individuals and untreated asthmatics. In the nal of patients with 
ar, as compared with placebo, allergen challenge increased inflammatory 
biomarkers, including: cslpi/slpi ratios, chymase levels, tryptase levels, and 
α2-macroglobulin levels. Correlations were observed between cslpi/slpi 
ratios and chymase levels and cslpi/slpi ratios and α2-macroglobulin levels; 
no correlation was seen between cslpi/slpi ratios and tryptase levels.
Conclusion: Our data indicate that cslpi reflects chymase activity in ar and 
asthma. Hence, cslpi may serve as a biomarker for disease activity and for 
monitoring the efficacy of novel anti-inflammatory treatments in chymase-
mediated diseases.
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Introduction 
The clinical hallmarks of asthma and allergic rhinitis (ar) are persistent 
airway inflammation and airway hyperresponsiveness (ahr) (1, 2). The obser-
vation that clinical symptoms and function do not fully reflect the severity 
of the underlying airway inflammation and ahr has initiated the search 
for more adequate biomarkers of asthma and ar (1, 3). Subsequently, the 
development and validation of non- and semi-invasive sampling techniques, 
including exhaled nitric oxide, induced sputum and nasal lavage, helped to 
identify several potential biomarkers of airway inflammation for both clinical 
practice and research purposes (4-6). However, there is still an unmet need 
to discover sensitive biomarkers from easily obtained samples that are closely 
linked to the inflammatory cascade that could serve to monitor the progress 
and treatment of airway diseases. The mast cell is an important effector-cell 
in the pathophysiology of allergic airway inflammation, ahr and airway 
remodeling (7-9). Degranulation of sensitized mast cells by relevant allergen 
causes the release of histamine and proteases (tryptase and chymase), and de 
novo synthesis of other inflammatory mediators (leukotrienes, prostaglan-
dins, platelet activating factor and bradykinin) (10-12). On the basis of pro-
teases content, mast cells can be subdivided into at least two phenotypically 
different subsets: connective tissue mast cells expressing chymase, tryptase 
and cathepsin G (mctc) and mucosal mast cells producing tryptase, but 
no chymase (mct) (13). Although not fully elucidated, chymase originating 
solely from mctc cells has recently been implicated in the pathophysiology 
of airway inflammation, ahr and remodeling of allergic airway disease (9, 14).
The proteinase inhibitors, α1-antitrypsin, α1-antichymotrypsin, α2-macroglo-
bulin and secretory leukocyte protease inhibitor (slpi), released from neu-
trophils, macrophages and epithelial cells within the respiratory tract, have 
been shown to inactivate chymase, providing local protection against allergic 
stimuli (15-18). In a previous in vitro study we have shown that slpi, is not only 
a chymase inhibitor, but also a substrate of chymase and that its cleaved prod-
uct, cslpi, is a biomarker of chymase activity in vitro (19).
Based on these data, we hypothesized that cslpi may be a biomarker of 
chymase activity in allergic airway disease in vivo. To this end, in two studies 
originally designed to assess allergic end-points in asthma and allergic rhinitis 
we retrospectively measured baseline levels of slpi and cslpi in relation to 
chymase levels. In the first study we examined slpi, cslpi and chymase levels 
in the sputum of subjects with allergic asthma in comparison with healthy 
subjects. In the second study, levels of cslpi, slpi, chymase, tryptase and 
α2-macroglobulin were measured in nasal lavage (nal) of individuals with 
ar, both under baseline conditions and following nasal allergen challenge. 
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Methods
subject groups
Asthmatic subjects study
This part of the study was conducted at the University of Southampton, uk. 
On one study occasion, hypertonic saline-induced sputum was collected and 
analyzed from 12 participants (6m/6f, 18-70 years), subdivided into 4 study 
groups with the following characteristics: 
Healthy non-atopic, non-smoking controls with no chronic respiratory 1. 
symptoms and no evidence of upper or lower respiratory tract infection 
in the last 6 weeks (fev1 > 80% predicted, normal fev1/fvc ratio; group 
1).
Non-smoking subjects with intermittent, atopic asthma (2. fev1 > 80%  
predicted, not on inhaled corticosteroids; group 2).
Non-smoking subjects with mild persistent, atopic asthma (3. fev1 > 80% 
predicted; regular use of inhaled corticosteroids (Beclomethasone 
(Qvar®) 100µg bd, Serevent 25µg bd; Fluticasone 100µg bd.; group 3).
Non-smoking subjects with moderate-severe persistent atopic asthma 4. 
(fev1 60-80% predicted ; symptomatic despite regular treatment with 
corticosteroids: Becotide 200µg qds; Seretide (1000µg fluticasone / 
200µg salmeterol) bd; Seretide (125µg fluticasone /25µg salmeterol) bd, 
Prednisolone 40mg od; group 4). 
All subjects gave written informed consent and ethical approval was obtained 
from the Joint Ethics Committee of Southampton Hospital and General 
Hospital. 
Subjects with allergic rhinitis
Nasal lavage (nal) specimens were obtained from 20 multi-sensitized, non-
smoking patients (10M/10F; 19-51 years) with clinically stable ar who were 
not on maintenance therapy, participating in a clinical study at the Centre for 
Human Drug Research, Leiden, Netherlands (20). All subjects provided writ-
ten informed consent and the study was approved by the Ethics Committee 
of Leiden University Medical Center, Leiden, Netherlands. 
sputum induction and processing
In the asthma and healthy subject cohorts (n = 3 per subgroup) sputum was 
induced by hypertonic saline according to European Respiratory Society 
(ers) recommendations (4, 21). Shortly, following salbutamol pretreatment, 
aerosolized hypertonic saline (4.5% NaCl) solution was inhaled at three 
5-minute intervals by tidal breathing with the nose clipped. In more severe 
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asthmatics, a modified ers protocol was used starting with normal saline and 
moving slowly to hypertonic saline only if there was no significant fall in fev1. 
At the end of each 5-minute interval, expectorated sputum was collected in 
a petri-dish and fev1 and pefr were recorded. If fev1 fell by >20% from the 
post-salbutamol baseline, the procedure was discontinued. Sputum samples 
were kept on ice and processed within 1 hour of collection as previously 
described (4). In summary, sputum was teased from the sample using a for-
ceps and collected into a fresh petri dish, avoiding contamination with saliva 
and squamous cells. One volume of selected sputum was diluted with four 
volumes of phosphate buffered saline (pbs). Four volumes of 6.3mM dithio-
erythreitol (dte) were added to one volume of selected sputum, to achieve 
a final concentration of 5mM dte. Subsequently, sputum samples were 
incubated at room temperature for 30 minutes on a bench roller. Sputum 
samples were individually filtered through a 100µm nylon mesh cell strainer 
in order to remove any mucus and debris, and centrifuged at 4°C, 1500 rpm 
for 10 minutes. Subsequently, sputum supernatant was transferred to a new 
15ml centrifuge tube and mixed well, samples were aliquotted and stored at 
-80°C pending analysis. For cytospins, an adequate sample of cell suspension 
was added into a cytospin tube to achieve a total number of 20-30,000 cells 
per slide, spun for five minutes, fixed and stained with Hemacolor staining to 
allow differentiation of cell types. Cytospin quality was regarded as adequate 
when squamous cell contamination was < 20%. 
nasal lavage 
The patients with ar randomly underwent a standardized nasal challenge 
with either a relevant allergen (house dust mite (hdm), cat or grass allergen; 
n=10) or its diluent (n=10) in a double-blind, parallel fashion (22). Selection 
of the intranasal allergen (hdm, grass pollen or cat dander) was based on the 
allergen causing the largest wheal in the skin prick test combined with the 
patient’s history of clinical symptoms and the season. The nasal response to 
allergen was documented by symptom scores previously validated by Lebel 
(23). nal collections were performed according to a modified protocol, sam-
pling the same nostril at pre-challenge, and at 20 minutes post-challenge (22). 
nal samples were collected, kept on ice and processed within 1 hour accord-
ing to a validated protocol (22). Briefly, samples were centrifuged for 10 min at 
400g; the supernatant was aliquotted and stored at –80 °C pending analysis. 
Frozen samples were shipped to site of analysis.
reagents
Recombinant slpi (rslpi) was obtained from r&d systems (Minneapolis, 
mn, usa). Rabbit anti-slpi antibody was obtained from Alexis (San Diego, 
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ca, usa). Mouse anti-human mast-cell chymase was obtained from Serotec 
(Raleigh, nc, usa). The secondary antibodies goat anti-mouse and Goat 
anti-rabbit were obtained from Pierce Biotechnology (Rockford, il, usa). 
Tryptase and α2-macroglobulin were determined according to the manu-
facturers directions in the nal samples with the following assay kits and 
detection limits: Tryptase by feia (Phadia, Uppsala, Sweden), 1 µg/L; and 
α2-macroglobulin by elisa (r&d systems, Minneapolis mn, usa), 10 ng/mL.
sample preparation for western analysis
During processing all samples were maintained at 4ºC or less to insure stabil-
ity of cslpi and slpi as determined previously (19). Ten µl of human sputum 
supernatant or nasal lavage supernatant was diluted to a total volume of 20 µl 
in loading buffer containing 50% Nupage lds sample buffer from Invitrogen 
(Carlsbad, ca, usa), 30% water and 20% 1M dtt from Sigma-Aldrich (St. 
Louis, mo, usa) and was maintained on ice. The samples were boiled for 6 
min at 95 °C.
slpi detection by western analysis
Denatured and reduced sputum supernatant and nasal lavage supernatant 
samples were applied to a 12% NuPage bis-tris gel from Invitrogen. The 
samples were electrophoresed and transferred to a pvdf membrane (Pierce 
Biotechnology). The blots were blocked in 5% milk /pbs-tween (pbs/0.4% 
tween-20) overnight at 4ºC. Subsequently, the blots were washed for 10 min-
utes and incubated in the primary antibody (goat anti-slpi at 1:1000) diluted 
in the blocking solution for 1 hour at room temperature. After three washes of 
pbs-tween the blot was incubated for 45 minutes at room temperature with 
the secondary antibody (goat anti-rabbit HRP) diluted 1:4000 in blocking 
solution. The blots were washed 6 times with pbs-tween and incubated for 
1 minute at room temperature with Western Lightning chemiluminescence 
reagents (Perkin Elmer, Boston, ma, usa) and developed on Biomax Light 
Film (Eastman Kodak, Rochester, ny, usa) in the darkroom. Densitometry 
was performed on each film to determine the relative amount of intact slpi 
(~15kD band) and cslpi (~10kD). The data was expressed as a ratio of cslpi/
slpi for normalization of each sample as done previously (19). The reliability 
of this assay was confirmed by using mass spectrometry analysis during its 
development (data not shown). 
chymase western analysis
Due to the lack of a commercially available chymase elisa, chymase levels 
were determined by western analysis. In brief, denatured and reduced spu-
tum supernatant and nasal lavage supernatant samples were applied to a 12% 
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NuPage bis-tris gel from Invitrogen. The samples were electrophoresed and 
transferred to a PVDF membrane (Pierce Biotechnology). The blots were 
blocked in 5% milk /pbs-tween (pbs/0.4% tween-20) overnight at 4°C. 
Subsequently, the blots were washed for 10 minutes and incubated in the 
primary antibody (mouse anti-human mast cell chymase at 1:1000) diluted in 
the blocking solution for 1 hour at room temperature. After three washes of 
pbs-tween the blot was incubated for 45 minutes at room temperature with 
the secondary antibody (goat anti-mouse hrp) diluted 1:4000 in blocking 
solution. The blots were washed 6 times with pbs-tween and incubated for 
1 minute at room temperature with Western Lightning chemiluminescence 
reagents (Perkin Elmer) and developed on Biomax Light Film (Eastman 
Kodak) in the darkroom. Densitometry was performed on each film to deter-
mine the relative amount of chymase.
statistical analysis
Data was analyzed using a non-parametric Mann-Whitney and 
Student’s t-test of endpoint data for the asthma trial. The chymase and 
α2-macroglobulin data from the allergic rhinitis trial was log-transformed in 
order to stabilize variance. Welch two sample t-test was performed on the 
slopes of pre-post experimental values. Pearson correlation coefficient was 
determined to evaluate the relationship between cslpi/slpi ratios and other 
biomarkers. 
Results
general
All sampling methods were well tolerated and no serious adverse events 
occurred. Analyzable sputum could be obtained from all but 1 asthmatic sub-
ject. Due to nal-sample limitations, chymase levels could only be analyzed in 
9 subjects challenged with placebo and 7 in the allergen arm. 
asthmatic subjects
In the sputum samples from asthmatic patients (a) cslpi/slpi ratios were 
determined. One subject from Group3 could not be analyzed due to low 
volume. As compared with healthy controls (hc) (group 1), cslpi/slpi ratios 
were increased in the sputum of asthmatic subjects (groups 2-4) (0.36 ± 0.02 
(hc); 0.45 ± 0.02 (a); p = 0.04, student’s t test; p = 0.049, non-parametric 
Mann Whitney test). On average sputum from untreated, atopic asthmatics 
(group 2) exhibited the highest cslpi/slpi ratio (0.50 ± 0.03), while treat-
ment with corticosteroids (groups 3 and 4; n = 5) had a lower cslpi/slpi ratio 
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(0.41 ± 0.02; p = 0.04). (Figure 1) In addition, we measured chymase levels in 
the same sputum samples and found that the chymase levels followed a simi-
lar trend as the cslpi/slpi ratios (929.1 ± 301.0 relative units (hc); 1469.4 ± 
141.5 relative units (a); p < 0.17)(Figure 2). Despite the low number of samples, 
a correlation between cslpi/slpi ratios and chymase levels in the normal 
and untreated atopic asthmatics was noted (r=0.83). 
figure 1 sputum cslpi/slpi ratios. Example of western analysis of lowest and highest cslpi 
expression (a.) as compared with healthy controls, sputum cslpi/total slpi ratios were 
significantly increased in allergic asthmatics (p=0.04, student’s t test; p=0.049,  
non-parametric mann whitney test). Corticosteroid use was associated with decreased 
cslpi levels (p=0.04, student’s t test) (b). 
 
allergic rhinitis
Nasal lavages were collected at baseline and 20 min post-challenge. As com-
pared with sham challenge (p), intranasal allergen (a) produced an acute 
allergic response with a mean symptom score (mean ± sem: 7.25 ± 0.56 (a); 
0.70 ± 0.26 (p); p = 0.001) at 10 min post-challenge. In parallel, there was a sig-
nificant increase in the cslpi/slpi ratio following allergen as compared with 
placebo challenge (Figure 3). Figure 3a shows the western analysis indicating 
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the cslpi band in the nasal lavage from allergen challenged (highest level 
example shown) (left) and placebo-challenged (lowest level example shown) 
(right) individuals. Using densitometry, the cslpi/total slpi ratio was 
determined for each time point during both allergen (Figure 3b) and placebo 
(Figure 3c), respectively. As compared with placebo (0.22 ± 0.02), there was 
a significant increase in cslpi/slpi ratio in the nasal lavage of allergen chal-
lenged individuals (0.41 ± 0.05; p =0.007) at 20 min post-challenge. 
Similarly, there was a significant increase in the nal-chymase levels in the 
allergen challenged individuals (1294.85 ± 688.50 relative units; Figure 4b) as 
compared with placebo-exposed individuals (706.01 ± 206.11 relative units; 
p=0.038; Figure 4c). Changes in cslpi/slpi levels and chymase levels from 
baseline to 20min post allergen challenge were highly correlated (r = 0.91) 
(Figure 5). If the highest point is removed the correlation is reduced to r = 
0.69, which still shows a strong relationship between chymase levels and the 
cslpi/slpi ratio. Using regression analysis with all points the slope is signifi-
cant (p < 0.001), with the highest point removed the trend is still significant 
(p < 0.006).
figure 2 sputum chymase levels and cslpi. Total slpi ratios. as compared with healthy 
controls, in patients with untreated allergic asthma sputum cslpi/total slpi ratios were 
significantly increased (p=0.03, student’s t test).  Chymase levels followed a similar trend 
with cslpi/total slpi ratios in both subject groups. 
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figure 3 nal cslpi/slpi ratio following nasal allergen compared with placebo.   
Example of western analysis of nal from placebo (lowest level cslpi) and allergen 
challenged ar–patients (highest level cslpi) (a). densitometry analysis of cslpi/total 
slpi ratios in nasal lavage from allergen challenged (b) and placebo challenged human  
ar– patients (c). Welch t test, p < 0.007, allergen challenged as compared to placebo 
cslpi/total slpi ratio induction from baseline to 20 min post challenge.  Legend refers  
to patient number.
figure 4 nal chymase levels levels following nasal allergen. Example of western 
analysis of nal from placebo (lowest level chymase) and allergen challenged ar–patients 
(highest level chymase) (a). Chymase levels (densitometry units) in nasal lavage from 
allergen challenged (b) and placebo challenged (c) human ar–patients. welch t test,  
p < 0.038, allergen challenged as compared to placebo from baseline to 20 min post 
challenge.  Legend refers to patient number.
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figure 5 correlation of cslpi/slpi and chymase levels in allergic rhinitis.Changes 
in nal cslpi/slpi levels and chymase levels from baseline to 20min post allergen 
challenge are highly correlated (r = 0.91).
In parallel to the increases in cslpi and chymase, there was a significant raise 
in the nal levels of α2-macroglobulin (a protease inhibitor) (6630 ± 4240 
ng/ml (a) vs. 50.75 ± 28.76 ng/ml (p); p = 0.00035) (figure 6a and b) at 20 min 
post-challenge. Similarly, tryptase (a mast cell protease) also increased in the 
allergen challenged group (4.3 ng/ml ± 2.01 ng/ml) as compared to placebo 
(undetectable levels; p< 0.056)(Figure 7a and b). A correlation analysis of 
cslpi/slpi ratios compared to each of the other biomarkers measured in this 
study shows a much stronger correlation between nal cslpi/slpi ratios and 
chymase levels (r=0.91) and cslpi/slpi and α2-macroglobulin levels (r=0.41) 
as compared to cslpi/slpi ratios and tryptase levels (r=0.07)(Figures 3-7). 
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figure 6 nal α2–macroglobulin levels following nasal allergen. α2-macroglobulin 
levels are elevated in nal following nasal allergen challenge ar–patients (a) versus placebo 
challenge (b). Welch t test, p = 0.00035, allergen challenged as compared to placebo from 
baseline to 20 min post challenge.  Legend refers to patient number.
figure 7 nal tryptase levels following nasal allergen. Tryptase levels are detectable 
only in nal following allergen challenge (a) while none is detected following placebo 
treated ar–patients (b). students t test, p = 0.056, allergen challenged as compared  
to placebo from baseline to 20 min post challenge.  Legend refers to patient number.
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Discussion 
The function of slpi is to protect tissues against the harmful effects of 
environmental irritants through its anti-inflammatory, anti-protease and 
anti-microbial properties. Within the respiratory tract, slpi is produced by 
a variety of cells including neutrophils, macrophages and epithelial cells (15). 
slpi is cleaved by chymase at a specific site and the level of this cleavage prod-
uct, cslpi, is indicative of chymase activity (15). Here, we report increased 
baseline cslpi levels in sputum and nasal lavage of subjects with untreated 
allergic asthma and allergic rhinitis (ar), respectively, with a further increase 
following nasal allergen challenge in the ar group. These findings are sug-
gestive of an enhanced chymase activity in allergic airway disease in vivo and 
hence, extend our previous in vitro observations. 
Based on in vitro data of our previous publication (19), cslpi can be used as a 
measure of chymase activity in biological samples. We described, that out of 
a panel of mast cell proteases consisting of proteinase 3, elastase, tryptase, 
cathepsin G, chymotrypsin and chymase, only chymase is able to cleave slpi 
(19). slpi acts as a first line of inhibition but is also cleaved by the chymase. 
This allows us to see a record of chymase activity before α-2-macroglobulin 
and other inhibitors inhibit it irreversibly. 
In the present study, we measured cslpi levels in airway samples from 
patients with allergic airways disease. Increased cslpi levels were demon-
strated in sputum of patients with untreated allergic asthma, while use of 
corticosteroids was associated with reduced cslpi levels. However, this 
finding is somewhat difficult to interpret since these individuals were also 
more severe asthmatics. Unfortunately, we are unable to obtain specimens 
from severe asthmatics who are not receiving either oral or inhaled corto-
costeroids. cslpi was also increased in nasal lavage of subjects with allergic 
rhinitis at 20min following an intranasal allergen challenge, which elicited an 
early nasal response. In accordance with previous observations (19), cslpi 
appeared closely correlated to chymase levels in both asthma (r=0.83) and  
ar (r=0.91). Taken together, these data suggest that cslpi may act as a bio-
marker of chymase activity in allergic airways disease in vivo.
Apart from cslpi and chymase, other markers of (mast-cell-related) airway 
inflammation were increased, including tryptase, a marker of mast cell activ-
ity, and α2-macroglobulin, a key inhibitor of chymase in ar (24, 25). Following 
nasal allergen challenge, all these biomarkers were further increased. 
α2-macroglobulin levels correlated well with the increased levels of cslpi 
(r=0.41). This was expected, as α2 macroglobulin is an inhibitor of chymase, 
and had a high correlation with chymase levels as well (r=0.62) (24). We 
observed an apparent 10-fold greater amount of tryptase as compared to  
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chymase and cslpi in the nasal lavage following allergen challenge. We attri-
bute this to the relatively greater amounts of tryptase stored in mast cells, up 
to 25% of cellular protein, as compared to chymase (26). Moreover, tryptase 
can originate from both mctc and mct cells, whereas chymase originates 
only from mctc cells, and the relative degranulation of each of these mast 
cell types to the allergic response varies (27). In addition, some of the dispar-
ity in relative changes in chymase and tryptase can be related to the differ-
ences in methods of measurement – highly quantitative elisa for tryptase 
and α-2 macroglobulin, while a qualitative Western was used for chymase and 
cslpi. Consequently, it is not surprising to note that the rise in the tryptase 
levels although indicative of mast cell activity did not correlate with cslpi/
slpi ratios (0.07) confirming that cleavage of slpi is not based on presence of 
tryptase as observed in our previous study (19). Interestingly one third of the 
subjects in the present nasal challenge study did not experience an increase 
in nal tryptase levels. It appears that tryptase is not necessarily elevated in 
all atopic individuals with airway disease. Bettiol et al showed that only 18% of 
asthmatics exhibited elevated tryptase levels (28). 
Until now, no direct measure was available for chymase activity in biological 
fluids due to its short half-life, mainly caused by the high content of chymase 
inhibitors (25, 29). The advantages of the use of cslpi as a biomarker of 
chymase activity are that slpi cleavage is easily detectable in readily acces-
sible human samples of saliva, sputum and nasal lavage. Additionally, known 
chymase inhibitors will inhibit the level of slpi cleavage (19). Furthermore, 
disease states such as ar and asthma result in higher amounts of cleaved 
slpi. Taken together, the data show that detection of these unique slpi cleav-
age products can act as novel biomarkers of chymase activity and chymase-
mediated disease. 
However we do acknowledge several shortcomings of this particular study 
that begins with the sample size. Despite obvious relationships between 
the inflammatory markers, low patient numbers make it difficult to achieve 
adequate correlation values. Furthermore, in this population some asthma 
patients were using (inhaled) corticosteroids, whereas others were untreat-
ed. Even though significantly lower levels were detected in those on corticos-
teroids, the effect of these drugs on cslpi levels needs to be prospectively 
evaluated in a well-powered, placebo-controlled studies. 
In conclusion, our data show that cslpi may be an in vivo biomarker of chy-
mase activity in allergic airway disease. Our findings need confirmation from 
larger prospective trials in patients with well-defined disease characteristics 
and various treatments. 
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Summary and general discussion
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In this thesis, a series of clinical studies have been described, in which we 
applied, evaluated or modified novel and existing non- or semi-invasive sam-
pling methods and detection techniques for the assessment of biomarkers in 
allergic airway inflammation.
Clinical studies – allergic asthma
In the first part of this thesis the focus is on drug and method development 
in allergic asthma. In chapter 3, the pharmacological effect of an inhaled 
Neurokinin1/Neurokinin2 receptor antagonist (ave5883) was initially evalu-
ated against exogenous Neurokinin A (nka) challenge. Subsequently, the 
efficacy was explored in the allergen challenge model of asthma. Although 
the drug provided partial protection against nka-induced bronchocon-
striction in asthmatics, a similar dose appeared ineffective in reducing the 
allergen-induced airway responses. Similarly, the drug failed to inhibit the 
allergen-induced increases in airway inflammatory biomarkers, such as spu-
tum eosinophils and exhaled no (eno) levels. 
In the subsequent chapter, the effect of bronchodilation on eno measure-
ments at 8 h following allergen inhalation causing a late allergic response 
(lar) was evaluated. It appeared that levels of eno further increased follow-
ing reversal of the allergen-induced airway obstruction by inhaled salbutamol 
(chapter 4). Since salbutamol administration per se does not affect eno, wid-
ening of the airway diameter caused this effect. Therefore, to enable a correct 
comparison of eno values in the individual patient, it should be considered 
to measure eno values following appropriate bronchodilation (1). Stationary 
eno chemiluminescence analyzers are validated devices but their applicabil-
ity is largely hampered by their bulkiness and high costs. The niox mino 
(mino) is a hand-held, relatively new and inexpensive device for online eno 
measurements. In chapter 5 the reliability and repeatability of the mino was 
tested by comparing the eno values with those measured by the Ecomedics 
chemiluminescence analyzer (eco). Exhaled no levels were reproducible 
and in agreement between both devices, underscoring the validity of eno 
samplings by the mino (chapter 5). 
Sampling of biomarkers in sputum and exhaled air, especially if performed 
by exhaled breath collection and analysis, is hampered by small sample vol-
umes, the denaturant effects of processing and the limited sensitivity of most 
detection assays. In chapter 6, novel processing (sputum dialysis and ultra-
centrifugation) and detection techniques (flow-cytometry using Luminex 
multi-analyte profiling beads, electrochemiluminescence analysis using 
Mesoscale multi-array microplates and gene-array) were evaluated in allergic 
asthmatics. In this exploratory study, we demonstrated that the recovery 
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of biomarkers was improved by ultracentrifuge-processing of sputum 
supernatant compared with dithiothreitol (dtt)-dialysis treated samples, 
when measured with Mesoscale. Luminex allowed the detection of similar 
and other biomarkers. In addition, we were able to isolate rna and perform 
expression profiling on the sputum cell pellet. The biomarkers in Exhaled 
Breath Condensate (ebc) samples were evaluated by Luminex only and most 
of these markers remained below the detection limit of the assay. 
Clinical studies – allergic rhinitis
In the second part of this thesis, the focus was on allergic rhinitis (ar). First 
the applicability and reproducibility of several commonly used biomarkers 
in ar was investigated. Serum specific immunoglobulin E (IgE) assays and 
skin prick tests (spts) exhibited good reproducibility in patients with clini-
cally stable allergic rhinitis. Most inflammatory biomarkers measured in nasal 
lavage (nal) fluid and nasal brush (nab) material exhibited a greater vari-
ability over 14-21 days. Nonetheless, performing these assessments repeat-
edly following a nasal allergen challenge, a clear increase in most of these 
biomarkers was observed at several time-points. Levels remained unchanged 
following a placebo challenge. Hence, these relatively simple, semi-invasive, 
sampling techniques are suitable for investigation of the kinetics of allergen-
induced upper airway inflammation (chapter 7). In the next chapter the lon-
gitudinal reproducibility of nasal no (nno) and its response to nasal allergen 
challenge is described (chapter 8). When measured at the same time of the 
day, nno was found to have a good reproducibility over a short time period 
(cv = 21.4% up to 7 days), but decreased over longer time periods (cv = 38.3% 
after 14-21 days), possibly due to (subclinical) weather changes or seasonal 
effects. An acute increase in nasal inflammation elicited by a nasal allergen 
challenge was accompanied by a paradoxal decrease in nno at 20 minutes 
post-allergen, followed by an increase in nno at 24 hours post-allergen. In 
contrast, placebo challenge did not affect nno. 
Clinical studies – allergic asthma & allergic rhinitis
Allergic asthma and ar have a similar pathophysiology and in the final clini-
cal chapter (chapter 9) the potential role of chymase (a biologically potent 
protease released by mast cells) and its cleavage product, cleaved Secretory 
Leukocyte Protein Inhibitor (slpi), was studied in both disorders. slpi is 
present in many biological fluids where its function is to protect the tissues 
through its anti-protease properties. The data indicate that levels of cleaved 
slpi in sputum are higher in asthmatics compared to non-asthmatic controls, 
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and increase in patients with ar following nasal allergen challenge. Hence, 
cleaved slpi may be a suitable marker to monitor chymase activity in both the 
lower and upper airways.
The overall goal of the clinical studies described in this thesis was to iden-
tify suitable non- or semi-invasive sampling methods for the assessment of 
biomarkers for early drug development and clinical monitoring of allergic 
airways disease. The implications of our findings are addressed by the follow-
ing questions. 
is induced sputum a recommendable sampling technique for 
inflammatory biomarkers?
Sputum induction is a semi-invasive procedure of collecting secretions from 
the lower airways to study components of airway inflammation (2). Although 
not fully interchangeable with bronchoalveolar lavage (bal) and bronchial 
biopsy, it has been shown to provide largely similar information on several 
inflammatory markers whilst being safer, cheaper and generally easier to 
perform (3,4). Despite these advantages, most subjects experience this pro-
cedure as a burden. In addition, the overall percentage of analyzable sputum 
samples in our trials was approximately 80% - which even in other specialized 
centers fails to reach 100% (5). Finally, many inflammatory markers in sputum 
supernatant are affected by the (standard) processing techniques and more 
sophisticated assays are needed for optimal biomarker detection (6). 
One of the major advantages of sputum sample analysis is the possibil-
ity of evaluating multiple inflammatory biomarkers. In the solid phase, 
inflammatory cell differentials can be evaluated. The predominant cell type 
(eosinophils or neutrophils) helps to characterize the asthma phenotype and 
monitoring of sputum eosinophilis provides information on the inflamma-
tory status within the airways and can also be used for treatment monitoring 
as was recently confirmed by a Cochrane review (7,8). More recently, the 
combination of sputum induction and rt-pcr allows the detection of mrna 
in sputum cells (9,10). These studies found an increased expression of several 
inflammatory cytokines (il-4, 5 and 13) in asthmatics compared to healthy 
controls and an increase in inflammatory cytokine expression profile follow-
ing low dose allergen exposure in asthmatics that was blocked by inhaled cor-
ticosteroids (9,10). Adding to these findings, in our study mrna was isolated 
from sputum cell pellets from asthmatics with similar expression profiles on 
two occasions. This opens the possibility to determine expression profiles 
of multiple inflammatory markers which, given the heterogeneity of asthma, 
can provide more information than previous sampling techniques, which 
focus on a limited number of inflammatory markers (11).
In the fluid phase of sputum, several inflammatory mediators are readily 
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measurable, whilst some measurements are unreliable due to the denatur-
ant effects of sputum processing with dtt and/or limited sensitivity of most 
detection assays. Erin et al developed a dialysis technique protocol, in which 
the dtt is filtered from the sputum sample and thus increasing the recovery 
of dtt-sensitive cytokines and chemokines (12). Possibly due to the complex-
ity of this technique or the usage of different antibody detection kits, we were 
unable to replicate these findings. However, in accordance with previous 
studies, mechanical homogenization of the samples (by ultra-centrifugation) 
resulted in a good recovery of spiked cytokines and chemokines, and subse-
quently, several cytokines and chemokines were quantified in sputum super-
natant (6). A drawback of this unrefined technique arises from the disruption 
of cells and subsequent spilling of intracellular content in the homogenate 
– which of course, can partly account for higher the biomarker concentra-
tions recovered (13). Similarly to rna expression profiling in the sputum cell 
pellet, combining multiple inflammatory mediators to evaluate the cytokine 
expression patterns in sputum supernatant is a valid method to define several 
aspects of the heterogeneous nature of the inflammatory airway reaction in 
asthma. Applying this multi targeted approach, Brasier et al were capable to 
identify distinct asthma phenotypes based on cytokine expression patterns 
in bal (11). Comparable studies need to be done in sputum supernatant from 
asthmatics.
In conclusion, we feel that based on the complexities of sputum induction 
and processing, this sampling technique is not suitable for routine disease 
monitoring. However, employing a motivated study population and an expe-
rienced laboratory staff in clinical trials of asthma, sputum induction is a 
useful tool to sample and evaluate multiple biomarkers of the inflammatory 
airway process. Appropriate inflammatory biomarkers should be selected 
that are insensitive to the processing techniques and readily detectable or 
validation of a novel collection and/or processing technique is required prior 
to implementation.
is exhaled no ready to be used as a key biomarker in research and 
management of asthma?
Exhaled no is widely perceived as a potential biomarker of inflammatory 
airways disease, particularly of allergic asthma. Advantages of standardized 
eno samplings are reproducible, non-invasive, online measurements achiev-
able in almost all patients of 4 years and older (14). The drawbacks consist of 
many (endogenous and exogeneous) factors affecting no measures. One of 
these factors is the airway diameter - and in line with previous observations 
at baseline, there was a clear effect of airway diameter on eno levels in an 
exacerbation model of asthma (15). Based on these findings, it may be recom-
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mended to measure eno following appropriate bronchodilation for reliable 
comparison in the individual patient and we suggest that this finding should 
be incorporated into the list of perturbing factors mentioned in the guide-
lines (16). Another important disadvantage of eno measurements is the 
bulkiness and costs of the equipment. In this respect, the recently introduced 
hand-held and relatively inexpensive no electrochemical analyzer (mino) 
seems an asset for widespread use of eno in both the clinic and in research 
(17). Exhaled no values measured with the mino were found to be repro-
ducible and in agreement with the stationary eco, an ats-approved chemi-
luminescence analyzer. These results are in agreement with previous data 
comparing the mino to the stationary niox unit (17,18). However, similarly to 
previous studies, the mino systematically yielded slightly higher values and 
this may impact clinical interpretation. Therefore, a recent study calculated 
a conversion factor to correct for this issue (19). Conclusively, most technical 
issues surrounding eno measurements appear to be solved or manageable 
and the remaining question is the clinical relevance (and disease specificity) 
of this biomarker. 
When compared to induced sputum or ebc, the clear disadvantage is that 
only one component from the airways is sampled even though this single 
biomarker is related to the underlying airway inflammation. Exhaled no lev-
els are correlated with sputum eosinophils in steroid naïve asthmatics and 
levels increase following a spontaneous exacerbation or allergen-induced late 
response (20-22). In addition, baseline eno levels have been shown to predict 
the clinical response to treatment with inhaled corticosteroids and levels 
decline after initiation of anti-inflammatory treatment (23,24). Baseline levels 
can also aid in the diagnosis of asthma. A cut-off value of >20 ppb has a sen-
sitivity and specificity of approximately 70% which is superior to spirometry 
(fev1) measurement (25,26).
In day-to-day asthma management the role of eno is controversial. On one 
hand, it seems that low levels of eno can predict a successful dose reduction 
in inhaled corticosteroids while maintaining asthma control (22). In children, 
a treatment regimen based on eno and symptoms, compared to symptoms 
alone, resulted in a significant reduction in disease-related parameters, 
including the severity of airway hyperresponsiveness, with a concomitant 
(but non-significant) reduction in asthma exacerbations requiring oral 
prednisone (27). On the other hand, a recent study reported that addition of 
eno as an indicator of asthma control on top of standard disease monitoring 
resulted in the prescription of higher doses of inhaled corticosteroids, with-
out additional clinically relevant improvements in asthma control (28). 
Currently, employing the single flow technique it is difficult to fully assess 
the airway origin of increased eno. If eno is measured at multiple expired 
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flow rates, it can be portioned into no from the bronchial or alveolar com-
partment. It has already been demonstrated that alveolar no is increased 
in severe asthma in comparison with mild to moderate asthma while there 
is no difference in eno between these groups (29). In the same study it was 
also shown that alveolar no is refractory to inhaled corticosteroids but is 
decreased following a course of oral steroids. This suggests alveolar no is a 
potential marker for distal airway inflammation, possibly also useful in copd 
and in clinical trials examining the effect of systemic anti-inflammatory 
therapy (30). The multiple flow technique is laborious and has not been fully 
standardized but in the future measuring no at different flow rates may fur-
ther refine this biomarker.
Overall, eno could serve as a biomarker of allergic airway inflammation in 
clinical trials. In clinical practice, it can help in the diagnosis of asthma and 
dose titration of subsequent anti-inflammatory treatment. Whether it can 
improve asthma control in patients treated according to current best practice 
is open for debate (31,32).
is ebc ready for implementation in drug evaluation and clinical 
practice?
ebc is an appealing sampling method, enabling repeated collections of fluid 
from the airways in a completely non-invasive and patient-friendly fashion 
(33). For the purpose of cooling and collection of the exhaled breath, many 
custom-made devices were initially developed – unsuprisingly, this yielded 
an array of sampling methods. Presently, commercially available devices 
(most widely used are the EcoScreen from CardinalHealth and the RTube 
from Respiratory Research) may help to overcome problems arising from 
the use of the early collectors using different collecting protocols. A recent 
ats/ers taskforce issued guidelines for better standardization of collect-
ing procedures allowing comparison across research centers (34). However, 
studies comparing commercially available devices have shown mixed data. 
Following identical collection, ebc levels of total protein, eotaxin and cystei-
nyl leukotrienes were found to be significantly higher in samples collected 
with the EcoScreen collector compared to the RTube device (35,36). The 
pH values also differed between samples from both asthmatics and allergic 
rhinitics (35-37). In addition, the volume of ebc collected with the EcoScreen 
was consistently higher as compared to the RTube (1.8 ± 0.1 and 1.4 ± 0.1 mL, 
respectively). This may be due to the differences in cooling the exhaled air: 
the Ecoscreen has a refrigeration device at a constant temperature of -20 0C, 
while the RTube uses a cooling sleeve (at -20 0C), that heats up to 15 0C after 
a 10 minute collection period. This ‘warming process’ may cause the degrada-
tion of heat labile substances, which may also account for the differences in 
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protein and lipid levels found between the two devices. A clear advantage of 
the RTube is its small size, which makes it suitable for home use. 
Apart from these sampling issues, problems with detection/quantification of 
inflammatory biomarkers in ebc is of even greater concern (33,38). This may 
be due to a limited sensitivity of the elisa technique to measure inflamma-
tory compounds in the ebc (39). However, using the very sensitive multiplex 
technology we were still unable to detect most inflammatory biomarkers in 
ebc samples collected with the EcoScreen from steroid-naïve patients with 
mild persistent allergic asthma. It is conceivable, that higher ebc concentra-
tions of these biomarkers are present in more severe asthma-phenotypes or 
under different conditions, e.g. following an exacerbation. Metabolomic anal-
ysis of ebc seems a promising approach in both adults and children (40,41). 
This analytical technique, using high-resolution proton nuclear magnetic 
resonance (nmr) spectroscopy, enables characterization of the metabolic 
compounds, providing a ‘fingerprint’ of the individual samples. This approach 
seems especially promising since it reflects the heterogeneous nature of 
asthma and can be obtained from generally small ebc volumes generally con-
taining low levels of inflammatory biomarkers. 
Alternatively, coating the collecting tube or employing glass tubing may 
improve the sample yield. A study by Tufvesson et al found that coating the 
plastic surfaces with Tween 20 detergent or bsa improved the detection of 
eicosanoids and cytokines, respectively (42). However, since these coating 
substances may interfere with several detection assays, a more sophisticated 
approach may be to employ a glass condenser. In a recent study, the in-vitro 
recovery of albumin and 8-isoprostane sprayed into the collection system 
was found to be significantly higher in glass and silicone condensers as com-
pared to teflon or polypropylene condensors (43). In a subsequent study 
in healthy volunteers, significantly more ebc volume yielding detectable 
biomarker was recovered using an optimized glass condenser compared to a 
silicone condenser and the EcoScreen (44).
In conclusion, despite optimization of the ebc collection and detection of 
biomarkers in recent years, this sampling technique awaits full validation and 
standardization before it can be implemented into research or clinical prac-
tice. For this purpose, it is worthwhile to incorporate ebc along with more 
standardized biomarkers sampling techniques in clinical trials and asthma 
management to help further development of this promising, non-invasive 
sampling technique. 
is nasal no useful biomarker to monitor ar as exhaled no in asthma?
Nasal no can be sampled from upper airways and may be useful for non-
invasive monitoring of airway inflammation in ar similarly to eno in asthma. 
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The first studies with nasal no were encouraging. Increased nno levels were 
found in both symptomatic and asymptomatic patients with ar - as opposed 
to non-allergic controls (45,46). Recently, nno measurements by the por-
table no-analyzer, mino, were validated against the gold standard chemi-
luminescence no-analyzer in both healthy volunteers and patients with ar 
(47). Hence, this simple, non-invasive sampling methodology could easily be 
added to the existing diagnostic and research tools.
To further explore the applicability of nno as a potential biomarker for ar, 
the longitudinal reproducibility of nno levels in patients with clinically stable 
ar was investigated. A good reproducibility over short time periods, dimin-
ishing over time was found. In chapter 8, we conclude that despite the large 
“natural” variability in nno, the large effect of anti-inflammatory treatment 
(nasal corticosteroids) seen in a previous study would still allow to detect a 
significant intervention effect, being a prerequisite of a suitable biomarker 
(46). In contrast, other authors found a poor reproducibility of nno over 
longer time periods in subjects with ar and in this study nasal steroids did 
not significantly decrease nno levels (48). Therefore, it is still controversial if 
nno is a suitable marker to monitor upper airways inflammation. 
What is the effect of intranasal allergen-induced inflammation on nno? 
Surprisingly, no levels significantly decreased following nasal challenge with 
a relevant allergen, as compared with sham challenge. This phenomenon can-
not be explained by a biological mechanism, but is most probably caused by 
mechanical obstruction of the nasal cavity during the acute phase post-aller-
gen with subsequent decrease in nno diffusion. This assumption has been 
previously confirmed in a study in patients with ar and nasal polyps (49). 
Nasal no levels appeared to be inversely correlated with polyp size and raised 
following treatment of the polyps, suggestive of a mechanical blockade of no 
diffusion from the nasal sinuses. Similarly to eno measurements in asthma, 
appropriate decongesting was thought to counteract the nasal blockade 
and would allow correct nno measurements during the allergen-induced 
acute phase. However, an acute fall in nno is seen following administration 
of intranasal xylometazoline, possibly decreasing no-diffusion as a result 
of xylometazoline-induced vasoconstriction (50,51). During the late phase 
response when most of the obstruction had subsided, nno was increased up 
to 24 h. Similarly, a challenge with intranasal eotaxin in patients with ar previ-
ously caused a significant increase in nno, at 24h post challenge (52). Thus, 
nno may be a useful biomarker in nasal allergen challenge studies, especially 
during the late phase in patients with ar, preferably not pre-treated with 
nasal decongestants.
In conclusion, nno measurement is a simple, fast and non-invasive biomark-
er in patients with ar. Substantial long-term intra-subject variation and the 
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marginal effect of anti-inflammatory therapy found in some studies, make it 
less suitable for disease monitoring (48,53). Nonetheless, nno may poten-
tially serve as a biomarker of (allergen-induced) nasal inflammatory response 
in clinical trials with novel anti-inflammatory therapy although confounding 
factors such as massive rhinorrhea, (partial) occlusion of the paranasal sinus-
es or pretreatment with nasal decongestants need to be taken into account.
can nasal lavage and brush be used to sample biomarkers of nasal 
inflammation?
Nasal lavage and nab are more or less standardized sampling methods, 
commonly applied in clinical research and early drug development (54). 
Both techniques share the following advantages: they are simple, relatively 
non-invasive, suitable for repeated samplings, take little time and cause 
minor discomfort which makes them suitable to study the kinetics of the 
inflammatory airway response/process and their responsiveness to anti-
inflammatory therapy (55). In addition, processing of the acquired samples 
is not as laborious as biopsy processing. Nevertheless, this flexibility seems 
to come at an expense. With the exception of IgE, data suggest a modest 
reproducibility of soluble biomarker levels in nal in clinically stable aller-
gic rhinitics. Also, many biomarkers remain below detection level. Similar 
observations were made by other authors employing a comparable nasal 
lavage technique (56,57). An alternative is to increase the dwelling time by 
occluding the nostril with an inflated balloon and subsequently instilling 
the lavage fluid (58). This technique yields higher levels of biomarkers and a 
better reproducibility. However, this is a less flexible procedure which does 
not allow repeated sampling. Another technique applies filter paper into the 
nose to absorb nasal secretions. This technique circumvents the problem of 
excessive dilution, encountered with nasal lavage and allows direct sampling 
of a region of interest. Indeed, in a recent study in patients with seasonal ar, 
Erin et al. showed generally higher levels of several inflammatory cytokines 
and chemokines in nasal filter paper than in lavage fluid (59). Whether this 
technique yields a superior reproducibility compared to lavage needs to be 
investigated. Similarly to ebc, more sensitive detection assays could aid in the 
quantification of biomarkers in nasal lavage fluid. In the study by Erin a mul-
tiplex bead array system was used for biomarker detection. Almost all cytok-
ines and chemokines were above the detection limit both in nasal filter paper 
and lavage fluid. This is in contrast to our study where traditional elisa/
feia quantification was used. Apart from traditional and more sophisticated 
quantification techniques, other evaluation techniques, such as metabolom-
ics and proteomics, may have potential to assess upper airway inflammation, 
although both techniques await evaluation in ar. Most nab material was 
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suitable for analysis (87%) in our study. However, eosinophil counts showed 
a modest reproducibility and appear to be more variable than the established 
nasal biopsies (60). 
Nasal lavage and brush techniques allow multiple sampling in a relatively 
short time period. Significantly increased levels of several soluble inflam-
matory biomarkers in nal and eosinophils in nab in combination with 
increased nasal symptom scores followed a nasal allergen challenge (chapter 
7). The cell samplings from the nasal mucosa also allow rna isolation and 
quantification in small amounts of material. Using this technique, Dreskin et 
al reported an increase in mrna for il-5 following nasal allergen challenge in 
patients with seasonal ar (61). Other authors previously reported decreases 
in nasal symptoms accompanied by reduced inflammatory markers sampled 
with nal and nab in ar patients treated with topical corticosteroids versus 
placebo-treated patients (62). 
In conclusion, these techniques allow simple and safe sampling of (clinically) 
relevant biomarkers of upper airway inflammation that are responsive to 
treatment effects. Their low reproducibility is a clear disadvantage that may 
be improved by employing refined sampling and detection procedures or 
multiple baseline measurements. 
could cleaved slpi serve as a potential biomarker of both asthma  
and ar? 
Development of biomarkers for both diseases seems rational because of the 
shared pathophysiology. Chymase is a potent pro-inflammatory protease 
that is released from mast cells, important effector-cells in the pathophysiol-
ogy of allergic airway inflammation (63-65). The protease inhibitor slpi is 
both a chymase inhibitor and a substrate of chymase and its cleaved product, 
cslpi, is a biomarker of chymase activity in vitro (66). In contrast with chy-
mase that has a short half-life upon release, cslpi is stable and readily mea-
surable in relevant body fluids including saliva, sputum and nasal lavage.  
We further explored the potential of cslpi as a biomarker of chymase activ-
ity in subjects with mild to moderate persistent allergic asthma and found 
increased baseline sputum levels compared to healthy controls. Inhaled 
corticosteroid-treated asthmatics had overall lower sputum chymase levels 
compared to untreated asthmatics, suggesting that cslpi is sensitive to anti-
inflammatory treatment effects. In untreated patients with ar, cslpi was 
increased in nal, 20 min post intra-nasal allergen challenge, accompanied 
by an increase in symptoms and other (local) inflammatory markers. These 
events did not occur following placebo challenge. This is in agreement with 
previous findings in atopic patients showing increased slpi levels in nal fol-
lowing a nasal allergen challenge (67). slpi could also serve as a (target for) 
178 non-invasive sampling methods of inflammatory biomarkers in asthma  
 and allergic rhinitis
novel drugs. In vitro experiments showed that slpi can inhibit IgE-mediated 
histamine release probably from mast cells and basophils in human nasal 
mucosa (68). This effect was confirmed in sensitized guinea-pigs in vivo: 
treatment with topical slpi suppressed the conjunctival recruitment and 
degranulation of eosinophils after antigen challenge for 6 h, thus inhibiting 
the development of allergic conjunctivitis. In the same study it was demon-
strated that slpi inhibited chymase activity in a dose-dependent manner, 
without affecting tryptase (69). Alternatively, direct chymase inhibitors are 
being developed as anti-allergic therapy and presently the first compounds 
are entering the early clinical phases.
Detection of cslpi is feasible in patients with asthma and ar and suggests 
that cslpi could act as a novel biomarker of chymase activity. The relationship 
with disease activity and the effect of anti-inflammatory therapy on cslpi lev-
els awaits prospective evaluation by well-powered, placebo-controlled stud-
ies. It may be speculated that cslpi may not only serve as a future biomarker 
of allergic disease activity but may also become a novel therapeutic agent.
Overall conclusion
An applicable biomarker possesses the characteristics of clinical relevance, 
sensitivity and specificity for the disease and responsiveness to treatment 
effects, in combination with simplicity, reliability and repeatability of the 
sampling methodology. All biomarkers for asthma and ar obtained with 
the sampling techniques described in this thesis meet at least some of these 
criteria. On a case by case basis, a decision will need to be made what bio-
marker suits best the purpose of the research pursued and fulfills most of the 
relevant selection criteria. 
With the future development of more sophisticated sampling and detection 
techniques, the described biomarkers will be further refined and possibly 
replaced by new ones.
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Allergisch astma en allergische rhinitis (ar) zijn verwante chronische ont-
stekingsziekten van respectievelijk de onderste en bovenste luchtwegen met 
wereldwijd een hoge prevalentie (astma 1-18% en ar 10-25%). Hoewel zelden 
levensbedreigend, hebben beide aandoeningen een grote invloed op de kwa-
liteit van leven en kunnen veel patiënten niet adequaat behandeld worden 
met de beschikbare medicatie. De klachten die patiënten met astma en/of 
allergische rhinitis uiten, zijn verschillend per patiënt, en kunnen gepaard 
gaan met de volgende symptomen: kortademigheid, piepende ademhaling, 
drukkend gevoel op de borst, hoesten, en ‘overgevoelige luchtwegen voor 
allerlei stoffen’, dan wel nasale congestie, jeuk, niezen en oogsymptomen. 
Beide aandoeningen komen vaak gezamenlijk voor en hebben hun oorsprong 
in de interactie van genetische constitutie met bepaalde omgevingsfactoren.
Het allergische ontstekingsproces kenmerkt zich door een immunoglo-
buline E (IgE) gemediëerde reactie op specifieke, externe prikkels (‘aller-
genen’), zoals huisstofmijten, pollen of huidschilfers van dieren. De hierop 
volgende ontstekingscascade wordt getypeerd door een complex netwerk 
van effectorcellen (voornamelijk mestcellen en eosinofiele granulocyten), 
ontstekingsmediatoren, cytokinen, chemokinen, neuropeptiden en signaal-
moleculen met onderlinge interacties. Dit leidt enerzijds tot migratie van 
ontstekingscellen naar de mucosa in de longen en de neus, en anderzijds 
tot een reactie met verschillende targetcellen (zoals gladde spiercellen, 
vaatwandcellen en mucusproducerende cellen) met als gevolg nasale cq. 
bronchiale obstructie en hyperreactiviteit. Onderzoek bij patiënten heeft 
aangetoond dat symptomen en longfunctieparameters, die veelal als leidraad 
voor de behandeling van astma worden gebruikt, niet de beste indicatoren 
zijn voor de mate van de onderliggende luchtwegontsteking. Om die reden 
staan huidige richtlijnen astmamanagement op geleide van astmacontrole 
voor - hetgeen een ‘multi-dimensionale’ parameter is. 
Een biomarker is een te meten variabele die gebruikt kan worden als een 
indicator voor normale biologische processen, pathologische processen en/
of het effect van een behandeling. Een goede biomarker is klinisch relevant, 
gevoelig voor veranderingen in het ziekteproces, betrouwbaar, reproduceer-
baar, en eenvoudig uitvoerbaar. Het ontstekingsproces bij astma en ar biedt 
verschillende potentiële biomarkers. Eosinofiele granulocyten, verkregen 
via niet-invasieve samplings van de onderste of bovenste luchtwegen, zijn 
een goed voorbeeld van een ontstekingsbiomarker. Het percentage eosino-
fielen kan enerzijds een indicator zijn voor het type en de activiteit van het 
onderliggende ziekteproces en als graadmeter dienen voor het monitoren 
van anti-inflammatoire therapie. Eosinofielen-tellingen kunnen worden 
gedaan op gekleurde cytospins uit het sputum (slijm uit de onderste lucht-
wegen). Sputum kan op een niet-invasieve manier worden geïnduceerd 
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middels inhalaties van o.a. hypertone zoutoplossingen, waarna de patiënten 
worden aangemoedigd om op te hoesten. Naast eosinofielen, kunnen uit het 
sputum diverse andere ontstekingsbiomarkers worden bepaald, waarvan 
er verscheidene gevalideerd zijn. Sputum is dus een geschikt medium om 
het ziekteproces bij astma te onderzoeken. Een andere sampling-techniek 
voor ontstekingsbiomarkers uit de longen bestaat uit het verzamelen en 
analyseren van gekoeld uitgeademd luchtcondensaat (ebc). Hierbij ademt de 
patiënt gedurende een tiental minuten in een collector die de uitgeademde 
lucht koelt. Met behulp van gevoelige detectietechnieken kunnen vervolgens 
ontstekingsproducten in de ebc gemeten worden. 
Een derde manier om de luchtwegontsteking bij astma te vervolgen is het 
meten van stikstofoxide (no) in uitgeademde lucht. Dit kan op een betrek-
kelijk eenvoudige wijze met behulp van moderne apparatuur. Uit diverse 
studies is gebleken dat de concentratie uitgeademd no de ernst van de lucht-
wegontsteking bij astma reflecteert en dat de no waarde daalt na adequate 
behandeling met anti-inflammatoire therapie.
Ook in de neus kunnen verschillende niet- of semi-invasieve sampling-
technieken toegepast worden om ontstekingsbiomarkers te bemonsteren en 
analyseren. Zo kan op vergelijkbare wijze als uitgeademd no bij astma, nasale 
no (nno) worden gemeten bij patiënten met allergische rhinitis. Twee ande-
re technieken, waarbij men op ‘semi’-invasieve wijze meerdere biomarkers in 
één keer verzamelt, bestaan respectievelijk uit neuslavage (nal), waarbij de 
neus wordt gespoeld met een isotone zoutoplossing, en neusbrush (nab), 
waarbij het neusslijmvlies lokaal wordt geborsteld met een klein borsteltje. 
Middels beide methoden kunnen verschillende biomarkers (respectievelijk 
ontstekingsmediatoren en ontstekingscellen) worden bepaald die deel uit-
maken van het ontstekingsproces bij ar.
Dit proefschrift omvat een aantal klinische studies waarin de beschreven 
technieken werden toegepast om componenten van de luchtwegontsteking 
bij patiënten met allergisch astma en ar, al dan niet in een interventie setting, 
te meten. Het doel van dit proefschrift was om deze samplingtechnieken te 
optimaliseren als ook om de reproduceerbaarheid van biomarkers en toepas-
baarheid van nieuwe detectiemethoden te onderzoeken. 
Het eerste deel van dit proefschrift betreft biomarkeronderzoek bij 
allergisch astma. Hoofdstuk 3 beschrijft het onderzoek naar de farmaco-
logische en klinische effectiviteit van een gecombineerde Neurokinine1/
Neurokinine2 (nk1/nk2) receptor antagonist (ave5883) in twee aparte 
studies. In de eerste studie bood geinhaleerd ave5883 bescherming tegen 
Neurokinine A-geïnduceerde luchtwegvernauwing bij patiënten met aller-
gisch astma. Echter, bij toepassing in een exacerbatie model van astma, 
bleek dezelfde dosis ave5883 niet effectief tegen allergeen-geïnduceerde 
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luchtwegvernauwing en hyperreactiviteit. Bovendien was de toename in 
luchtwegontstekingscomponenten (cq biomarkers), namelijk sputum 
eosinofielen en uitgeademd no, niet verminderd door behandeling met 
ave5883. In een volgende studie (hoofdstuk 4) werd uitgeademd no tijdens 
een allergeen-geinduceerde late reactie voor en na recuperatie met salbuta-
mol bepaald. Er was een sterke stijging van uitgeademd no na opheffing van 
de allergeen-geïnduceerde luchtwegvernauwing na salbutamol-inhalatie. 
Hierbij correleerde de toename in uitgeademd no met de toename in 
longfunctie (fev1). Uit onderzoek bij patiënten met klinisch stabiel astma, 
bleek eerder dat luchtwegvernauwing gepaard gaat met lagere no waarden. 
Gezien de relatie tussen uitgeademd no en luchtwegdiameter, concluderen 
wij dat voor een juiste vergelijking en interpretatie van deze biomarker in de 
klinische setting, no gemeten dient te worden na een adequate luchtwegver-
wijding. In het volgende hoofdstuk werd de betrouwbaarheid van een draag-
bare no meter (niox mino®) in vergelekijng met de ‘gouden standaard’ 
onderzocht (hoofdstuk 5). De no waarden gemeten met de niox mino bij 
gezonde vrijwilligers, rokers en patiënten met onbehandeld allergisch astma 
waren reproduceerbaar en kwamen overeen met metingen met behulp van 
een gevalideerde uitgeademd no analyser (Ecomedics). De vergelijking tus-
sen niox mino met ‘zijn grote broer’, niox stationary, toonde destijds ver-
gelijkbare resultaten. De niox mino is draagbaar, goedkoper, eenvoudiger 
in gebruik en onderhoud en daardoor potentieel beter inzetbaar in de kliniek 
dan de traditionele (stationary) analysers, de niox en de Ecomedics. Het 
meten van biomarkers in sputum en ebc wordt vaak bemoeilijkt door te klei-
ne hoeveelheden materiaal, gevoeligheid van biomarkers voor voorbehande-
ling en beperkt meetbereik van de meeste traditionele detectie-technieken. 
In hoofdstuk 6, werden nieuwe voorbehandelings- en detectietechnieken in 
sputum en ebc van patiënten met allergisch astma getest. In deze explora-
tieve studie, bleek ultracentrifugatie van sputum hogere spiegels aan diverse 
biomarkers op te leveren dan de traditionele voorbehandeling met dithiotrei-
tol (dtt). Dit laatste ondanks toepassing van een (eveneens nieuwe) dialyse 
techniek, waarmee het voor biomarkers schadelijke dtt na de homogeni-
satie uit het monster werd gezuiverd. In het ultragecentrifugeerde sputum 
konden met twee gevoelige analyse technieken, i.e. Mesoscale en Luminex, 
biomarkers worden gemeten, die normaliter niet detecteerbaar zijn na voor-
behandeling met dtt. Daarnaast was het mogelijk om rna te isoleren uit de 
sputumcellen en het expressie niveau te bepalen. In ebc bleven de meeste 
biomarkers onder de detectielimiet, ondanks toepassing van Luminex. 
Het tweede deel van dit proefschrift beschrijft biomarkerstudies bij 
patiënten met ar. Hierin bleken de veelvuldig gebruikte allergiemarkers, 
serum IgE waarden en huidpriktesten, een goede reproduceerbaarheid te 
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vertonen (hoofdstuk 7). Daarentegen waren biomarkers in nal en nab vaak 
niet meetbaar of vertoonden over een periode van 3 weken een aanzienlijke 
variabiliteit ondanks de stabiele klinische status van deelnemers. Mogelijk dat 
een andere sampling-procedure, met behulp van filtreerpapier dat vloeistof 
in de neus absorbeert, een oplossing kan bieden voor dit probleem dat deels 
samenhangt met een te sterke verdunning van de biomarkers vooral in de 
nal. Ondanks dit minpunt, bleek in tegenstelling tot de placebo challenge, 
een nasale provocatietest met een relevant allergeen een duidelijk effect te 
hebben op verschillende ontstekingsmarkers in de neus. Hierbij waren met 
name α2 macroglobuline, eosinofiel cationisch proteïne (ecp) en tryptase 
verhoogd in de nal, en de eosinofielen in de nab. In dezelfde patiëntengroep 
werd eveneens de reproduceerbaarheid van de ‘baseline’ nasale no waar-
den getest als ook het effect van een nasale allergeen provocatietest hierop 
(hoofdstuk 8). Uit onze bevindingen bleek dat bij patiënten met klinisch 
stabiele ar, nno metingen gedurende korte observatie-perioden (< 1 week) 
reproduceerbaar zijn, maar dat reproduceerbaarheid afneemt over langere 
perioden (al vanaf 2-3 weken). Mogelijk kunnen a-symptomatische seizoens- 
of weersinvloeden de nno schommelingen verklaren. Interessant genoeg 
induceerde nasaal allergeen enerzijds wel een toename van symptoomscores 
en ontstekingsmarkers in de nal, maar anderzijds een daling van nno waar-
den tijdens de vroege allergische reactie. Deze daling werd waarschijnlijk 
veroorzaakt door een mechanische blokkade van de sinus maxillares door 
massieve slijmsecretie en slijmvlieszwelling en was vermoedelijk niet het 
gevolg van een biologische reactie. Vergelijkbare bevindingen werden eerder 
gedaan bij patiënten met neuspoliepen. Hierbij waren de nno concentraties 
initieel omgekeerd evenredig aan de poliepomvang en stegen na behande-
ling van de poliepen. Vierentwintig uur na de allergeenprovocatie, toen de 
nasale obstructie grotendeels was geweken, bleken de nno waarden signifi-
cant verhoogd. 
Het onderliggende ontstekingsproces bij astma en ar heeft vergelijkbare 
ontstekingskenmerken. In de laatste jaren wordt wederom veel aandacht 
besteed aan de mestcel als belangrijke effectorcel in beide aandoeningen.  
In hoofdstuk 9 werd exploratief onderzoek verricht naar een mogelijke rol van 
chymase (een protease afkomstig uit mestcellen) en diens afbraakpro- 
duct (cleaved secretory leukocyte protease (cslpi)) bij beide aandoeningen. 
cslpi geeft een indicatie van chymase activiteit (hetgeen een relevanter 
parameter is dan de concentratie) en is stabieler dan chymase, en ergo, een 
betrouwbaarder biomarker. In deze studie vonden wij hogere chymase- en 
cslpi concentraties in het sputum van patiënten met onbehandeld allergisch 
astma in vergelijking met monsters van astmapatiënten die met anti-inflam-
matoire therapie werden behandeld en gezonde vrijwilligers. Bij patiënten 
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met ar induceerde intranasaal allergeen (in tegenstelling tot placebo) een 
significante stijging van chymase en cslpi in de nal. Tevens was er een 
positieve correlatie tussen de chymase concentraties en de ratio slpi/cslpi 
(maat voor chymase activiteit). 
Conclusies en aanbevelingen:
is sputum een geschikte techniek om biomarkers te bepalen?
Een belangrijk voordeel van sputumbepalingen is dat een groot aantal bio-
markers, afkomstig uit het ontstekingsproces in de luchtwegen, tegelijk kan 
worden bepaald. Moderne detectiemethoden maken bepalingen van een 
steeds toenemend aantal ontstekingsmarkers mogelijk uit zowel het super-
natant als uit sputumcellen. Echter, naast de belasting van de patiënt, houden 
factoren als het ingewikkelde opwerkproces, de geavanceerde detectietech-
nieken als ook de celdifferentiatiebepalingen, het gebruik van deze techniek 
beperkt tot specialistische centra en klinisch onderzoek 
is uitgeademd no een goede biomarker voor astma?
Uitgeademd no is niet-invasief, eenvoudig meetbaar en reproduceerbaar. 
Daarnaast kan een verhoogde no waarde ondersteuning bieden bij het stel-
len van de diagnose ‘astma’. Andere voordelen zijn diens gevoeligheid voor 
veranderingen in de ontstekingsgraad van de onderste luchtwegen (zowel 
voor als tijdens behandeling met anti-inflammatoire geneesmiddelen) en de 
voorspellende waarde voor een verminderde astmacontrole/exacerbatie. 
Minpunten zijn diverse storende factoren die de uitkomsten kunnen beïn-
vloeden, zoals de luchtwegdiameter, sigarettenrook en bepaalde voedings-
middelen. Het is vooralsnog onduidelijk welke rol uitgeademd no zal spelen 
bij het helpen optimaliseren van de lange-termijn behandeling van astma.
kan ebc gebruikt worden bij klinisch onderzoek en in de kliniek?
Vooralsnog biedt ebc als enige samplingmethode de mogelijkheid om op 
volledig niet-invasieve en eenvoudige wijze biomarkers uit uitgeademde 
lucht te verzamelen. Echter, de thans beschikbare apparatuur en techniek 
zijn nog niet volledig gestandaardiseerd hetgeen aanzienlijke verschillen in 
studieresultaten heeft opgeleverd tussen de verschillende onderzoekcentra. 
Bovendien grenzen de concentraties van verschillende biomarkers aan de 
detectielimieten van de meest gangbare assays. Ter verdere ontwikkeling en 
optimalisatie, dient deze veelbelovende techniek te worden gecombineerd 
met gestandaardiseerde methoden en gespiegeld aan meer gevestigde bio-
markers.
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zijn nal en nab bruikbare samplingtechnieken voor biomarkers?
nal en nab zijn gestandaardiseerde, relatief patiëntvriendelijke en eenvou-
dige, semi-invasieve technieken die herhaaldelijk kunnen worden aangewend 
om meerdere biomarkers te monsteren. Belangrijkste nadelen vormen de 
lage concentraties en grote variabiliteit van de meeste biomarkers in de ver-
kregen monsters. Grote(re) patiëntpopulaties, langere ‘dwellingtime’ in de 
neus (nal) en het gebruik van gevoelige detectietechnieken kunnen moge-
lijk uitkomst bieden.
is nno net zo bruikbaar voor ar als uitgeademd no voor astma?
Nasale no kan op een eenvoudige en niet-invasieve manier gemeten worden 
en de concentraties zijn over het algemeen hoger bij patiënten met onbehan-
delde ar vergeleken met patiënten die anti-inflammatoire therapie gebrui-
ken en gezonde controles. Echter, andere studies rapporteerden een behoor-
lijke overlap in nno waarden tussen gezonde vrijwilligers en patiënten met 
ar. Wellicht worden de nno waarden in belangrijke mate beïnvloed door de 
variabele slijmvlieszwelling. Mogelijk is dit - naast weers- en seizoensinvloe-
den - een belangrijke reden, waarom nno metingen over langere perioden 
variabel zijn en dus minder geschikt voor klinische monitoring bij patiënten 
met ar. Nasale no metingen kunnen misschien wel gebruikt worden in 
‘korte termijn studies’, bijvoorbeeld als biomarker van (allergeen geïnduceer-
de) acute nasale inflammatie als gecontroleerd wordt voor interfererende 
factoren, zoals nasale congestie.
is cslpi de toekomstige biomarker voor ziekteactiviteit bij allergisch 
astma en allergische rhinitis?
Cleaved slpi bleek in vitro een marker te zijn voor chymase activiteit. Deze 
observaties worden bevestigd door onze in vivo data, waarbij hoge concen-
traties cslpi werden gemeten bij patiënten met onbehandeld astma en bij ar 
patiënten met allergeen geïnduceerde nasale ontsteking. Gelet op de centra-
le rol die de chymase-bevattende mest- cellen mogelijk spelen bij allergische 
luchtweginflammatie en hyperreactiviteit, dient de rol van cslpi verder te 
worden onderzocht in grote prospectieve studies. 
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